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Abstract
ABSTRACT
Rheumatoid arthritis is a widely spread disease of which causes remain relatively 
unexplained. The existing therapies for RA have shown limited effects; one reason for 
that being the presence of hypoxia in the rheumatic joint. This decreased level of 
oxygen inthe tissues is the consequence of the inadequate perfusion of the joint due to 
deficient distribution and quality of the vasculature resulting from angiogenetic 
processes and pressure rises triggered by increased inflammation and exercise, 
occluding parts of the capillary bed. Hypoxia is responsible for important 
physiological changes which render conventional treatments inactive, and triggers the 
production o f entities such as reactive oxygen species and poly(ADP- 
ribose)polymerase.
The aim of the present study is to use a bioreductive compound or carrier for the 
specific targeting of a drug to areas of hypoxic and/or ischaemic tissues, in which the 
desired drug species is linked to a non-cytotoxic counterpart.
Two series o f novel potentially bioreductivatable prodrugs bearing anti-inflammatory, 
anti-arthritic agents have been synthesised for the selective delivery of these drugs to 
areas of inflammation characterised by low oxygen concentrations.
The first series is based on a l,2-dimethyl-5-methoxyindole-4,7-dione trigger. The 
synthesis of the first potential prodrug l-[(l,2-dimethyl-4,7-dioxo-5-methoxyindol-3- 
yl)methyl]-4-(prednisolone-21-yl) butanedioate resulted from the successful 
nucleophilic attack from the steroidal drug moiety on the trigger. The PARP inhibitors 
isoquinolin-l-one, and its 5-bromo and 5-iodo-analogues were used for the synthesis 
of four prodrugs. The Mitsunobu reaction was used to link the trigger and effector. 
The site of attachment of the two subunits varied with the drug moity used. The non­
substituted isoquinolin-l-one gave the ester derivative whereas N-alkylation took 
place in the case of the 5-bromoisoquinolinone. 5-Iodoisoquinolin-l-one gave both 
derivatives separately.
Abstract
The second series is 5-mtrothiophene-2-ylmethyl-based. The nucleophilic species 
generated from 5-nitro-2-thienylmethyl derivatives reacted with acetylsalicyloyl 
chloride to give the aspirin prodrug 5-nitrothien-2-ylmethyl 2-acetoxybenzoate. 
Couplirg of a nitrothienylmethyl succinate active ester with prednisolone generated 
the steroid prodrug 1 -[(5-nitro-2-thienyl)methyl]-4-(prednisolone-21 -yl) butanedioate. 
The Miisunobu reaction between 5-nitro-2-thienylmethanol and isoquinolin-l-one and 
its 5-iodo and 5-bromo analogues gave the ether derivatives. No N-alkylation was 
observed.
The release studies were carried out using chemical systems representing in vivo 
reductive conditions. Drug release was monitored by HPLC and, in a new 
development, by NMR. Release was observed for the indole-isoquinoline ethers after 
stoichiometric reduction of the potential prodrugs but the N-alkylated and the steroid 
derivatives gave no signs of drug release.
Reduction of the nitrothiophene trigger was observed for each target, and release of 
the isoquinolinone effector moiety was detected. The aspirin and steroid prodrugs 
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Rheumatoid arthritis (RA) is one of the many forms of musculoskeletal disorders. It is 
an inflammatory arthropathy, one of the six main classes of musculoskeletal disorders. 




Connective tissue diseases: Systemic lupus erythe­




rheumatoid, infectious and juve­
nile chronic arthritis, seronegati­
ve spondyloarthritises, diffuse co­
nnective tissue disorders, crystal- 
related, metabolic and endocrine
arthropathies.
—25 /o
Osteoarthritis: secondary osteoarthritis, idio­
pathic mono-and polyarticular osteoarthritis.
Figure 1: Musculoskeletal disorders and their distribution in the population 
concerned.
Although back pain and periarticular disorders seem to be the most common (> 25%), 
followed by osteoporosis and osteoarthritis (20 to 30%), inflammatory arthropathies 
still represent around 2.5% of the population presenting musculoskeletal disorders and 
are often more severe (Figure I).1,2,3





bursitis, tendon disorders, 
fibromyalgia.
Introduction
RA has a worldwide distribution and affects 1 to 3% of the population (1% in the 
UK). The disease often begins in middle age and increasingly occurs in older people, 
but children and young adults are also touched. Typically the most common age of 
onset is 30-50. Women before the menopause are affected 2 to 3 times more then men. 
After the menopause, the frequency of onset is similar between sexes.4,5
RA, like all other types of arthritis, has a considerable financial and social impact. The 
main impact being through the very high rates of disabilities but the rate of mortality 
is very low (0.02%). Other major effects of the disease, such as pain but also 
depression, anxiety and feelings of helplessness impair the abilities of people severely 
touched by RA to carry out normal daily activities. Furthermore the medical and 
surgical treatments together with the loss of income add up to considerable costs.4,5
1.1 THE MAIN FEATURES OF RHEUMATOID ARTHRITIS
RA is a chronic symmetrical polyarthritis. It is a systemic disorder characterised by 
chronic inflammatory synovitis (inflammation of the synovial tissue) of mainly 
peripheral joints. Its course is extremely variable and is associated with non-articular 
features. It causes pain, swelling, stiffness and loss of functions in the joints. In the 
main, peripheral joints are affected, such as fingers and wrists, but it has been shown 
that the disease involves the tendons, tendon sheaths and bursae in some patients. 
Other organs, e.g. skin, eyes, peripheral nerves, pleura, pericardium and the heart 
itself could also be touched.3,5
RA often occurs symmetrically. If one hand is involved, the other will be.
The diseaise varies from one person to another; it can last a few months or years and 
disappear without causing noticeable damage. It can be moderate with periods of 
flares and remissions. It can also be severe, active at most times, last for years and 
lead to joiint damage and disability.3,5
Introduction
1.2 Pa t h o l o g y .
Bone Cartilage Ligamentous Synovium Joint cavity Pannus 
capsule synovial
fluid
Figure 2: Schematic view of the effects of RA on a human knee joint.3
A normal joint is surrounded by a ligamentous capsule that protects it and offers 
resistance to pressure in any direction. The joint capsule is lined with a type of tissue 
called synovium. This produces synovial fluid, which is responsible for lubricating 
and nourishing the cartilage and bones inside the joint capsule.1,2,3
When RA occurs, the immune system attacks the cells of the joint capsule. The 
reasons for this are still unclear. The production of rheumatoid factors (RFs) by 
plasma cells in the synovium and the local formation of immune complexes are 
thought to play an important part leading to rheumatoid synovitis (inflammation of 
synovial lining of joints, tendon sheaths and bursae).1,2,3
The synovium becomes greatly thickened and results in a joint that is swollen and 
puffy to the touch. The synovium proliferates into a villous pattern and is infiltrated 
by a variety of inflammatory cells, including polymorphs, which migrate through the 
tissue into the joint fluid, lymphocytes and plasma cells. The normally thin surface 
layer of lining cells becomes hyperplastic and thick. There is severe angiogenesis and 
increased permeability of blood vessels which, in the synovial lining layer, leads to 
joint effusions containing lymphocytes and dying polymorphs. Activated lymphocytes
Introduction
and macrophages in the synovium produce a rich mixture of cytokines, including 
interleukins, prostaglandin and tumour necrosis factor alpha (TNFa).1,2,3
The growing synovium spreads from the joint periphery onto the cartilage surface. 
This inflamed spreading pannus blocks the normal route for cartilage nutrition and, by 
the conjugated effect of cytokines on the chondrocytes, the cartilage gets damaged. It 
becomes thinner, exposing the underlying bone. During active synovitis, local 
cytokine production and the lack of joint mobility combine to cause juxta-articular 
osteoporosis (Figure 2).
The proliferating synovium also grows between the synovial margins and the 
epiphyseal bone cavity and damages the bone, responsible for “erosions” seen on X- 
rays. Those are generally irreversible and are associated with joint deformity.1,2,3
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Figure 3: Inflammatory cells involved in rheumatoid inflammation (APC: antigen 
presenting cell, Ag: antigen, MHC: major histocompatibility complex, TCR: T cell 
receptor, iNOS: inducible nitric oxide synthase, TNF: tumour necrosis factor, IL: 
interleukins).6
The chronic synovial inflammation may be caused by the continuous T-cell activation 
or may be maintained by the local production of rheumatoid factors and persistent
4
Introduction
stimulation of macrophages via IgG Fc preceptors3,4,5. However, it was observed that 
minimum amounts of the inflammatory factors are produced by T-cells (interferon and 
interleukins IL-2 and IL-4). The mechanism of T-cell activation might, therefore, not 
be the target of choice. On the> other hand, the cytokines (EL-1, IL-8, TNFa, 
granulocyte macrophage colony stimulating factor, GMC-SF) and chemoattractive 
cytokines produced by macrophages (macrophage inflammatory protein MIP, and 
monocyte chemoattractant protein MCP) and fibroblasts (EL-6) are abundant. Tumour 
necrosis factor alpha (TNFa) is expressed in significant quantities; it is known to play 
a pivotal role in the disease and is an interesting target for therapy 6,7(Figure 3).
Synovial fibroblasts have high levels of the adhesion molecules, such as vascular cell 
adhesion molecules (VCAM-1), which support B lymphocyte survival and 
differentiation. They may facilitate the formation of abnormal lymphoid tissue in the
f\ nsynovium *. The triggering antigen remains unclear. The hypothesis has been made 
that immunoglobulins could become antigenic in RA following deficient 
glycolysation2,4. There is little evidence that collagen type H is the triggering antigen, 
although it is a cause of arthritis in animal models. Bacterial or slow virus infections 
have been implicated but they are unproven as causes.2,4
1.3.1 Rheumatoidfactors
Rheumatoid factors (RFs) are circulating antibodies (autoantibodies), directed against 
altered or negative gammaglobulin. They occur as IgM, IgG and IgA immuno­
globulins and have specificity for antigenic determinants on the Fc fragment. RFs are 
usually a complex of an IgM acting as an antigen with another acting as the 
antibody2,4. The temporary production of RFs is an essential part of the body’s normal 
mechanism for removing immune complexes but, in RA, their production is persistent 
and occurs into the joint2,4. They may be of any immunoglobulin class (IgM, IgG, or 
IgA), but the most common tests employed clinically detect IgM rheumatoid factor. 
Around 70% of patients with polyarticular RA have serum IgM rheumatoid factor in 
the serum. When the standard test for IgM is persistently negative, the term 
seronegative RA is used. Seronegative patients tend to have a less severe case of
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synovitis. RFs are not found in synovitis associated with psoriasis, ankylosing 
spondylitis and inflammatory bowel disease, or in reactive arthritis. IgM rheumatoid 
factor cannot be used as a diagnostic for RA; it can only be extra information to 
predict the severity of the disease. > A persistently high titre in early disease implies 
more persistently active synovitis, more joint damage and greater disability 
eventually.2,4
1.4 Th e  treatm ents .
There are a variety of approaches to treat RA. The objectives of the treatment are to:
• Relieve pain
• Reduce inflammation
• Slow down or stop joint damage
• Improve the patient’s sense of well-being and ability to function
Patients with RA may have to adapt their lifestyle to the disease, find a balance
between rest and exercise, take care of the joints involved (use of splint), reduce their 
level o f  stress and go on a healthful diet.
Surgery is still one of the major answers for patients with severe conditions; this 
involves joint replacement, tendon reconstruction, and synovectomy (hardly used 
nowadays) but, above all, medication is the most common therapy for RA 
(Table 1),5A9
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Medication Uses/ effects Side effects
NSAID nonsteroidal 
anti-inflammatory drugs 




Reduction of pain swelling 
and inflammation. 
Generally part of early and 
continuing therapy.
Stomach disorder ten­
dency to bruise easily, 
fluid retention ulcers 




drugs or SAARDs slow- 
acting antirheumatic drugs






Alteration of the course of 
the disease and prevention of 
joint and cartilage des­
truction.
May produce significant 
improvement for many 
patients Mechanism of action 
unknown.
Patients can use several over 
the course of the disease 
Takes a few weeks or months 
to have an effect.
Toxicity
Gold: skin rash, mouth 
sores, stomach and 
kidney disorders, low- 
blood count. 
Antimalarials: stomach 
and eye disorders 
Penicillamine: skin rash, 










Restriction of the overly 
active immune system 
Potential toxicity diminishing 
effectiveness over time 
Methotrexate can result in 
rapid improvements, seems 
effective.
Azathioprine used for 
patients not responding to 
other drugs
Chemotherapeutic agent. 
Used in combination therapy 
Cyclophosphamide 
chemotherapeutic agent, used 
only in veiy severe cases of 
RA for potential toxicity.
Toxicity
Methotrexate: stomach 
and liver disorder, low 
white blood cell count 
Azathioprine: potential 
blood abnormalities, 
low white blood cell 
count, increased cancer 
risks.
Cyclophosphamide: 
low white blood cell 









Dramatic improvement in 
very short time 
Used early while waiting for 
DMARDS to work 
Used for severe flares and 
when no response to NSAEDs 
and DMARDs
Osteoporosis, mood 
changes, fragile skin, 
easy bruising, fluid 
retention, weight gain, 
muscle weakness, onset 
or worsening of 
diabetes, cataracts 
increased risk of 
infection, hypertension, 
potential for serious side 
effects at high doses
5 8 9Table 1: Four classes of treatments used for RA, drugs, effects and side effects. ’ *
Introduction
1.5 In f l a m m a t io n , a n g io g e n e s is  a n d  h y p o x ia .
Although we have seen that the immunological reasons behind RA are still unclear, 
research has allowed the slow dissection of some important mechanism and 
phenomena. Those are the elements permitting the development of therapies.
Different groups have reached different conclusions on what is the main driving force 
in RA, setting different priorities for the target to reach in the development of new 
therapies.
1.5.1 Angiogenesis
Angiogenesis is the process by which new blood vessels are created. This constitutes 
one of the earliest changes within the rheumatic joint; blood vessels develop providing 
nutrients, oxygen and cells to the growing pannus2,4. During pathological 
angiogenesis, endothelial cell activation, via various cytokine mediators and/or 
adhesion molecules, is abnormally prolonged as a result of an imbalance between
* j
angiogenesis-enhancing and inhibiting factors * .
By highlighting the similarities between synoviocytes and tumour cells, Weber et al10 
propose that angiogenesis promotes rheumatoid synovitis in a similar way that it 
promotes tumour progression. The hypothesis relies on the close relation between 
inflammation and angiogenesis. Vascular cell adhesion molecule (VCAM-1) and E- 
selectine adhere to endothelial cell surface; they are cleaved by lymphocytes and 
released as soluble molecules. They induce a chemoattractant effect on neighbouring 
vascular cells thus causing early activation of angiogenesis.
Angiogenic factors are thought to play an important part in the following stages, 
namely interleukin 8 (IL-8), tumour necrosis factor alpha (TNFa), vascular 
endothelial growth factor (VEGF), and hepatocyte growth factor (HGF) released by 
macrophages and lining layer cells.10
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1.5.2 Hypoxia and rheumatoid arthritis
The synovial intra-articular pressure observed in a normal joint is subatmospheric 
(between 2 and 10 mm Hg), whether the joint is in motion or at rest. The maintenance 
of this pressure ensures that the blood vessels remain patent on exercise. In the 
rheumatic joint, the inflammation induces pressure rises, which increase further during 
exercise, exceeding the capillary perfusion pressure; parts of the capillary bed are 
consequently occluded, inducing hypoxia. The synovium is described as chronically 
hypoxic in RA7,11,12. Hypoxia is a major stimulant of VEGF, which is thought to play 
an important role in the regulation of angiogenesis via the production of hypoxia 
inducible factor (HIF-1).10,13
Chronic rheumatoid synovitis might be a consequence of persistent angiogenesis.13 
The normal synovial membrane is densely vascularised and is composed of one or two 
layers of synovial cells. In RA, the synovial layer becomes hyperplastic and locally 
invasive. Fibroblast proliferation and important neovascularisation occur. 
Inflammatory infiltrates are present. The new capillaries are generally redistributed 
towards the deeper parts of the synovium and the vascular density remains hardly 
changed. The new blood vessels contain a high level of pericytes, and a low level of 
angiotensin-converting enzyme, overexpression of E-selectine, integrin av(33 and 
metalloproteinase. The endothelial cells express markers for proliferation (similar to 
tumour and skin repair proliferation). The simultaneous proliferation and apoptosis of 
endothelial cells explain the quasi non-existent change in vascular density. The 
accelerated vascular turnover may result in deficiencies in the new vascular system 
like absence of vasoregulating neuropeptide receptors (substance P), and lack of 
functionality. Those deficiencies prevent tissue healing and induce persistent hypoxia 
and acidosis, which trigger more inflammation, pain and tissue damage inducing more 
severe arthritis.13
Another approach was developed by Blake 6,7 and Bodamyali et a l7, who propose that 
hypoxia is the main driving force in RA.
Theiper lymphocytes have been shown to play part in RA. Thi response is characterised 
by TGFp, IFNy, TNFa, EL-1 and IL-2 expression. Th2 seems to show increased
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production of IL-4, EL-5, IL-10, and IL-13 (anti-inflammatory cytokines). Levels of 
TNFa and IL-1 are high in RA whereas the level of IL-2 is low which constitutes an 
abnormality in the Thi response profile6,7.
Previous studies7 have shown that hypoxia up-regulates TNFa and IL-1 and down- 
regulates IL-2. The predominant expression of a certain type of cytokines may 
influence Thi / Th2 differentiation. Furthermore, this differentiation takes place after 
binding of the cytokines to the T cell precursor receptors and is mediated by 
phosphorylation of the relevant signal transducers and activators of transcription. 
Hypoxia appears to influence both cytokine production and phosphorylation and, 
therefore, would be responsible for the Th2 to Thi switch.
Although T-cell cytokines are thought to be involved in the development of abnormal 
inflammatory response, studies have shown that patients with RA and HIV still suffer 
from destructive RA pathology when all immune activity has ceased (production of T- 
cells and cytokines has stopped). In RA, the apparent T cell hyporesponsiveness is 
also suggested to be related to hypoxia7. Under hypoxia, there is an increased 
production of ketones during glycolysis. These are available to form an increased 
number of Schiff bases with endogenous primary amines. The formation of these 
Schiff bases regulates the interaction of T cells and antigen-presenting cells. Thus the 
nature and concentration of carbonyl precursors for the carbonyl-amine condensation 
will influence the inhibition of T cell responses and may lead to T cell anergy. Finally, 
the growth factor and cytokine profiles of rheumatoid synovial cells in vivo match 
more closely to those of macrophages and fibroblasts in vitro than they do to those of 
T cells in vitro. This suggests that those cytokines and growth factors would be 
produced by the synovial cells rather than by T-lymphocytes. It is also known that 
hypoxia influences macrophage-derived expression of cytokines (IL-1, IL-6, TNFa, 
GM-CSF).7
All this evidence, according to Bodamyali et al , suggests that hypoxia, rather than 
angiogenesis, induces chronic RA. They also report that studies o f the vascular system 
of rheumatic synovium brings some more evidence. The capillary density in the 
rheumatic synovium is one third of the one observed in normal synovium, the distance
in
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between capillaries and joint cavity increases in RA, indicating inadequate perfusion. 
The pannus was shown to be relatively avascular and mainly hypoxic. Bodamyali et 
a l7 then conclude that there is obvious lack of angiogenesis and that hypoxia is the 
main factor causing chronic synovitis.
The rapid review of those two approaches suggests that the immune mechanism of RA 
is complex, with pleiotropic cytokines and redundancy in some of the regulatory 
networks. It may then be necessary to target different sites of the immune cascade at 
the same time.
Walsh13 showed that targeting the identified important factors inducing angiogenesis 
sets the problem of selectivity, since vascular growth is a normal mechanism in 
humans observed in tissue repair and female reproduction.
Chikanza6 drew attention to the fact that none of the existing treatments for RA can be 
considered to be curative and definitive therapies for the disease. Those reported are in 
development, and based on different strategies: T cell targeting, monocytes/ 
macrophages derived cytokines inhibition, adhesion molecule inhibition, antioxidant, 
free radical scavengers and NO production inhibition, bioreductive cytotoxic agents 
delivery, induction of immune tolerance (collagen therapy, subreum), inhibition of 
metalloproteinases, induction of apoptosis, hormonal immunomodulation.6,14
Although it is clear that targeting of cytokines and sites of the inflammatory cascade is 
an important mean of regulating RA, it is important to remember that cytokines are 
highly important in normal homeostasis. Selective blockade of disease-causing or 
potentiating cytokines could induce serious adverse effects.
One of the characteristics of the rheumatic joint that has been underlined several times 
so far is the presence of hypoxia15,16. This low oxygen concentration makes the tissues 
very different to oxic tissues from a physiological but also biological point of view 





17Hypoxia was first described and identified in solid tumours . Tumour cells proliferate 
more rapidly than their supporting vasculature. They also invade, compress, injure or 
obliterate blood vessels, leading to a permanently interrupted blood flow. Poor tumour 
vascularisation is thought to result in poor delivery of oxygen leading to the presence 
of chronically hypoxic tumour cells. A fraction of the hypoxic region is composed of 
transiently hypoxic cells, resulting from a temporary interruption of the blood flow 
that may last for seconds or minutes.10
Tumour venous and capillary vascular morphology and physiology are abnormal, as 
demonstrated by phenomena such as dilated and tortuous veins, sinusoids, 
arteriovenous shunting and vascular channels with incomplete vascular endothelium. 
Blood flow and red cell velocity are much lower than in normal tissues. The low blood 
flow is believed to be due to a vastly expanded venular and capillary network without 
a concomitant increase in arterial supply.18
In RA, the hypoxic nature was suggested originally on the basis of measurements of 
oxygen concentration within the inflamed cavity. The description of the physiological
ft 17and pathological events in tumours matches closely that of RA * . Synovial cells 
proliferate at a high rate to create this pannus membrane; angiogenesis is also 
accelerated but cannot keep pace with the rate of synovial thickening. Analysis of the 
capillary density showed it to be one third of that in normal synovium; the new blood 
vessels are distributed more deeply. The loss of highly organised vascular structure 
causes relatively less uniform perfusion through the tissue. Subsequent poor blood 
flow (blood occupies 2.9% of the volume of a normal joint but only 1.2% of that of a 
rheumatoid joint) aggravates hypoxia by diminishing the oxygen gradient out o f the 
vessels20. The oxygen gradient can be explained by the fact that cellular respiration 
depletes oxygen as it diffuses from blood vessels through packed layers of cells, with 
chronic hypoxia occurring at distances of 150-200 pm from capillaries, where almost 
all the oxygen has been used.20,21 In normal tissues, the oxygen concentration varies 
from 3.1% to 8.7% (oxygen partial pressure of 24 to 66 mm Hg) whereas 
concentrations measured in hypoxic tissue range from 1.3% to 3.9% (10 to 30 mm
i?
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Hg) ’ ’ . With sustained hypoxia, the capillaries become paralysed and lose their 
vasoactive responses. In addition to the hypoperfusion, mobility of the inflamed joint 
results in increased intra-articular pressure, exceeding the capillary perfusion pressure. 
Parts of the capillary bed are occluded, inducing acute ischaemia and hypoxia. The 
qualitative blood vessel abnormalities previously described also prevent tissue healing 
and induce persistent hypoxia6,12,15,16.
Many different techniques are available for the measurement of oxygen in tissues to 
assess hypoxia20. These include vascular density measurements, oxygen electrodes 
(most widely used and reliable), fibre optic biosensors, spectroscopic methods, 
bioreductive chemical probes (e.g. 2-nitroimidazoles) and intrinsic markers (e.g. 
proteins and mRNA)20. Expression of several glycolytic and respiratory enzymes and 
their mRNA is oxygen-dependent. In differentiating human myoblasts, hypoxia 
induces accumulation of RNA transcripts for glycolytic enzymes, such as pyruvate 
kinase and reduced levels of transcripts for enzymes used in oxidative energy 
metabolism20.
As well as having diminished oxygen concentrations, hypoxic cells develop 
physiological perturbations that alter their behaviour and characteristics17"22. Hypoxia 
can result in an accumulation of cells in G l, arrest cells at their cell cycle position or 
prolong cell cycle times. This reduction in cell division is one of the reasons why 
chemotherapy is relatively inefficient for treating hypoxic tissues. Energy metabolism 
will be perturbed and depletion of ATP levels is observed (anaerobic oxidation of
A L
glucose produces less ATP than the Krebs cycle and increased Ca concentration). 
RNA and protein synthesis will be decreased but specific stress proteins may be 
induced and synthesised.12,17,20,22 The concentration of cytolytic Ca2+ is increased, 
inducing decreased energy production, increased energy consumption by calcium- 
dependent ATP-ases, membrane lipid degradation and degradation of functional and 
structural proteins. The profile and activity of many enzyme systems will be altered, 
leading to numerous changes in cellular metabolism. Biochemical studies have shown 
that metabolism within the rheumatoid synovium is glycolytic (i.e. anaerobic); the 
activities of enzymes such as glyceraldehyde-3-phosphate dehydrogenase, glucose-6- 
phosphate dehydrogenase and lactate dehydrogenase will then increase. Redox 
imbalance is also detected, leading to the generation of reactive oxygen species
n
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(ROS), which damage important biomolecules, such as the polyunsaturated fatty acids 
of the cell membrane, DNA, carbohydrates and proteins12,17,20,22. Intracellular pH may 
fall (inefficient clearance of metabolic acids from chronically hypoxic cells can reduce 
the mean extracellular pH). Generally, a normally oxygenated cell will maintain a pH 
gradient across the cell membrane of approximately 0.5 pH units when exposed to an 
acidic extracellular environment.20As a result, the intracellular pH will be higher than 
the extracellular pH but may fall below the physiological value. Cells in severe 
hypoxia, however, may be unable to maintain this pH gradient across the cell 
membrane; in severely hypoxic cells, therefore, the intracellular pH may fall to match 
the pH of the extracellular milieu. 1217 20 22
These alterations in cell physiology will alter the ability of cells to tolerate and repair 
injury, inducing more severe hypoxia, and will also alter the ability of cells to 
transport, activate, and metabolise many therapeutic drugs. 12,17‘22
3. BIOREDUCTION AND BIOREDUCTIVE DRUGS
Bioreductive drugs are activated by metabolic reduction in tumour cells to form 
cytotoxins. The hypothesis that hypoxic cells were offering a more favourable 
environment to reductive reactions than were their normoxic counterparts was 
developed by Lin et al2A, based on observations made by Hewitt and Porter25,26 that 
anaerobic cultures of microbes had a lower half-wave reduction potential than did 
aerobic cultures. The growing cultures, under both aerobic and anaerobic conditions, 
became more hypoxic through crowding and their apparent redox potential became 
more negative. By analogy, hypoxic cells in solid tumours were suspected to exist in 
an environment facilitating reductive processes.
Bioreductive drugs exploit the presence of hypoxia in tumours, since oxygen (O2) can 
reverse the activating step by one-electron oxidation (futile cycling, Scheme 1), 
thereby greatly reducing drug activity in most normal tissues27'34. Selectivity in 
activation of bioreductive drugs by tumour cells can also depend on the level of 
expression, concentration and activity of the particular reductases for which a drug 
can act as a substrate. These include obligate two-electron reductases, such as DT-
14
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diaphorase, and one-electron flavoproteins, such as the various P450 isoenzymes,
97 7Qcytochrome P450 reductase, xanthine oxidase and xanthine dehydrogenase.
1 e' reduction
N N 0 2
r\
^ N ^ N O z*
R
Scheme 1: Example of futile cycling
The concentration or level of expression of these reductases seems to be often greater 
in tumours and hypoxic tissues than in normal tissues. However, differences 28,29 do 
exist in enzyme expression between tumour types.
Bioreductive drugs can be used in combination with either radiotherapy or with other 
chemotherapeutic agents. The drugs developed so far fall into several subgroups, 
including nitroheterocycles, aromatic N-oxides and various quinone-based compounds
(Figure 4) 30-35
o





Figure 4: Chemical structure of some redox-active compounds: diaziridinyl
benzoquinones (1), SR 4233 (tirapazamine 2), CB 1954 (3), RSU 1069 (4), 
AQ4N (5), mitomycin C (6).
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3.1 THE ACTIVATING ENZYMES.
Hypoxia and high level of specific reductive enzymes are the conditions that are 
needed for the bioreduction of a chosen bioreductive compound. The approach could 
be different; identifying the predominant enzymes in a type of hypoxic tissue could be 
the first step before choosing the appropriate bioreductive substrate. The enzyme 
systems involved in the metabolic activation pathways of quinones and 
nitroheterocycles include NADPH: cytochrome P450 reductase, NADPH: cytochrome 
bs reductase, NADPHiquinone oxidoreductase (NQOl, DT diaphorase), xanthine
0*7 i n  i c j i i
oxidase and xanthine dehydrogenase, amongst others. "
NADPH:cytochrome P450 reductase is widely distributed in human tissues and, 
although its main function is to reduce the various forms of the cytochrome P450, it is 
believed to play a key role in the reductive activation of certain toxic compounds. The 
activity of cytochrome P450 reductase in some tumours has been found to be 
significantly higher than in the normal tissue, and this has prompted extensive 
research on the synthesis of compounds which can be activated by this enzyme. 
Similarly, certain cell lines, which are resistant to drugs such as mitomycin C, show 
decreased levels of the enzyme. Cytochrome P450 and P450 reductase have been 
shown to reduce nitroimidazole, the first one to the nitro radical anion (1-electron 
reduction), P450 reductase is involved in the final stage, the amine formation.35
Studies3^ 43 on the role of the other one-electron reducing enzymes in the activation of 
compounds in tumour cells have brought interesting results. It has been shown that the 
conversion of xanthine dehydrogenase into xanthine oxidase occurs in hypoxic tissues 
(mechanism linked to ATP depletion). Anderson et a f l observed the conversion of 
xanthine dehydrogenase (XDH) to xanthine oxidase (XO) in two tumour types during 
prolonged clamping off of the blood supply to the studied tissue. It was suggested that 
the same phenomenon could occur naturally in chronically hypoxic cell, making it a 
potential marker for hypoxia. Under ischaemic conditions, depletion of ATP occurs 
producing hypoxanthine, which is a substrate for XDH and XO, making the two 
mechanisms closely linked.41
i  1 6II
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Two-electron reduction can be catalysed by the NAD(P)H:(quinone acceptor) 
oxidoreductase (quinone reductase, DT-diaphorase) ’ * ’ . There is evidence that the 
levels of this enzyme are increased in some tumours. It is believed that the two- 
electron reduction of a compound is a protective mechanism. This is because 
extensive studies with simple quinones, such as menadione, have shown that 
inhibition o f the diaphorase system potentiates the cytotoxicity of the quinones. It is 
shown that, by removing the quinone via the two-electron reaction, less quinone is 
available for the more damaging one-electron reaction (because of the subsequent 
production of superoxide radicals) or for the quinone-mediated depletion of 
intracellular thiols38,39.
Q + 2 RSH -------- ► QH2 - RSSR (Equation 1)
There are several other examples in which the diaphorases can be instrumental in 
preventing the potential mutagenicity or carcinogenicity of different compounds. 
However, studies38,39,44 have shown that some compounds which can undergo 
reaction, such as mitomycin C and AZQ (diaziquone, 1, Ri = R2 = NHCOOCH2CH3), 
can be activated by diaphorases to form cytotoxic species.
Further complications can arise when compounds which have the capacity to be 
reduced by the one-electron reducing enzymes, come into equilibrium with the two- 
electron reduced form.
D~ + D~ D2' + D {Equation 2)
Even in situations where equilibrium is favoured towards the right-hand side, free 
radicals could be produced during the aerobic oxidation of the D ' forms.
D2' + 0 2 + 2H* -------- ► D + H2O2  {Equation 3)
In general, the rate of aerobic oxidation of the two-electron reduced species, in the 
absence of suitable catalysts, is much slower than that for one-electron reduced
17
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species but the overall net reaction can be accelerated for some hydroquinones by 
superoxide dismutase as observed by Cadenas et al36.
Bioreductives can therefore undergo interrelated one-electron or two-electron
AQ
reductions ’ . The question arises as to which enzyme process within a cell type will 
dominate for a particular drug. The relative activities o f the different enzymes and the 
availability of their co-factors is a major consideration. This approach has led to 
suggestions that the relative enzyme activities in the hypoxic tissues of individual 
patients should be determined even before the start of drug treatment.
3.2 M it o m y c in  C
Mitomycin C is a clinically important antibiotic and antitumour agent isolated from 
Streptomyces caespitous. This quinone-based alkylating agent, functions by inhibiting 
DNA replication. It contains, in addition to a fused aziridine ring, two potentially 
reactive centres, a CIO carbamate moiety and a para-quinone44. MMC was shown to 
exhibit hypoxia selectivity.44 FR900482 possesses the same carbon framework as 
MMC. Isolated from Streptomyces sandaensis, it is also known as an antitumour 
antibiotic acting by DNA bis-alkylation.45
NH
m OCONH2
Figure 5: Structure of mitomycin C (6) and natural product antitumour antibiotic 
FR900482 (7).
MMC (Figure 5) requires reductive activation, as does FR900482, but the 
mechanisms of activation leading to the active intermediate (structurally similar 7- 
aminoleucoaziridinomitosene) responsible for DNA alkylation are different.46
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Detailed structures of the major MMC-DNA adducts (mono- and bi-functional) have 
been elucidated. The main covalent binding sites are at the aziridine C-l and the 
carbamate C-10 positions, which link with guanine at the N-2 positions in CG-GC rich 
regions (Figure 6).44^ 9





Figure 6: The structure (8) proposed44,47 for the DNA-mitomycin C-DNA cross-link, 
showing the links between C-l of mitomycin C and N-2 of guanine and 
between C-10 of mitomycin C and N-2 of guanine’.
Structure-activity studies on the toxicity of a number of mitomycin analogues towards 
human tumour cell lines have shown a significant correlation between the reduction 
potentials of the analogues and their cytotoxicity44. It has long been assumed that 
MMC was only activated by the one-electron reducing enzymes such as cytochrome 
P450 reductase or xanthine oxidase (one-electron reduction potential Elf. -310 mV). 
The resulting semiquinone radical is unstable in air, presumably implying great 
hypoxia selectivity, but it was observed that the toxicity of MMC semiquinone radical 
towards hypoxic cells was also accompanied by a relative degree of toxicity towards 
oxic cells.44
It is now believed that the covalent binding of MMC to DNA occurs through the two- 
electron-reduced form, which can be produced by one- or two-electron systems. It has 
been shown that MMC can be activated to the cytotoxic form by DT-diaphorases in 
the presence of oxygen and the cytotoxicity can be related to the activity of the 
diaphorase in cell lines. The proposed mechanism is that the MMC binds to the 
enzyme and undergoes a specific two-electron reduction to the active form of the drug
IQ
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which can then interact with DNA. Intracellularly, these processes would have to take 














Scheme 2: Proposed activation mechanism of mitomycin C.47
3.3 M it o m y c in  C a n a l o g u e s .
The strong interest in the antitumour potential of the indoledione class of 
bioreductively activated cytotoxic drugs has led to the synthesis of a large number of 
MMC analogues50"64. Compounds of note include the diols E09 and E07, of which 








Related mitosenes (MMC analogues with an aromatic 5-membered ring, Figure 7) 
also show much improved properties over the naturally occurring mitosanes (non- 
aromatic 5-membered ring) such as MMC and many analogues have been produced 
over the past 20 years52,53. >
3.3.1 Cyclopropamitosenes
In recent years, other classes of indolediones, such as the mitosene-based 
cyclopropamitosenes53'56 and the non-fiised cyclopropylindolediones, have also been 
developed and these compounds have also emerged as highly potent compounds, the 
latter showing efficacy in animal tumours. The earlier cyclopropamitosenes resembled 
the MMC structure (Figure 8) but the latter compounds also had features that were 
similar to E09, namely the 5-aziridinyl substituents and the 3-hydroxymethyl group 
(Figure 10)57. It was suggested54 that the cyclopropyl ring at the C-2 position may be 
opened through the activation mechanism (utilising one-electron reductases) and that 
this might be involved in the enhanced hypoxic cytotoxicity observed. This has now 
been further explored.58,59
R =H
12 CH2OH 13 CH2OCONH2
CH2OCONH2
Figure 8: Cyclopropamitosene derivatives.
3.3.2 Other mitosenes.
A wide range of mitosenes based on the MMC substructure have been synthesised by 
many groups60-64. Mitosenes possessing at least one good leaving group at the C-l 
and/or the C-10 position showed greater toxicity than MMC. Other analogues have 
been synthesised which possessed poor leaving groups and, here, only low activity
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was observed (Figure 9)53'54 Under hypoxic conditions, the toxicity of the mitosenes 
in V79 cells was increased, as compared with aerobic toxicity. DNA cross-linking 
experiments demonstrated the need for efficient leaving group at positions activated 
by reduction. The penetration of these compounds into the tumour cell (related to 
lipophilicity) seems to be a more important factor than structural variation, although 
the absolute configuration of the C-l of some of the synthetic chiral mitosenes, 
appeared to be important for enzymatic reduction and DNA cross-linking.
R1
o c h 3 R1 = H R2 = H R3 = CH3
o c h 3 o c o c h 3 o c o c h 3 c h 3
Az o c o c h 3 o c o c h 3 c h 3
o c h 3 H o c o n h 2 H
Az H o c o n h 2 H
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Figure 9: Mitosene derivatives.
3.3.3 E09 and analogues.
Analogues of E09 and their regioisomers have been synthesised in order to 
investigate the relative contributions of substituents at the C-2, C-3 and C-5 positions 
of the indole ring with respect to the cytotoxic effects (Figure 10). Replacement of the 
5-aziridinyl with a methoxy moiety (E07) showed a marked loss of potency under 
both aerobic and hypoxic conditions. Replacement of the 5-aziridinyl with a 2- 
methylaziridinyl moiety showed a slight loss of potency overall but more so under 
aerobic conditions; further reductions were observed with greater aziridine 
substitution50. These compounds were also highly hypoxia-selective agents but were 
less potent than E 0957. Removal of the C-2 substituent of E09 resulted in a 
compound that showed similar potency under both aerobic and hypoxic conditions. 
When the C-3 was removed, a loss of potency was observed. As a result of this study, 
it was suggested that the aziridinyl substituent was the predominant factor in 
producing the observed cytotoxicity, followed by the C-3 hydroxymethyl group, 
which was thought to be involved in alkylating processes. Replacement of the 5- 
aziridine group with 2-methylaziridine gave a compound (E08) with a greater 
hypoxic cytotoxicity ratio (HCR), which was accredited to its lesser aerobic potency
Introduction
(due to the fact that E08 is a poorer substrate for DT diaphorase than E09), rather
c7
than hypoxic toxicity, in both rodent and human cell lines .
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Figure 10: E09 analogues.
Other indoledione analogues similar to E09 have been synthesised in which the C-2 
position was substituted with various alkyl groups50. With the exception of E09, a 
trend was observed in which increasing bulkiness at the C-2 position resulted in a 
decrease of both aerobic and hypoxic potency (Figure 11). This indicated either that 
the incoming DNA (or other nucleophilic species) at the C-3 position was hindered or 
that reductase enzyme specificity was being altered. Bulky C-2 substituents may also 
influence the ease of formation of the iminium species, in which the 3-indolyl CH2 
must become sp hybridised and achieve planarity. The straight alkyl side-chain of 
E 09 may have a lesser effect in this respect. However, the potency of E09 suggests 
that other processes must be involved in enhancing its hypoxic cytotoxicity, such as 








Figure 11: Indoledione derivatives.
Recently, a series of 2-alkyl and 2-cycloalkyl indolediones has been evaluated50 as 
bioreductively activated cytotoxins that show in vivo activity against solid tumours 




Of particular importance is the potential for 3-indolyl carbinyl substituents in 
derivatives of (11) to undergo a “retro-Michael” elimination process upon reductive 
activation, through the participation of the 1-nitrogen lone pair of electrons which are 
deactivated in the quinone parent prodrug (Scheme 3). The resulting iminium species, 
distinct from the quinone methide generated by simpler quinones, is then a potential 
cytotoxic species via DNA-alkylation or other critical biomolecules, or other cell- 
damaging species. These compounds have the potential to release a variety of drugs in 
a reductive environment, and may thus be designed to give a secondary effect in 
addition to the cytotoxic iminium derivative formed.
This process is rendered possible because of the conjugation between the lone pair of 
electrons on the nitrogen atom, the double bond on the aromatic 6-membered ring and 




Scheme 3: Reductive activation pathways for indolediones leading to elimination of 
leaving group and trapping of the resulting iminium intermediate.
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3.4 N it r o im id a zo le s .
A second category of bioreductive agent is that of the nitro(hetero)arenes, the 
prototypes of which are misonidazole and metronidazole (Figure 12). This categoiy 
of compounds arose from the group of agents known as radiosensitisers. The 
neurological toxicity of misonidazole and other nitroimidazoles limit their clinical 
effectiveness, therefore, new agents are being produced which maintain this hypoxic 
cell toxicity and exhibit decreased neurotoxicity.
It has been recognised for several years that most of the biological properties of 
nitroheterocyclic compounds are determined by their ease of reduction. The 
nitroimidazoles were originally investigated for their ability to act as radiosensitisers 
in hypoxic cells. However more recent studies have shown that some of these
O ft “5 0  z c  Z 7








Figure 12: Structures of misonidazole (17) and metronidazole (18).
When nitroimidazoles are incubated with anaerobic cell extracts, nitro radical anions 
(RNO2') can be produced32. In normoxic cells, these radicals are normally reoxidised 
to the parent drug in the presence of oxygen due to the equilibrium :
D~ + 0 2 ^  ■w D + O f  (Equation 4)
However, in the absence of oxygen, the nitro radical can dismutate to form DNA 
damaging species:
D ~ + D ~ ^ ------~  D2' + D (Equation 2)
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Further reduction leads to the generation of intermediate metabolites and to the amine 































Scheme 4: Proposed reduction scheme of 2-nitroimidazoles.
RSU 1069 (Figure 1) showed many improved properties, compared to misonidazole, 
and has been widely studied. Many other analogues are being produced to improve the 
selectivity and cytotoxicity of the nitroimidazoles.68
3.5 N it r o h e t e r o c y c u c  trigg ers .
Much effort has been expended on development of radiosensitisers with electron 
affinity and bioreductively activated cytotoxins for selective therapy of hypoxic tissue, 
and of a variety of prodrugs to deliver cytotoxins selectively to tumours. Substituted
2-nitroimidazoles are known to be selectively retained in hypoxic tissue by reductive 
metabolism66. The exploitation of the physiological difference in concentration of 
molecular oxygen between normal and hypoxic tissue leads to the design of 
biologically inactive prodrug systems which upon selective bioreduction in hypoxic 
tissue would release known therapeutic drugs only in that tissue.
76
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Bioreductively triggered release systems based on 2-nitroarylamines and 4- 
nitrobenzyloxycarbonyl prodrugs have been reported, and reductive elimination of 
leaving groups have been studied involving 2-, 4- and 5-nitroimidazoles, 5- 
nitrofurans, 5-nitropyrrole and nitrobenzene.
Extensive work on nitrobenzyl systems for cancer therapy has been reported. 
Substance such as nitrobenzyl quaternary salts and nitrobenzyl mustards gave 
encouraging results69'74. Those mustard-based hypoxia-selective cytotoxins (HSC) 
were designed following the same pattern. They consisted of a trigger unit (hypoxia 
selective (oxygen-sensitive) and undergoing the reductive process), an effector 
(activated following reduction of the trigger) and a linker which connects the two 
other domains and communicates the change (Figure 13).74
LINKERTRIGGER EFFECTOR
Figure 13: Denny’s concept for the design of anti-cancer prodrugs.74
Amongst other systems (nitro-deactivated aniline mustards, cobalt(IH) complexes of 
aliphatic mustards and nitrobenzyl quaternary mustards), nitrobenzyl quaternary 
mustards due to their ability to release a leaving group following one-electron 
reduction, seemed to have the quality required to be used for the design of HSCs.69 76
Nitrobenzyl radicals, resulting from the fragmentation of nitrobenzyl halides, proved 
to be cytotoxic, nearly equally to both oxic and hypoxic cells. In the case of 
nitrobenzyl quaternary salts, hypoxia selectivity was improved and less toxicity was 
attributed to the more stable benzyl radical. Studies on nitrophenyl quaternary 
mustards (Scheme 5) also permitted to identify some important physicochemical 
properties influencing the efficiency of the HSCs. Aqueous solubility and one-electron 





Scheme 5: Reductive fragmentation of a typical nitrobenzyl quaternary mustard.
The one-electron reduction potential (E1?) of nitro aromatics, and most bioreductive 
compounds should be within the range -250 to -500 mV for selective enzyme- 
catalysed reduction to take place. Aqueous solubility can be influenced by the 
introduction of acidic or basic groups. The introduction of basic functionalities 
(cationic charges) induced an increased potency of some bioreductive drugs in cell 
cultures together with improved solubility. Positively charged compounds (Scheme 5) 
gave poor biological results. The lack of activity in vivo could be due to the trapping 
effect of low pH cellular organelles or to the reversible DNA binding also observed 
for positively charged compounds. In both cases, the decreased concentration of free 
drug reduced the rate of passive diffusion through the tissues to the site of activation. 
The introduction of anionic groups (weak acids) ensured a better cellular uptake in 
low pH environment.
Following these results, 4-nitrobenzyl carbamate prodrugs were produced for gene- 
directed enzyme prodrug therapy (GDEPT)31 and antibody-directed enzyme prodrug 
therapy (ADEPT)31. This concept involves the use of tumour-specific endogenous 
enzymes, which are capable of activating bioreductive drugs, by deliberately 
introducing foreign enzymes into the cell population. ADEPT implies the use of 
tumour-specific antibodies in order to locate the foreign enzyme; in the case of 
GDEPT a foreign gene is used in order to generate the enzyme selectively. 
Assessment in vitro showed release of the drug moiety. Activation of the nitro group 
occurred via the conjugated effect of an oxygen-insensitive nitroreductase (NTR, from 







Scheme 6: Reduction of nitrobenzyl carbamate by NTR.
A number of 4-nitrobenzylcarbonyl derivatives including actinomycin D, mitomycin 
C, an endiyne, amino-seco-cyclopropylindoline derivatives and tallimustine analogues 
have been shown to be substrates for the enzyme, but with a different degree of 
activation, pH and leaving group effect did influence the rate of release of the 
effector.72,77'79
In the family of the 5-membered-ring nitroheterocycles, 2-nitroimidazole is amongst 
the most studied. 2-Nitroimidazole derivatives are used and studied for many cancer 
related therapeutic purposes but mainly for radiotherapy and as hypoxia markers. 
Their redox potential is very favourable for potential bioreductive activation by 
endogenous enzymes (ES = -389 mV for l-alkyl-2-nitroimidazole)80. A number of 2- 
nitroimidazole-derived prodrugs have been synthesised.
Hay et a/81 reported the synthesis and evaluation of a 2-nitroimidazole carbamate 
prodrug of amino-seco-CBI-TMI for use in ADEPT and GDEPT. The reduction of the 
prodrug using a nitroreductase from Escherichia coli B in conjunction with NADH or 
NADPH showed the release of the amine effector, together with good hypoxia 
selectivity and cytotoxicity on two different cell lines.
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Everett et a t 1 used 2-nitroimidazole to generate a series of prodrugs using aspirin or 
salicylic acid as the effector moiety. The drug counterpart was linked through the 
(imidazol-5-yl)methyl position of the trigger unit. Release of the effector drugs was 
observed after activation by CO2 , a model one-electron reductant generated 
radiolytically. The prodrugs exhibited improved water solubility compared to 
quinone-based prodrugs, partiy due to the substitution at the imidazol-l-yl position. 
Studies showed that the release of the drug moiety occurred after 4-electron reduction, 
leading to the hydroxylamine derivative80'82.The rate of drug release was still slower 





Scheme 7: Proposed mechanism for the elimination of aspirin from the bioreduction 
of the 2-nitroimidazole prodrug.82
Parveen et alm used a similar prodrug system for the release of 5- 
bromoisoquinolinone, a PARP inhibitor. The secondary amide of the isoquinolinone 
moiety, main site for activity, was masked by 2-nitroimidazol-5-ylmethyl. The 
chemical reduction of the nitroimidazole to the amine created an increase in electron 
density of the 7i-system, resulting in the expulsion of the drug moiety.
5-Nitrofurans have a relatively high redox potential which makes them more favoured 
for bioreductive activation (E^ = -325mV for 2-methyl-5-nitro-N-(prop-2-enyl)furan-
3-carboxamide) than 2-nitroimidazole; they are activated by enzymes such as 
cytochrome P450 reductase83'85. Compounds with a one-electron reduction potential 
closer to the redox potential of oxygen (-180 mV) are more likely to gain an electron 
and are therefore more oxidising. They are consequently less hypoxia-selective and
in
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are often more toxic. On the other hand, compounds with more negative ES are less 
oxidising and less likely to gain an electron (Scheme 8).
Bioreduction




Scheme 8: Proposed mechanism for the bioreductively triggered release of drugs from 
nitrofuranylmethyl prodrugs.83-85
Naylor et a f 5 synthesised a series of nitrofurancarboxamides which were evaluated as 
radiosensitisers and bioreductively activated cytotoxins but showed poor hypoxia 
selectivity and increased toxicity. The carboxamide side chain in these prodrugs was 
described as influencing the redox potential markedly. Compounds with a one- 
electron reduction potential, E1? = -335 mV, i.e. slightly lower, showed increased 
hypoxia selectivity.
Nitrofurans were used as the trigger unit by Berry et a/83. A 5-nitrofuranyl-2- 
methylene was linked directly to the 2-position of isoquinolinone and through a 
carbamate to a carboranylpropylamine. Biomimetic reduction of the nitro group 
initiated the expulsion of the isoquinolinone drug moiety (Scheme 9) and of the 







Scheme 9: Reductively activated release of isoquinolinone from nitrofuran based 
prodrug83.
Mahmud et a f A reported the preparation of a nitrofuran-based prodrug obtained from 
the condensation of 5-nitrofuran-2-carboxaldehyde with two different diols, giving the 
corresponding cyclic nitrofuranyl acetals. Biomimetic reduction of these prodrugs 
with sodium borohydride and palladium on carbon induced the release of the diols. 
Reduction of the nitro group was rapid (1 to 5 min) but the maximum yield of diols 
was only obtained after an hour.
Nitrothiophene prodrugs were prepared and studied as 5-carboxamide derivatives 
bearing N-(a)-aminoalkyl) side chains, designed to be evaluated as radiosensitisers and 
potential bioreductively activated cytotoxins86. The difference in one-electron 
reduction potential between the 2- and 3-nitrothiophene derivatives was of 200 to 
250 mV, the 2-nitro being more oxidising (ES = -271mV). Their in vitro potency as 
radiosensitisers was greater than that observed for misonidazole and 2-nitroimidazole 
derivatives. The neurotoxicity and lack of hypoxia selectivity of the compounds was 
attributed to the influence of the side chain.
The results obtained for the nitrobenzyl prodrugs, but especially for the 2- 
nitroimidazole and 2-nitrofuran prodrugs suggested the interesting potential of 
nitrothiophene to act as a bioreductive delivery tool. With a more negative ES than 





The toxicity of the aminofuran moiety resulting from the reduction of the prodrugs 
synthesised by Berry et a/83 has not been yet evaluated87.
Bioreduction




Scheme 10: Speculative scheme of eventual bioreductively triggered release of drugs 
from nitrothienylmethyl prodrugs.
4. DRUGS FOR DELIVERY IN RHEUMATOID ARTHRITIS
4.1 PARP INHIBITORS.
Poly(ADP ribose) polymerase (PARP) is a nuclear enzyme which is activated by 
single DNA strand breaks (The enzyme N terminus has two zinc finger motifs which 
bind to the cleaved DNA chain). It then binds NAD+ (P-nicotinamide-adenine 
dinucleotide), via C-terminal domain and catalyses the synthesis of poly(ADP)ribose. 
A side product of this process is nicotinamide, which has been recognised as an 
inhibitor of PARP (studies have shown that this inhibition is weak and non-specific). 
Extensive DNA damage leads to over stimulation of PARP, which results in depletion 
of the “cellular energy currency” molecules NAD+ and ATP and to cell death. This is 
known as the “suicidal hypothesis” and ensures that no unwanted mutations arise.88
PARP is then thought to play an important role in maintaining genomic integrity and 
facilitate chromatin structural changes during DNA repair. It somehow influences 
gene expression, DNA replication, rearrangement, differentiation and mutagenesis. 
Isoforms of the enzyme have been discovered with similar catalytic domains. The 
exact functions of PARP are still unclear but the study of different classes of the
oo





Reactive oxygen species (ROS), such as superoxide, hydroxyl radicals and hydrogen 
peroxide have shown to be important inducers of PARP activity. Inflammation and 
rheumatic diseases exhibit cellular redox imbalance and hyperactive immunity which 
trigger increased levels of ROS and nitric oxide. Injuries in RA caused by 
hypoxia/reperfusion sequences induce high levels of PARP. Studies on PARP knock­
out rodents with induced hypoxia or ischaemia (where ROS are shown to be present 
and cause tissue damage) presented decreased tissue damage.
An investigation of the role of PARP in rheumatoid arthritis was carried out by Miesel 
et a f 9 RA was induced in rodents by using K3C1O 8. The in vivo decay of the 
potassium peroxochromate to superoxide, singlet oxygen, hydroxyl radicals, hydrogen 
peroxide and C rO /' caused chronic inflammation and arthritis, mainly by depletion of 
intra- and extracellular antioxidants and conjugated inhibition of the main anti­
oxidases, such as superoxide dismutase. Nicotinamide 29, one o f the first substances 
tested for PARP inhibition88, was selected as the inhibitor to determine the anti- 
arthritic activity. It proved to reduce K^CrOg-induced RA by 35% in rodents and 
inhibited the phagocytic generation of ROS. Nicotinamide and 3-aminobenzamide, 
another type of PARP inhibitors, were shown to decrease TNFa-mediated cytotoxicity 
which triggered the reduction of ROS production (TNFa influences NADPH oxidases 
leading to the increased production of ROS)88,89. Other inhibitors were developed to 
give more potent substances against ROS, such as GPI 6150, (l,llb-dihydro- 
p/Zjbenzopyranof^^-^ejisoquinolin^-one)90. This substance proved to be potent 
against PARP in models of focal cerebral ischaemia, traumatic brain injury, regional 
myocardial ischaemia, streptozotocin-induced diabetes, septic shock and arthritis. GPI 
6150 was reported to protect a specific cell line against hydrogen peroxide-induced 
cytotoxicity by preventing PARP activation and depletion of its substrate, NAD+. No 
side effects, such as impairment of repair and expression of damaged DNA, were 
reported. The substance exhibited low potency towards mono-ADP-ribosyltransferase 
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Figure 14: Structures of PARP inhibitors mimicking the nicotinamide moiety of the 
substrate: nicotinamide, 3-aminobenzamide, 3,4-dihydroisoquinolin-l- 
ones, 2,8-disubstituted quinazolin-4-ones, benzoxazole-4-carboxamides 
and benzimidazole-4-carboxamides91'94.
The results of these studies suggest the important role of PARP in the inflammatory 
cascade observed in RA. However, nicotinamide and 3-aminobenzamide (Figure 14) 
have been shown to be less potent than the more recently tested substituted 
isoquinolin-l-ones. Suto et a t1 and Watson et a f z reported the synthesis and 
evaluation of 5-substituted isoquinolin-l-ones, namely 5-bromo and 5- 
iodoisoquinolinone. Their potency against PARP was superior to that of the 3- 
substituted benzamide family in vitro. Another member of the isoquinolinone family, 
5-aminoisoquinolinone, reported by McDonald et a f A showed high activity for PARP 
inhibition in human cardiac myoblasts. It also diminished the multiple organ injury 
and dysfunction caused by severe haemorrhage and resuscitation (which in turn 
caused tissue ischaemia, ROS and NO production, DNA damage and PARP 
activation)94,95.
R
Figure 15: Structure of 5-aminoisoquinolin-l-one, 5-iodoisoquinolin-l-one, 5- 
bromoisoquinolin-1 -one.




The interesting results given by 5-substituted isoquinolin-l-ones, together with the 
evidence that PARP inhibition reduces inflammatory conditions observed in RA, 
justify the choice of compounds 33,34 and 35 as drug moieties for the present study.
4.2 Gl u c o c o r tic o id s .
This category of drugs has now been used for 50 years in the treatment of rheumatic 
diseases. Their profound anti-inflammatory activity is balanced by their serious risk of 
side-effects in the long term.
They exhibit complex anti-inflammatory and immunomodulatory effects. They inhibit 
migration of leucocytes to sites of inflammation and interfere with the function of 
leucocytes, endothelial cells and fibroblasts. They suppress production and release of 
factors involved in the inflammatory response such as cytokines, prostaglandins and 
leukotrienes. Although the effect of corticosteroids is mainly inhibitory, they also 
























Table 2: Cytokines and anti-inflammatory factors induced or inhibited by 
corticosteroids.
The side effects observed when using corticosteroids can be explained from the fact 
that most cells in all the different types of tissue in the body possess specific receptor 
for corticosteroids known as glucocorticoid receptors (GR). The glucose and lipid 
metabolism are affected as well as the skeletal tissues, CNS, renal, immune and 
cardiovascular systems. This is illustrated by phenomena of hyperglycaemia, weight 
gain, depression, psychosis, osteoporosis, hypertension, skin disorders, glaucoma, 
cataracts, oedema, thromobosis, gastrointestinal disorders, hypersusceptibility to
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infection and many others. The mechanism of action of glucocorticoids can give rise 
to transcription or repression of the targeted gene2,4,5.
The glucocorticoid binds to an intracellular receptor (GR) which controls gene 
expression by hormone dependant regulation of transcription. This regulation can be 
positive or negative. Since steroids are highly lipophilic, they cross the cell membrane 
easily to reach the receptor (cell membrane binding sites have been described and are 
thought to be involved in transport). The activated receptor then binds to a specific 
region of DNA called HRE (hormone response element) to regulate the transcription 
of adjacent genes. Activation of the receptor via hormone binding triggered a 
conformational change of the receptor that allows it to regulate transcription. The 
activated hormone-receptor complex translocates from the cytosol to the nucleus and 
binds to DNA in a dimeric form (Figure 16).2,4,5
The HRE is normally upstream from the promoter of the target gene; binding of the 
activated complex to the HRE either stabilises (positive regulation) or interferes 
(negative regulation) with binding to the accessory transcription factor. This step is 
essential for RNA polymerase II to bind tightly to the promoter and initiate 
transcription. The receptor is made of a single polypeptide chain containing two 
highly conserved regions. The first one is the DNA binding region; it is cysteine-rich 
and has two zinc binding fingers for HRE specificity. The second is the carboxy- 
terminal portion, which contains the hormone-binding and dimerisation domains. The 
amino-terminal region and the area between the two conserved regions are not 
essential for DNA binding but may have an influence. However, these areas interact 
with the transcription factor and target the receptor to the nucleus.2,4,5
17
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Figure 16: Binding of the Hormone (H) causes translocation of the protein to the 
nucleus, dimerisation and formation of a complex of proteins at the 
promoter. Members of the steroid receptor family bind to DNA at the 
HRE (Hormone Response Element) and facilitate or inhibit the formation 
of active transcription complex at the promoter.
Some of the corticosteroids commonly used for anti-inflammatory purposes are 
betamethasone, cortisone acetate, dexamethasone, hydrocortisone, methyl- 
prednisolone, prednisolone, prednisone etc. In rheumatoid arthritis, prednisolone is 
one of the most commonly used glucocorticoids. It has been shown to reduce the 
development and progression of erosion. However, it is still not known whether the 
potential benefits are maintained after treatment or if they are outweighed by long­
term side effects.2,4,5,96'98
Steroids are still not the therapy of choice in early disease. Their use depends on the 
severity of the disease. They are used for patients refractory to other treatments and 
for those who have low tolerance for NSAIDs. They are also used to induce remission 
in severe RA and maintain it until the delayed response of an eventual disease- 
modifying drug therapy started at the same time. Side effects for prednisolone have 





Figure 17: Structure of prednisolone.
Although other steroids are being developed to decrease those side effects, the 
potency of prednisolone still makes it the substance of choice for anti-inflammatory 
treatment in RA. If prednisolone could be delivered as an inactive prodrug to the site 
of inflammation and released specifically there, it is believed that the side effects due 
to this drug would be drastically reduced, making it a very powerful and efficient 
therapy for RA. These aspects motivated the choice of prednisolone as the second 
drug moiety for the present study.
Aim and Objectives
5. AIM AND OBJECTIVES
5.1 A im
MMC analogues exhibit an optimum “trapping” potential when hypoxia is profound 
and imidazole analogues are selectively retained in hypoxic tissue by reductive 
metabolism. This is believed to form the basis for their selectivity. Consequently, the 
idea is to use a bioreductive compound or carrier for the specific targeting of a drug to 
areas of hypoxic and/or ischaemic tissue, in which the desired drug species is linked to 
a non-cytotoxic counterpart.
The method proposed would involve the synthesis of prodrugs capable of targeting 
drugs to sites of inflammation within the body associated with hypoxia and/or 
ischaemia, e.g. to the synovium in the treatment of rheumatoid arthritis. This method 
not only has the effect of reducing the risk of systemic side effects of the drug but also 
enhances the therapeutic effect of the drug "*101. The bioreductive prodrugs have to be 
substantially stable in an oxygenated environment, but under hypoxic conditions, 
reductive activation occurs. The therapeutic agent is then released from the 
bioreductive moiety.
Some redox drugs have already been used in the past to act as trigger moieties for 
drug delivery systems. However, after delivery of the drug, that is to say after 
activation of the prodrug, the bioreductive moiety is often converted to a cytotoxic 
species80'83,102,103. Providing a nucleophilic centre within the bioreductive compound 
itself may reduce the cytotoxicity of the bioreductive moiety. Following release of the 
drug, an alkylating centre is formed However, the proximity of a nucleophilic centre 
would ensure that intramolecular alkylation occurs in preference to alkylation of any 
biomolecules such as DNA. In this way, substantially no cytotoxic species would be 
formed. Such systems are said to be “self-alkylating”. Alternatively, the bioreductive 
compound may be rendered non-cytotoxic following drug delivery by means of the 
introduction of steric hindrance preventing nucleophilic attack at the newly formed 
reactive centre. This is achieved by the presence of a bulky group either at or in close 
proximity to any potential alkylating centre generated after drug release.
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Aim and Objectives
5.2 Ob je c t iv e s
In the present study, it was proposed to synthesise two series of agents with potential 
as prodrugs; a first series being based on an indoledione trigger, the second on a 5- 
nitro-2-thienylmethyl trigger. The drugs moieties selected were prednisolone, 
isoquinolinone and its 5-iodo and 5-bromo analogues, and aspirin.
c h 3
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Figure 18: Proposed prodrugs with an indoledione trigger and prednisolone or 
isoquinolin-l-one effectors and with a 5-nitro-2-thienylmethyl trigger 
and prednisolone, isoquinolin-l-one or aspirin effectors.
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Aim and Objectives
The two series of prodrugs were designed to be tested for drug release under reductive 
conditions. Chemical reductive systems were to be investigated to bring evidence for 
drug release after the chemical reduction of the paraquinone and of the nitro group, 
motifs which are known to be bioreduced in vivo24'21 The potential drug release was 




6 .1 ,2-DIM ETHYU-(H YDROX YMETH YL)-5-METHOX Y- 
INDOLE-4*7-DIONE TRIGGER.
The first synthetic target was 21-0-(l,2-dimethyl-4,7-dioxo-5-methoxyindol-3- 
ylmethyl)prednisolone (37). Composed of an indole-4,7-dione trigger, namely 1,2- 
dimethyl-3-(hydroxymethyl)-5-methoxyindole-4,7-dione (11), and of prednisolone, 
the retrosynthetic analysis was, at first, fairly simple and convergent. The two subunits 
could be treated separately and linked in the final stage of the synthetic pathway. The 
drug moiety was commercially available and the trigger chosen, for the first part of 
the present study, was a known substance for which chemical routes had been 
previously designed50,52. Prednisolone could be linked to the trigger parent compound 
by nucleophilic substitution at the chloromethyl group attached at position 3 of the 
indole nucleus.
c h 3
Figure 19: Structure of the first synthetic target compound 37.
The synthesis of the trigger, although previously reported51, proved to be more 
complicated than was expected. The instability and poor reactivity of some 
intermediates decreased the reported yields significantly51. Investigation of other 
existing routes was required50. The unreactivity of prednisolone with the indole trigger 
in basic media required a change in strategy and the introduction o f a linker.
Results and Discussion
The synthesis of E09 analogue indolediones has been investigated in the past, but 
recent studies have outlined some new chemical pathways. Naylor et a l50,5'proposed a 
first chemical route to l,2-dimethyl-3-(hydroxymethyl)-5-methoxyindole-4,7-dione 
(Figure 20)50, soon complemented by an updated method, leading to the same target 
in an improved overall yield.51
OH
11
Figure 20: Structure of l,2-dimethyl-3-(hydroxymethyl)-5-methoxyindole-4,7-dione.
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As discussed in part 3.3, previous studies ' * have highlighted the mechanistic 
importance of indole-4,7-dione-based triggers. Upon reductive activation, 3-indolyl 
carbinyl in derivatives of 11 potentially undergo a “retro-Michael” elimination 
(Scheme 3) generating a potential alkylating agent.
However, substituents on indoledione-based analogues of E09 are shown to have a 
considerable importance on the redox potential, inducing or suppressing hypoxia 
selectivity, influencing cytotoxicity, substrate selectivity for the activating enzymes 
etc. According to the literature57, 11 would be characterised by a reduced potential 
toxicity due to the influence of the methoxy group at position 5 and the steric 
hindrance induced by the methyl group at position 2, and increased hypoxia selectivity 
from the influence of the hydroxymethyl substituent at position 3. Consequently, 11 
showed a high potential for the release of drugs in a reductive environment together 
with a reduced risk of genotoxicity.57
Results and Discussion
6.1 P r e p a r a t io n  o f  1 ,2 -d im e th y l-3 - (h y d r o x y m e th y l) -5 -m e th o x y -  
in d o le - 4 ,  7 -d io n e  (11)
There are a number of ways to synthesise compound 11. Naylor et al have developed 
three routes50,51. The choice of the method was based on the high yields published by 
Naylor et al51 in their latest chemical route to l l 51. However, some modifications 
proved to be necessaiy (Scheme 11).
54 55 11
Scheme 11: Synthetic pathway 1 to l,2-dimethyl-3-(hydroxymethyl)-5-methoxy- 
indole-4,7-dione 11. Reagents: i, KH, Mel, DMF; ii, HN03, AcOH; iii, Sn, HC1, 
H20 , EtOH; iv, (K 03S)2N 0, M e^O, NaH2P0 4 /Na2HP(VpH 6.0; v, Na2S20 4; vi, 
DffiAL-H then FeCl3; vii, LiAIKU, THF; viii, (K03S)2N 0, Me2CO, 
NaH2P04/Na2HP04/pH 6 .O.45
The starting material, ethyl 5-hydroxy-2-methylindole-3-carboxylate 48, was 
commercially available. Deprotonation and dimethylation using iodomethane afforded 
49 in 85% yield in the first step. Nitration of 49 using concentrated nitric acid in acetic
45
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acid gave a mixture of regioisomers 51 and 52 in 14% and 63% yield respectively. 
Increasing the reaction time gave the dinitro compound 50 in 80% yield. It is 
known 104 that indoles possessing electron-donating groups at position 1 and 2 and a 
strong electron-withdrawing group at position 3 (carbonyl) usually direct nitration at 
position 6 and eventually 4 in a lower yield. Substitution at position 3 of the pyrrole 
ring protects the benzene ring against oxidative attack and allows nitration to take 
place. The presence of the methoxy group at position 5 directs nitration to position 4 
preferentially. The 4-nitro group is not sufficiently deactivating (as an electron- 
withdrawing group) to prevent a second nitration (at position 6) at longer reaction 
times, affording 50.104
Reduction of 52 with tin powder in conc. aq. HC1 gave the aminoindole 53. This 
compound proved to be unstable, probably due to the presence of three relatively 
strong electron-donating groups. It was therefore used directly in the next step without 
further purification. After optimisation of the pH of the buffer required, compound 53 
was oxidised with Fremy’s salt to the paraquinone derivative 54. This method of 
oxidation, called the Teuber reaction, allows the oxidation of phenols to the 
corresponding quinone. Aromatic amines get similarly oxidised but the product 
formed depends on the structure of the starting amine: primary aromatic amines often 
undergo an oxidative condensation, secondary aromatic amines are oxidised to the 
quinone imines which are then hydrolysed to quinones. The transformation proceeds 
via a radical mechanism.105
The final step towards 11 was based on three consecutive reactions, first reduction of 
the quinone to the hydroquinone derivative using sodium dithionite, followed by the 
reduction of the ester with diisobutylaluminium hydride and work-up under air to 
ensure re-oxidation of the hydroquinone to the quinone 11. These three combined 
steps proved to be unreliable and led to the expected target on only one occasion, with 
a yield of 6.4%. The air-sensitivity of the intermediate hydroquinone-ester was 
postulated to be critical but no improvement was observed when the first two steps 
were carried out completely under inert atmosphere.
Efforts were then concentrated on the reduction of the ester using an alternative 
method. One role of the ester in the synthetic route was to increase the stability of the
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aromatic amine by withdrawing electron-density from the aromatic system and, 
possibly, by intramolecular hydrogen bonding; therefore, the reduction step was 
introduced after formation of the quinone. In the method used by Naylor et al51, the 
quinone was reduced to the hydroquinone before the ester was reduced. Hydrogen 
bonding between the 4-hydroxyl group on the hydroquinone and the oxygen of the 
carbonyl from the ester functional group was predicted to facilitate the reduction of 
the ester. Analogous reductions with sodium borohydride and with lithium aluminium 
hydride also failed to give the hydroxymethyl derivative, under a variety of 
conditions.
Since reduction of the ester had been unsuccessful, attempts were then made to 
hydrolyse or dealkylate the ester and subsequently reduce the carboxylic acid. The 
ester 54 was resistant to all attempts at hydrolysis under basic or acidic conditions.
Similarly, attempted dealkylations using chlorotrimethylsilane and sodium iodide in 
acetonitrile106, and aluminium bromide and tetrahydrothiophene107 also proved to be 
unsuccessful. It is reported that ethyl esters are amongst the most difficult esters to 
dealkylate106,107. However, although very strong conditions were used, no alteration of 
the molecule was observed.
The oxidation state of the substituent at position 3 was then considered. Its alteration 
for a group with a lower oxidation state but remaining a stabiliser of the amine would 
be an option to overcome the unreactivity of the ester.
The initial route to 11 designed by Naylor et al50 (Scheme 12) was similar to the one 
discussed above51 (Scheme 11) in the general strategy of building up the indoledione- 
based trigger. In this second route, the starting indole nucleus was only substituted at 
positions 2 and 5, and the one-carbon electron-withdrawing group at position 3 was 
introduced in the second step in the form of an aldehyde (lower oxidation state). In 
comparison to the route described above, the aldehyde derivative obtained after 
quinone formation was expected to be easier to reduce.
The yields of the intermediate steps were lower than for the previous method used but 














Scheme 12: Second synthetic pathway to l,2-dimethyl-3-(hydroxymethyl)-5- 
methoxy-indole-4,7-dione introducing a group with a lower oxidation 
level at position 3. Reagents: i, NaH, Mel, DMF; ii, DMF, POCl3 then NaOAc, 
H20; iii, fuming HNO3, AcOH; iv, Sn, HC1, H20 , EtOH; v, (K03S)2N 0, Me2CO, 
NaH2P0 4 /Na2HP(VpH 6.0; vi, NaBtt,, MeOH, Ar then air. 44
N-Methylation of the commercially available compound 57 in basic conditions in the 
presence of iodomethane gave 58 in high yield. Formylation of 58 was initially carried 
out by using phosphoryl chloride and N-methylformanilide. The Vilsmeier complex 
had to be formed before addition of the starting material and the yield obtained was 
low. The alternative one-pot reaction using DMF and phosphoryl chloride allowed the 
formation of the complex in situ, and gave a 10% yield improvement without increase 
in reaction time. Position 3 of the indole ring is known to be the most reactive towards 
electrophilic attack104. Substituents at this position also influence the reactivity of the 
fused benzene ring by influencing the electron density104. The aldehyde was identified 
as being a stabilising factor for the amine derivative but also as a directing factor for 
the preceding nitration reaction104.
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The nitration of 1,2 -di methy 1-5 -methoxyindol e-3 -carboxaldehyde was carried out in 
fuming nitric acid. Nitration was mostly directed at position 4 (60% yield) although 
the regioisomer was detected in negligible amount. Reduction of 60 to the amine, 
followed by oxidation to the paracjuinone, was achieved via the method previously 
described. The aldehyde of 62 was reduced with sodium borohydride to afford 1,2- 
dimethyl-3-hydroxymethyl-5-methoxyindole-4,7-dione 11 in 33% yield, with much 
starting material recovered.
The proton NMR data matched the structure of the compound. The signal for H-6 was 
observed as a singlet at 8 5.61 followed by four singlets in the aliphatic region 
assigned, respectively, to the methylene protons of the 3-hydroxymethyl group at 8 
4.65, the methoxy protons at 8 3.86, the N-methyl protons at 8 3.81 and the 2-methyl 
protons at 8 2.21.
This linear multi-step sequence gave 11 in low overall yield and was expensive in 
time and reagents. The small amounts that could be obtained limited the subsequent 
coupling reactions using 11.
In their improved route (Scheme 11), Naylor et a l 51 highlighted the possibility of 
reducing the ester in the 4-aminoindole 53, before the oxidation to the paraquinone. 
This sequence generated an intermediate which presented no stabilising group for the 
intermediate aromatic amine. However, investigation of this last route gave surprising 
results. Reduction of ester 53, using lithium aluminium hydride, afforded 4-amino-
l,2-dimethyl-3-(hydroxymethyl)-5-methoxyindole (56) in high yield. Interestingly, no 
signs of autoxidation of the amine were observed during the work-up but the 
intermediate 56 was used in the next step without further purification. Oxidation using 
Fremy’s salt gave 11 in 75% yield105.
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6.2 P o te n tial  p r o d r u g s  d e r iv e d  f r o m  1,2-d im e t h y l -3-(h yd ro x ym eth yl) -5 -  
m e t h o x y -in d o l e -4, 7-d io n e  a n d  p r e d n iso l o n e
The hydroxymethylindoledione 11 was the starting point of a wide variety of 
analogues used for studies on hypoxia selectivity and cytotoxicity50,51. Many of those 
were different from 11 by the nature of their substituent at position 3, implying a 
reasonable ease of reaction at this position of the molecule.
The first approach was to attach prednisolone to an electrophilic derivative of 1,2- 
dimethyl-3-hydroxymethyl-5-methoxyindole-4,7-dione bearing a leaving group at the
3-CH2, via a nucleophilic substitution. 3-(Chloromethyl)-l,2-dimethyl-5-methoxy- 
indole-4,7-dione 63 was chosen as the derivative of 11 to react with prednisolone in a 
basic medium. It was generated by treatment of 11 with thionyl chloride.
Sodium hydride was used to deprotonate prednisolone to generate the potentially 
nucleophilic 21-alkoxide species. Treatment of this alkoxide with 63 failed to give the 
expected conjugate 37, even in the presence of the nucleophilic catalyst, sodium 
iodide at various temperatures. Replacement of the base with potassium hydride, 
which was easier to handle, also failed to bring about the desired nucleophilic 
substitution. Similar experiments using stronger bases (lithium bis(trimethylsilyl)- 
amide and n-butyl lithium) under various conditions of time and temperature also 
failed. Since all of these bases are strong and will easily generate the alkoxide, it is 
possible either that the alkoxide is not sufficiently nucleophilic to react with the 
relatively weak electrophile in 63 or that the nucleophile is relatively hard and the 
electrophile is too soft.
An alternative target in which the prednisolone is linked to the indoledione through a 
carbonate was then investigated. Compound 11 decomposed on treatment with 
phosgene, rather than generating the corresponding chloroformate. Synthesis of the 4- 
nitrophenyl carbonate 64 of 11 was achieved by treating 11 with 4-nitrophenyl 
chloroformate under basic conditions. Treatment of this carbonate with the alkoxide of 




The poor reactivity was suspected to be the consequence of a lack of interaction 
between nucleophile and electrophile due to steric hindrance. The introduction of a 
linker under the form of a longer carbon chain was then considered. The commercially 
available prednisolone-21-hemisuccinate was selected. The hemisuccinate derivative 
is metabolised in vivo by esterases to prednisolone102, thus not altering the activity of 
the drug.
Denny et a l 101, in the context of the design of anticancer prodrugs for use in ADEPT 
and GDEPT (antibody-directed and gene-directed enzyme-prodrug therapies 
respectively), described the three elements that should compose a suitable prodrug: 
trigger-linker-effector. Each unit has to be clearly distinct and has a specific role. The 
trigger unit is characterised by its tumour selectivity and its selective activation by the 
appropriate enzyme, the released effector has to be potent and diffusible, the linker 
has to be a separate and distinct part of the prodrug or just a mechanism by which 
activation of the trigger leads in changes in the effector group. Although the present 
work is not included in ADEPT or GDEPT therapies, the prodrug design approach 
applies to the present study. The hemisuccinate moiety in this particular case matches 
the definition of the linker unit given by Denny et a l101.
To limit the number of influencing factors on the reaction, the sodium salt of 
prednisolone-21-hemisuccinate was used under basic conditions and reacted with 63 
under reflux (Scheme 13) to afford conjugate 65 in reasonable yield Evidence for the 
formation of the conjugate was obtained by ]H NMR. Shifting of the indole 3-CH2 
group signal from 8 4.86 to 8 5.16 was observed due to the more deshielding effect of 
the ester, compared to chlorine in the precursor. In CDCI3 and in DMSO, this CH2 
resonated as a singlet. In contrast, the spectrum run in CD3OD showed that the two 
methylene protons are diastereotopic (magnetically inequivalent), demonstrating that 
the indoledione unit was attached to a chiral molecule. Mass spectrometry and 








Scheme 13: Synthetic pathway to l-[(l,2-dimethyl-4,7-dioxo-5-methoxyindol-3- 
yl)methyl]-4-(prednisolon-21-yl) butanedioate. Reagents, i, SOCl2; ii, 
prednisolone-21-hemisuccinate sodium salt, THF, heat.
Carboxylates are softer nucleophiles than alkoxides. Using the softer carboxylate in 
prednisolone 21-hemisuccinate salt as the nucleophile, the synthesis of the first target 
65 was achieved, linking a compound, which can be bioreductively activated, to a 
steroidal drug moiety. The ester linkages present in the molecule constituted an 
interesting element to observe during the release studies.
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6.3 P o te n tial  p r o d r u g s  d e r iv e d  f r o m  1,2-d im e t h y l -3-(h yd ro x ym eth yl) -5 -  
METHOXY-INDOLE-4, 7-DIONE AND ISOQUINOUN-1-ONES / MELAMINES
6.3.1 Isoquinolin-l-ones.
5-Substituted isoquinolinones have been reported83,92'94’109,110 to be potent PARP 
inhibitors. PARP is an enzyme activated by DNA damage and catalyses its repair. 
Reactive oxygen species have been reported to be important inducers of PARP. As 
previously mentioned in chapter 1, part 1.5, and in chapter 2, the rheumatic state is 
characterised by a redox imbalance, hypoxia / reperfusion sequences and hyperactive 
immunity that trigger tissue damage, NO production and ROS generation leading to 
increased levels of PARP.83,92"94,109,110 It is believed that inhibition of PARP could 
result in an important reduction of the inflammation in the case of rheumatic joints.89
Several different routes to 5-substituted isoquinolin-l-ones have been described. For 
example, 5-nitroisoquinolin-l-one was formed by rearrangement of 5-nitroiso- 
quinolin-N-oxide111. Berry et a /83 and Eloy and Deryckere112 have used the Curtius 
rearrangement of T -substituted cinnamic acids, followed by cyclisation of the 2- 
arylethenylisocyanates at high temperatures (Scheme 14). This cyclisation is restricted 
to synthesis of isoquinolinones where the 5-substituent is not strongly electron- 
withdrawing and is thermally stable. In the routes developed by Berry et a/83, 2’- 
bromocinnamic acid 70 (R = Br) was synthesised in an iodine-selective Heck coupling 
of propenoic acid with 2-bromoiodobenzene 71, whereas 2’-iodocinnamic acid 69 
(R = I) was prepared by Knoevenagel condensation of 2-iodobenzaldehyde 67 (from 
oxidation of 2-iodobenzyl alcohol 66) with propanedioic acid. The iodocinnamic acid 
was converted into acid chloride; treatment with sodium azide gave the acid azide 72. 
Curtius rearrangement of the acid azide at high temperature led to the cyclisation. The 
resulting 5-iodoisoquinolinone 34 was reported to be obtained in 42% yield; the 5- 
bromo analogue 35 was obtained with a 10% yield. However, these sequences have 
proved to be somewhat unreliable and, since high temperatures and potentially 





34 R= I 73 R= I 7 2
35 R= Br 74 R= Br
Scheme 14: Synthesis of isoquinolinones. Reagents: i, pyridinium dichromate, CH2C12; ii, 
HC(OEt)3, SOCl2, EtOH; ill, CH2(C 02H)2, piperidine, pyridine; iv, H20=CHC02H, 
Pd(OAc)2, Et3N, EtCN; v, SOCl2, DMF; vi, Et02CCl, Et3N, Me2CO; vii, NaN3, water, 
1,4-dioxane or Me2CO; viii, heat, Ph20  or (MeOCH2CH2OCH2CH2)20.
Parveen113 designed another route to the 5-haloisoquinolin-1 -ones from 5-aminoiso- 







34 R = I 82 R = I
35 R = Br 83 R = Br
Scheme 15: Synthesis of 5-bromo and 5-iodoisoquinolinone. Reagent: i, MeOH, SOCl2;
ii, DMF, DMFDMA; iii, Si02; iv, THF, aq. HC1, Pd/C, H2; v, H20 , NaN02, aq. H2S 04, 
CuBr/KJBr or KI; vi, 2-methoxyethanol, NH3.
Results and Discussion
2-Methyl-3-nitrobenzoic acid 75 was converted into its methyl ester 76. Condensation 
with dimethylformamide dimethylacetal (DMFDMA) in DMF at high temperature led 
to compound 77, as an unpurified intermediate. The ]H NMR spectrum of crude 77 
shows the alkenic protons at 8 6.28 and 8 5.60 as two doublets with a coupling 
constant of 13.5 Hz, suggesting that it is the is-stereoisomer {trans configuration). 
Cyclisation of the enamine 77 on silica gel gave 5-nitroisocoumarin 78 in 32% overall 
yield. The cyclisation appears to be catalysed by the acidity of the silica gel (Scheme
16). NMR spectroscopy confirmed the compound formation with no sign of the 
N(CH3)2 or of the methyl ester peak. The 4-H resonated as a doublet at 8 7.39 coupled 
to 3-H, also as a doublet at 8 7.44. 8-H appeared at 8 8.64 as a doublet of doublets, a 
consequence of the ortho coupling to 7-H and meta coupling to 6-H. The same 
splitting pattern was observed for 6-H at 8 8.51. 7-H resonated as a pseudo triplet due 
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Scheme 16: Proposed mechanism for the cyclisation of the enamine and its side 
product.
Results and Discussion
Further elution gave 3-methoxy-5-nitro-3,4-dihydroisocoumarin 79 in 10% yield. The 
!H NMR spectrum shows aromatic peaks slightly downfield than those of 78, possibly 
due to the lack of an extended conjugated system. The methoxy group is seen as a 
singlet at 5 3.55, the adjacent methine proton resonates as a triplet at 8 3.59 due to 
vicinal coupling (coupling constant J  = 3.2 Hz) with the methylene protons 
themselves coming as a doublet at 8 5.52. The splitting pattern observed for the 
methylene protons is unexpected; they are adjacent to a chiral centre, therefore the two 
protons are expected to be magnetically inequivalent and two signals should be 
observed. The reasons for this are still unclear.
5-Nitroisocoumarin 78 was converted into 5-aminoisocoumarin 80 by catalytic 
hydrogenation (Scheme 15). Reduction of the double bond of the isocoumarin ring 
occurred with prolonged reaction time giving 5-amino-3,4-dihydroisocoumarin 81. 
After one hour under the described conditions, a mixture of 50% 5-amino-3,4- 
dihydroisocoumarin 81 / 50% 5-aminoisocoumarin 80 was obtained. Tin(II) chloride 
has been reported by Bellamy and Ou115 as an alternative reducing agent, limiting the 
risk of over-reduction. Tin(II) chloride reduces selectively the aromatic nitro group 
and does not affect the double bond but the yield and the reaction time are less 
satisfactory. Evidence for the formation of 80 was obtained by !H NMR. The NH2 
signal was seen at 8 3.96 as a broad singlet and the aromatic protons are shifted 
upfield, typical of the shielding effect of the amino group compared to the nitro group 
(6-H shifts from 8 8.51 to 8 7.04). The over-reduced compound 81 showed 3-H2 and
4-H2 as triplets at 8 4.5 and 8 2.8, respectively.
Diazotisation of 5-aminoisocoumarin with sulfuric acid and sodium nitrite, and 
treatment with copper(I) bromide / potassium bromide afforded 5-bromoisocoumarin 
83 in 37% yield (Scheme 15). The iodo analogue 82 was obtained similarly from 
diazotisation of 5-aminoisocoumarin in concentrated hydrochloric acid and sodium 
nitrite, followed by treatment with potassium iodide. Reaction between the sodium 
nitrite and the sulfuric acid generates nitrous acid converting the aromatic amine into 
the diazonium salt. The resulting diazonium species is very reactive and can be 
displaced by a nucleophile (Sandmeyer reaction). The mechanism was long thought to 
be SnI but the hypothesis of a radical mechanism has also been reported.116 In both
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cases, the absence of the broad NH2 peak on the lH NMR and the shifting downfield 
of the aromatic protons due to the negative inductive effect from the bromide or iodide 
matched the compound’s structure.
Finally, ammonia in boiling 2-methoxyethanol gave the expected compounds, 5-iodo 
and 5-bromoisoquinolin-l-one 34 and 35 in 68% and 71% yields, respectively. TLC 
analysis and the observation of a broad single peak at 8 11.1 ppm (highly 
characteristic of the hydrogen-bonded NH of isoquinolin-l-ones) in the TH NMR 
spectrum indicated the formation of the compounds.
5-Aminoisoquinolinone 33 was recently reported to be a powerful inhibitor of PARP. 
McDonald et a l94 reported the route to 5-aminoisoquinolinone hydrochloride from 5- 
nitroisocoumarin, in other words using the same first steps as Parveen113. Bearing in 
mind that 5-aminoisoquinolinone was to be attached to a trigger, it has to be part of 











Scheme 17: Proposed chemical pathways to the Boc-protected 5-aminoisoquinolin-l- 





Parveen’s route to the 5-aminoisocoumarin 80 was initially examined. Protection of 
the 5-amino group with a Boc group and treatment of the resulting 5-Boc-amino- 
isocoumarin 84 with ammonia in 2-methoxyethanol would have led to 85 (Scheme
17). The NMR spectrum obtained of 84, after protection of the amine 80, showed 
the 9 protons of the Boc protecting group as a singlet at 8 1.54.
Treatment of 84 with ammonia gave an unexpected result. TLC analysis brought 
evidence for the complete conversion of the starting material to a new compound. The 
indicated polarity of the substance seemed, however, too low compared to the 
expected polarity of 85. *H NMR results suggested that the compound formed was not 
the expected isoquinolin-l-one 85 but may be a derivative of 84 produced by ring 
opening by methoxyethanol and rearrangement. However, the structure of this 
compound has not been completely elucidated.
The reaction was repeated and gave the same unique compound. Solvent effects were 
investigated. 2-Methoxyethanol was suspected to be at the origin of the ring opening 
at position 1 of the isocoumarin. A high-boiling non-nucleophilic solvent, 1,2- 
diethoxyethane, was used instead and the same compound was formed. Replacement 
of the oxygen by nitrogen was not achieved with this method.
A different strategy was then chosen. The replacement of the oxygen of the 5-nitro- 
isocoumarin 78 by nitrogen to obtain the isoquinolinone 86 was carried out before the 
reduction of the nitro group and subsequent Boc protection (Scheme 17). The 5- 
nitroisoquinolin-l-one 86 was obtained in 60% yield. The NH group was identified by 
*H NMR spectrum at 8 11.8, confirming, together with mass spectrometric results, the 
formation of the compound.
Compound 86 was then reduced to the amine 33 following the procedure previously 
described. Shifting of the aromatic protons upfield was observed, as for compound 80, 
under the electron-donating effect of the NH2 group. The exocyclic amine of 33 was 
then protected by treatment with di-terr-butyl dicarbonate. The Boc compound 85 was 
obtained in 60% yield, despite the very poor solubility of the starting material in
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suitable reaction media. The diBoc derivative 87 was also obtained in small yields 
from some runs.
6.3.2 Pentamethylmelamine
In the present work, pentamethylmelamine was used as a model drug moiety, since it 
was relatively easy and cheap to synthesise, compared to isoquinolin-l-ones. One of 
the reasons that motivated the use and study of pentamethylmelamine and its analogue 
hexamethylmelamine in the past was their antitumour properties. They proved to be 
neurotoxic and were not used for that therapeutic purpose. Other uses have been 
recorded for those substances but the chemical features of pentamethylmelamine were 
the only interest for this study.117'118
Pearlman and Banks119 described the synthesis of a series of 2,4-bis-substituted 
amino-6-chloro-l,3,5-triazines. Cyanuric chloride 88 was used as the starting material 
for the preparation of the substituted chlorodiaminotriazines. The preparation of un- 
symmetrically substituted compounds involved following a strategy relying on the 
order of introduction of the different amines and their relative reactivity.119 Reaction 
of cyanuric chloride with ammonia replaced one chlorine substituent below 0°C and 
two below 100°C, interaction with dimethylamine replaced all three chlorine atoms at 
25°C.119 The basicity of the amine was proved to be only one of the factors 
influencing the reactions. Sufficiently low temperature allowed, even in the case of 
reactive amines, displacement of only one chlorine.
In this case, it was desired to introduce only one kind of amine, namely 
dimethylamine, to replace two of the three chlorines in the first step but its reactivity 
required careful temperature control to avoid displacement of the third chlorine on the 
triazine. Cyanuric chloride 88 was treated with dimethylamine in aqueous medium at 
0°C. Heating the mixture to 20°C allowed the displacement of the second chlorine to 
give 89 in good yield. The symmetry of the molecule is responsible for the presence of 




Borkovec and DeMilo120 reported a method for the displacement of the last chlorine 
by an amine of a different nature from the ones already present on the ring to form an 
asymmetrically substituted triazine. It proceeded under harsher conditions compared 
to the previous reaction conditions. In the present work, displacement of the last 
chlorine atom was achieved by treating 89 with methylamine under boiling 
concentrated basic aqueous conditions to give 90 in good overall yield (Scheme 18). 
Evidence for the formation of 90 was obtained by !H NMR. The expected isolated 
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Scheme 18: Synthesis of pentamethylmelamine and its deuterated analogue. Reagents: i, 
MejO, H20/ice then 20°C, (CH3)2NH, ii, H20, CH3NH2, NaOH, heat; iii, H20, 
CD3NH3+C1\ NaOH, heat.
A novel deuterated 91 derivative was also synthesised for the structural investigation 
(assignment of the NMR spectrum) of the conjugate formed between pentamethyl­
melamine 90 and the indoledione 11. The CD3 compound 91 was prepared using tri- 
deuteromethylamine. In the 13C NMR spectrum, the 13CD3 signal was seen as a septet 
with a one-bond coupling constant Jc-d =  20.8 Hz. The mass spectra were consistent 
with the NMR data. This deuterated isotopomer may also have applications in drug 
metabolism studies, in addition to its planned use here.
Results and Discussion
6.3.3 Coupling o f indolediones with isoquinolin-l-ones and with pentamethyl­
melamine.
Alkylation of the anions derived from isoquinolin-l-ones usually takes place at the 2- 
nitrogen.80,83’121,122 For example, Berry et a/83 and Parveen et alm deprotonated 5- 
bromoisoquinolinone with lithium bis(trimethylsilyl)amide and treated the 
nucleophilic species with chloromethylheterocycles. Alkylation occurred at nitrogen 
showing that this base deprotonated effectively the isoquinolinone used. 
Pentamethylmelamine 90 has also been converted into its anion which can be 
alkylated at the exocyclic secondary amine.123
Reaction between 3-(chloromethyl)indoledione 63 and isoquinolin-l-one 28 or penta­
methylmelamine 90 under these conditions did not give the conjugates expected but 
only led to recovery of the starting materials. Investigation of the leaving group, 
solvent and base effect on the reactivity of the trigger, as previously discussed (part 
6.2), did not affect the course of the reaction.
However, Naylor et al51 used Mitsunobu-type reactions for building up different 
groups at position 3 of the indole nucleus from 11. The Mitsunobu reaction is known 
to allow the replacement of alcohols by nitrogen functions. Pentamethylmelamine 
possesses an exocyclic secondary amine. Isoquinolin-l-one contains a secondary 
amide motif which is essential for its pharmacological activity.92 Therefore, to 
produce potential prodrugs, these secondary amine/amide motifs would have to be 
masked. Such masking could be achieved by coupling to the trigger moiety (carrying a 
primary alcohol) through the Mitsunobu procedure.
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6.3.3 1 Mitsunobu reactions
The Mitsunobu reaction is a very versatile and useful method in organic synthesis 
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Scheme 19: Mechanism of the Mitsunobu reaction.
Addition of the phosphine to the weak N=N n bond is the first step of this reaction 
that gives the quaternary phosphonium salt with a nitrogen anion stabilised by one of 
the ester groups. This anion is sufficiently basic to remove the proton from the 
alcohol. The affinity between oxygen and phosphorus promotes the attack of the 
newly formed alkoxide ion on the positively charged phosphorus displacing the 
second nitrogen. The result of this reaction is the formation of an alkoxyphosphonium 
salt and of the basic nitrogen anion. The nitrogen anion can deprotonate the 
nucleophile, which can, in turn, attack the alkoxyphosphonium derivative via an Sn2 
reaction with phosphine oxide as a leaving group (Scheme 19). The Sn2 mechanism 
also implies inversion of configuration at the electrophile. This diethyl 
azodicarboxylate / triphenylphosphine reaction system falls under the general category 
of redox reactions, since triphenylphosphine is oxidised to triphenylphosphine oxide 
and diethyl azodicarboxylate is reduced to diethyl hydrazinedicarboxylate.
Results and Discussion
Amongst many other possibilities, the transformation of an alcohol into an amine is 
one of the interesting options offered by the Mitsunobu reaction. Primary and 
secondary alcohols can be converted to amines and amine derivatives. The pKa of the 
acid (nucleophilic) component has* been shown to be a key in the success of those 
reactions. Typically it has to be less than 14. This explains partly why this reaction is 
essentially used for the formation of carbon-heteroatom bonds. Mitsunobu reactions 
with carbon acid participants have been explored for the formation of carbon-carbon 
bonds. The choice of the phosphine / azo-derivative system can also influence the 
reaction. Henry et al125 and Edwards et al126 reported the synthesis of protected 
amines and secondary amines from alcohols via the Mitsunobu reaction.
Other alternatives are known to obtain this transformation, Murahashi et al127 reported 
a ruthenium-catalysed system allowing the synthesis of secondary and tertiary amines 
from alcohols. Grigg et al128 reported the use of other transition metals for the 
catalysis of such reactions.
Diethoxytriphenylphosphorane (DTPP) has also been used in the more specific
1 ?Qexample of aziridine formation from 1,2-aminoalcohols
Indole chemistry has been influenced, as well, by this type of reaction from the 
building up of substituents to the formation of the indole ring. Castro et al130 reported 
the alkylation of sulfonamides with an hydroxymethyl group at position 5 of the 
indole ring. Bhagwat and Gude131, Kaneko et al132 and Ohkubo et al133 used the indole 
as the nucleophilic moiety. Bhagwat and Gude125obtained a range of low to reasonable 
yields depending on the substituents on the indole ring. Activation of the NH was 
optimum when two electron-withdrawing groups were found at positions 2,3 or 2,5. 
Ohkubo et a l133 studied the nature of the phosphine / azo derivative system as a means 
to improve the yield of the indole N-alkylation. Macor and Wehner134 used the 
reaction for building up the 5-membered ring of the indole; 2-(5-methoxy-2-nitro- 
phenyl)acetonitrile was deprotonated with a DEAD / PPI13 complex and treated with 
the desired alcohol. The product obtained was hydrogenated and subjected to heat and 
gave the corresponding indole.
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6.3.3.2 Model reactions following the Mitsunobu principle
As noted above, Berry et a P  and Parveen et a P  tested their alkylation methodology 
on a model system which consisted of deprotonating isoquinolin-l-one and selected 5- 
substituted isoquinolin-l-ones and alkylating the anions with (bromomethyl)benzene 
and its p a r a  substituted analogues. Alkylation took place exclusively at nitrogen in 
each case.
In the present work, it was attempted to reproduce this simple model using the 
Mitsunobu reaction to give information on the nucleophilic reactivity of the 
isoquinolin-l-ones. The first model Mitsunobu reaction was carried out using benzyl 
alcohol 92 and isoquinolin-l-one 28 (Scheme 20) DEAD and PPh3. A colourless oil 
was obtained, as reported83 for 2-benzylisoquinolin-l-one, but proton NMR showed 
different chemical shifts compared to the ones reported for this N-alkylated material.83
o
PPh3 / DEAD
*  u u  — -
28
Scheme 20: Model reaction between benzyl alcohol and isoquinolin-l-one. Reagents: i, 
PPh3, DEAD, THF.
In particular, the signal for the CH2 was observed further downfield than expected: 
shifting from 5 5.20 to 5 5.58. The H-3 resonance was noticeably shifted downfield, 
from 8 7.05 to 8 8.00. The H-4 and H-5 signals followed the same trend, although not 
as profoundly as that of H-3. The mass spectrum gave the expected mass ion, with a 
similar fragmentation pattern to that of the N-benzyl compound. The deshielding 
effects observed together with the MS evidence led to consideration of a different 
structure for the compound. The benzyl moiety was alkylated on the oxygen of the 
isoquinolinone and not on the nitrogen, giving 1-benzyloxyisoquinoline 93. This 
compound has acquired fuller aromaticity in the heterocyclic ring, causing the major
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deshielding of H-3 and H-4 and the milder effect on the protons of the fused benzene 
ring. Further evidence for O-alkylation was provided by the 13C NMR spectrum, in 
which the methylene carbon signal was at 6 69.4, showing that it is of the OCH2 type, 
rather than in the region 8 30 - 8 40 typical of PhCH2N carbons. Mitsunobu reactions 
on isoquinolon-l-ones are previously unknown but Manhas et al135 reported that 
treatment of 2-arylquinazolin-4(i//)-ones with propan-2-ol and with 2-(pyrrolidin-l- 
yl)ethanol in the presence of DEAD and PPh3 gave the corresponding ethers in high 
yields. Similarly, pyrimidine-2,4-dione, when treated with cholestan-3a-ol gave the 
corresponding diether. The method did not lead to ether formation when tertiary 
alcohols were used. Studies on conjugated amides also proved unsuccessful in 
forming the ether. Manhas et a /135 suggested that the reaction is due to the 
participation of the enolic form of the amide. No parallel formation of the ether and N- 
alkyl derivative in any one reaction was reported. Investigations on solvent effect and 
order of addition o f the reagents proved to have no influence on the course of the 
reaction. However, this suggestion must be regarded sceptically, since the actual 
reactive nucleophilic intermediate is the corresponding anion, which is not tautomeric 
(Scheme 21).
<? o
Scheme 21: Resonance forms of the isoquinolinone anion generated in the Mitsunobu 
reaction.
The evidence that isoquinolinone could be used as a nucleophile in the Mitsunobu 
reaction was given with the formation of 93. The next step was to demonstrate that the 
indoledione 11 could be used as a potentially electrophilic alcohol.
The model reaction for that was based on the use of pentamethylmelamine (PMM) as 
the nucleophilic component. The amine targeted as the attachment site was relatively 
free of steric hindrance and is likely to have a pKa less than 14. The reaction was 
carried out under the conditions used for the formation of 93.
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Proton NMR analysis of the product formed showed interesting results. The signal 
assigned as the CH2 group was observed further downfield than expected: 8 6.42 
indicating that these methylene protons (on an sp carbon) were in a more deshielding 
environment than the aromatic indole proton H-6 (on an sp2 carbon). The signal was 
also a multiplet, suggesting a conformation rigid enough for the molecule to be unable 
to rotate and rendering the two protons magnetically inequivalent. The possible 
attachment sites of 11 on the 90 were considered.
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Scheme 22: Tautomeric forms of pentamethylmelamine.
It is known that PMM exists in other tautomeric forms in which it is relatively stable, 
although crystal structures of PMM from the literature report the structure with 
exocyclic NHCH3119 (Scheme 22). In the intermediate anion, the negative charge may 
be delocalised onto the ring nitrogen atoms. In other words, in the alkylated product, 
the indole could be bound to one of the ring nitrogens, explaining why the methylene 
would have such a chemical shift; the nitrogen being part of the aromatic ring would 
exert a greater electron-withdrawing effect than the exocyclic NHCH3 on the CH2 
group (Scheme 23). The compound decomposed rapidly and no further analyses could 
be carried out.
Repeats of the experiment carried out subsequently did not give such chemical shifts, 
although the coupling reaction was taking place. This might suggest that the first 
reaction occurred to give a less stable product which then underwent rearrangement 
and migration of the substituent from the ring to the exocyclic nitrogen atom to give a 
more stable isomeric form. This was also considered to explain the non-repeatability 







Scheme 23: Synthesis of 1,2-dimethyl 3-{N-[[4,6-bis(dimethylamino)-l,3,5-triazin-2- 
yl]-N-methyl-amino]methyl}-5-methoxyindole-4,7-dione. Reagents: i,
PPh3, DEAD, THF.
Mitsunobu reaction between 11 and the deuterated PMM 91 gave the expected 
isotopomer 96 (Scheme 24). A moderate yield (40%) was obtained for both reactions. 
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Scheme 24: Synthesis of 96, the deuterated derivative of 94. Reagents: i, PPh3, DEAD, 
THF.
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The deuterated derivative was designed to solve the problem of assignment of the 
NCH3 signals in the NMR spectra. Typically, the ]H NMR spectrum obtained for 
conjugate 94 showed the indole proton H-6 at 8 5.61. The CH2 signal came at 8 5.12 
which was more upfield than for the first compound obtained but the signal was still a 
multiplet, indicating the non-equivalence of the two methylene protons. CH3O and 
CH3N were observed as singlets at 8 3.85 and 8 3.81, respectively, followed by the 
melamine N(CH3)2 at 8 3.11 and CH3N at 8 2.94, both as singlets. Similar chemical 
shifts were obtained for the deuterated derivative; the singlet at 2.94 ppm was missing 
since CD3 gave no signal. NMR analysis of this derivative proved that the melamine 
CH3N is more shielded then the indole N-methyl observed further downfield. Further 
evidence of the formation of the conjugates was obtained by mass spectrometric 
analysis.
Evidence for the reactivity of both trigger and drug under Mitsunobu reaction 
conditions were brought by the model reactions. The series of target compounds could 
then be synthesised by this method. Isoquinolin-l-one 28 was the first drug used in 
this series of reactions.
6.3.3.3 Mitsunobu reactions of indoledione 11 and isoquinolin-l-ones.
Treatment of 28 with the indoledione 11 in the presence of DEAD and PPI13 gave two 
compounds, together with some starting material. Proton NMR identified the first 
compound as being the conjugate between 11 and 28. The structure of the second 
compound could not be resolved but one may speculate that it could be the dimer 98 









Scheme 25: Mitsunobu reaction between isoquinolin-l-one and l,2-dimethyl-3- 
(hydroxymethyl)-5-methoxyindole-4,7-dione. Reagents: i, PPh3, DEAD, 
THF.
There was considerable difficulty in separating the products from the side-product 
diethyl hydrazinedicarboxylate. The literature124 on the Mitsunobu reaction reports 
contamination and difficult purification due to the presence of triphenylphosphine 
oxide but diethyl hydrazinedicarboxylate is not mentioned. Colleagues noted 
(unpublished results) the formation of complexes between conjugates formed by the 
Mitsunobu reaction and diethyl hydrazinedicarboxylate. In the present study, 
recrystallisation from methanol enabled the isolation of the target compound.
The NMR spectra showed some interesting results, which correspond to the ones 
observed from 93, obtained from isoquinolinone and benzyl alcohol. In the case of 97, 
the methoxy, N-methyl and 2-methyl group from the indole moiety showed little 
changes in their chemical shift compared to the starting material. H-6 was still around 
8 5.62, but the CH2 group was observed further downfield, at 8 5.72, from 8 4.65 in 
the starting material, already showing important downfield shifting and suggesting 
linkage to oxygen. The isoquinoline protons were, as in the case of 93, importantly
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shifted downfield from their positions in the spectrum of isoquinolin-l-one. The H-4 
signal resonated as a doublet at 6 7.2 followed by H-7 observed as a pseudo triplet, 
coupled to H-8 and H-6, at 5 7.45. H-6 was observed as a pseudo triplet at 8 7.61, H-5 
as a doublet at 8 7.70 and was coupled to H-6. H-3 was 1 ppm downfield compared to 
its chemical shift in the starting material and was seen at 8 8.0. Finally, H-8 resonated 
as a doublet of doublets at 8 8.17, with a small meta coupling with 6-H. Similarly to 
93, the change in chemical shift affected H-4, H-3 and H-5 more than the three other 
protons. The 13C NMR spectrum indicated the presence of CH2 at 8 53.4, which 
suggests that this group is linked to the oxygen of the isoquinolinone. If it had been 
adjacent to the nitrogen atom, its chemical shift would have probably been seen about 
20 ppm upfield. Mass spectrometric analyses confirmed the structure of the 
compound.
Isoquinolin-l-one was shown to have reduced activity against PARP compared to its 
5-substituted analogues80,83,92'94,109'110. Three 5-substituted isoquinolin-l-ones were 
selected and synthesised to be linked to the indoledione trigger 11, namely, 5-iodo-, 5- 
bromo- and 5-aminoisoquinolin-l-ones.
Synthesis of the bromo analogue 40 was carried out using the same reaction 
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Scheme 26: Synthesis of l,2-dimethyl-3-(5-bromo-l-oxoisoquinolinyl-2-methyl)-5- 
methoxyindole-4,7-dione. Reagents: i, PPh3, DEAD, THF.
TLC analysis showed evidence for the formation of two compounds: one was the 
target compound 40, the second one is speculated to be a dimer of the parent trigger. It 
was expected to obtain a similar ]H NMR spectrum to 97, without the signal from H-5
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since that position of the indole ring was now substituted with a group having a 
negative inductive effect. However the CH2 protons, 3- and 4-H from the isoquinoline 
were less deshielded than expected. The methylene protons resonated downfield from 
the indole 6-H, at 5 5.30. 4-H resonated slightly more upfield than in the previous 
conjugate, at 6 6.77. The pseudo triplet for 7-H was at 6 7.27, 6-H resonated as a 
doublet since it was only coupled to 7-H, at 8 7.82, so did 3-H. Finally, the signal for
1 'X8-H was observed at 8 8.36. C NMR analysis showed the CH2 group signal at 8 32.6, 
indicating that the trigger was linked to the nitrogen of 35 instead of the oxygen as 
previously seen for compounds 93 and 97.
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Scheme 27: Synthesis of l,2-dimethyl-3-(5-iodo-l-oxoisoquinolinylmethyl)-5- 
methoxyindole-4,7-dione. Reagents: i, PPh3, DEAD, THF.
!H NMR analysis showed that the chemical shifts observed for 39 corresponded to the 
ones obtained for 40. The 6-H and 3-H signals were observed, respectively, at 8 8.01 
and 8 7.8, suggesting that the dioxoindole-CH2 is also linked at the nitrogen atom in 
39.
However, a repeat experiment under apparently the same conditions led to compound 
99 which had the same Rf as 39 on TLC analysis but had a different appearance and 
exhibited different NMR results (Scheme 28). In the !H NMR spectrum, 8-H was 
observed at 8 8.12, followed by 6-H and 3-H at 8 8.15 and 8 8.08, respectively. 4-H 
was observed at 8 7.40, downfield from 7-H at 8 7.16. The methylene protons were 
observed at 8 5.71 instead of 8 5.62, downfield from 6’-H. The chemical shift of the
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methyl group suggested that the compound was linked, more probably, to the oxygen 
than to the nitrogen of the isoquinolinone due to the deshielded character of CH2 and 
3- and 4-H. Mass spectroscopic analysis showed the same mass ion for 99 and 39. It is 
interesting to note that 3-H and 4-H were the two protons that seemed the most 
affected, suggesting O-alkylation. 13C NMR showed an important shift downfield of 
the CH2 group of approximately 20 ppm compared to the chemicai shift of the CH2 
group for 39, explained by the difference in electronegativity between nitrogen and 
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Scheme 28: Synthesis of l,2-dimethyl-3-(5-isoquinolin-l-yloxymethyl)-5-methoxy- 
indole-4,7-dione. Reagents: i, PPh3, DEAD, THF.
Finally, conjugate 100 was prepared from the Boc protected aminoisoquinolinone 85. 
The reaction conditions were similar to the ones previously used (Scheme 29) for 39, 
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Scheme 29: Synthesis of compound 100.
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Evidence for the formation of this compound was observed by TLC analysis and 
proton NMR. The chemical shifts obtained matched the ones of compounds 40 and 
39, indicating that the indoledione is alkylated onto the nitrogen atom of the 
isoquinolinone derivative in 100. The low yield of the reaction did not allow the 
subsequent deprotection of the amine. The conjugate 100 decomposed on mass 
spectrometric analysis.
In this part, the strategy and synthesis of a series of analogues based on an indoledione 
trigger 11 and some 5-substituted isoquinolinone PARP inhibitors were discussed. 
The method used was selected after it was shown that simpler and more classical 
methods were not appropriate. The yields are uniform throughout the four reactions; 
however, the alkylation pattern observed remains unexplained. Temperature, 
concentration and order of addition were shown to have no influence on the course of 
the reaction. Further studies could be carried out on the improvement of the yield 
using this method and possibly modifying the nature of the Mitsunobu complex136.
6.4 A p pr o a c h e s  to  po te n tia l  p r o d r u g s  w ith  1 ,2-d im e t h  yl-5-m e th o x yin d o le -  
4, 7-d io n e  trig g e r  a n d  n if e d ip in e  e f f e c to r .
Nifedipine 101 is known to be a calcium channel blocker from the family of the 
dihydropyridines. It was initially selected to be one of the drug moieties for prodrug- 
mediated delivery. Co-delivery of nifedipine with the active substance would 
potentially ensure that the drug delivered would remain trapped in the site of delivery.
The first approach to link indoledione to nifedipine 101 was to deprotonate the NH 
group of the drug to form a nucleophile that would displace the chloride leaving group 
attached to the CH2 group in 63, as investigated for prednisolone and isoquinolin-l- 
one. The reaction was carried out in the presence of sodium hydride as a base. No 
reaction was observed. The choice of the base was critical; sodium hydride readily 
decomposes in the presence of any trace of moisture and it is difficult to handle. It is 
also known to promote the decomposition of the starting materials in some cases.
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An alternative was to use lithium bis(trimethylsilyl)amide as a base. However, the 
initial small supply of the indoledione 63 motivated the use of a model reaction with 
benzyl chloride. The reaction between nifedipine 101 and benzyl chloride was 
successful with a yield of 40%. (Scheme 30)
Scheme 30: Model reaction between benzyl chloride and nifedipine. Reagents: i, 
LiN(SiMe3>2 , Nal, DMF.
Repeating the reaction with 6 3  instead of 102 did not lead to the expected conjugate. 
Explanations for this lack of reactivity are not obvious. Steric hindrance was the main 
factor considered.
As for the prednisolone series, attempts were then made to link the indoledione to the
117nifedipine via a carbonyl group, in this case a carbamate. Remy et al reported 
acylation of a series of dihydropyridines using sodium hydride in THF and methyl 
chloroformate, forming the methyl carbamate. However, treatment of nifedipine 101  
with the nitrophenyl carbonate 6 4  gave no apparent reaction (Scheme 31).
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Scheme 31: Attempted syntheses of conjugate 104 from 101 and derivatives of 11.
Reagents: i, NaH or LiN(SiMe3)2, Nal, THF, Ar; ii, for Xj only, DEAD, PPh3, THF.
Finally, the Mitsunobu reaction was attempted but variations in concentration of the 
Mitsunobu complex, temperature or order of addition did not lead to N-alkylation of 
the nifedipine.
Another way of approaching the problem would have been to “build” the 
dihydropyridine using the Hantzsch synthesis of 1,4-dihydropyridines (Scheme 32). 
The bicyclic molecule can be prepared from the condensation of N-alkyl P-amino- 
crotonates and benzylidine acetoacetic esters. Patterson138 showed that the precursor 
aminocrotonate can be N-alkylated before condensation using groups as bulky as 
benzyl groups. This example suggests that N-alkylation by the indole group could lead 
to the target molecule using this method.
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Formation of side products, such as the cyclohexadienamine 108, formed through 
cyclisation of the intermediate enamine with the carbon rather than the nitrogen 
(Scheme 33), has been reported by Patterson138 together with low yields.
Scheme 33: Tautomeric forms o f the intermediate in the Hantzsch synthesis of N- 
alkylated 1,4-dihydropyridines.
Change in solvents often solved the reported problems. Ethanol favoured the 
formation of the side product whereas non-protic solvents, such as benzene or toluene, 




7. DESIGN OF A NEW INDOLE TRIGGER
The idea motivating the synthesis of a new trigger was to allow the release of the drug 
as efficiently as possible after reductive activation of the trigger. The nature of the 
linker was thought to have a noticeable effect on the activation potential and release 
efficiency. Modification and synthesis of a new trigger permitting synthesis of a series 
of potential prodrugs similar to the one discussed in part 6.0 would have been a 
valuable element o f comparison. The extension of the conjugated system by the 







Scheme 34: Proposed mechanism for the bioreductively triggered release of drugs 
from indoledione-3-propynyl potential prodrugs.
The formation of a four-carbon cumulene after potential reduction and release of the 
drug is a valid hypothesis since the formation, isolation and characterisation of such 
compounds has already been reported.139
The main difference in the synthetic route initially designed compared to the route to 
11 was the Heck-Castro coupling of an acetylene group at position 3 of the indole 
nucleus. The Heck-Castro coupling reaction is a palladium-copper catalysed reaction 
of vinyl or aryl halides with terminal acetylenes. The reaction proceeds via the copper 
alkynide formed in situ as represented below (Figure 21). Usually the coordinatively 
unsaturated catalysts Pd(PPh3)2Cl2 and Pd(MeCN)2Cl2 are more active than Pd(PPh3)4. 
Among the bases, piperidine is particularly effective but triethylamine and 












Figure 21: Heck-Castro coupling mechanism.
To achieve the coupling, it was necessary to iodinate the indole at position 3. 1,2- 
Dimethyl-5-methoxyindole 58 was initially chosen as the starting material. Reaction 
of 58 with iodide monochloride in the presence of pyridine did not give the expected 
iodinated derivative. The literature104 suggested that the nature of the N-substitution at 
position 1 would explain this phenomenon. In the absence of substituent (R = H) or if 
an electron-withdrawing group is present (reducing electron density, thus limiting 
poly-iodination), iodination at position 3 should occur with reasonable yield.
The same reaction was carried out with 2-methyl-5-methoxyindole 57, affording the 
iodinated compound but with a relatively low yield. The instability to air and light of 
109 made it difficult to purify.
The iodinated derivative 109 was used for the Heck-Castro coupling reaction using 
two different acetylenes, namely propargyl bromide and propargyl alcohol, and two 
different palladium catalysts (tetrakis(triphenylphosphine)palladium and dichlorobis- 
(triphenylphosphine)palladium) and copper iodide under basic conditions. No reaction 
was observed, the starting material was recovered.
Sakamoto et al140 reported a series of palladium-catalysed coupling reactions of 3- 
iodoindoles, possessing an electron-withdrawing group at position 1 or 2, with 
terminal acetylenes. Starting from an unsubstituted indole ring, in the presence of 
potassium hydroxide, and iodine, selective iodination took place at position 3 of the
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indole ring, which is the most reactive to electrophilic attack. 3-Iodoindole was poorly 
stable during purification and was therefore treated with methanesulfonyl chloride 
under basic conditions to give l-methylsulfonyl-3-iodoindole, which was more stable 
and could therefore be purified and undergo the subsequent palladium-catalysed 
reaction.
57 109 110
Scheme 35: Synthetic pathway to 3-iodo-5-methoxy-2-methyl-l-(methylsulfonyl)- 
indole. Reagents: i, I2, KOH, DMF; ii, MeS02Cl, NaOH, Bi^NBr, benzene, water.
A similar protocol was followed for the preparation of 110 (Scheme 35). The 
relatively low yield obtained for both steps is suggested to be due to the presence of 
the electron-donating methyl group at position 2. The electron-withdrawing group on 
the nitrogen atom is responsible for the improved stability of the molecule, as reported 
by Sakamoto et a /.140
Proton NMR analysis of the first two compounds showed some changes in chemical 
shift of the aromatic protons as electron-withdrawing substituents were inserted. After 
iodination at position 3 of the indole ring, the methyl and methoxy protons previously 
seen as two singlets at 8 2.37 and 8 3.80, respectively, remained unchanged. H-3 
observed at 8 6.10 in the starting material was not present in the iodo-derivative. H-6 
came as a doublet of doublet due to ortho coupling with H-7 and meta coupling with 
H-4, at 8 6.73 in both the starting material and 3-iodo-5-methoxy-2-methyl-l 77- 
indole. H-7 seen as a doublet at 8 7.18 in the precursor indole remained unchanged 
after iodination. H-4, observed as a singlet, shifted from 8 7.00 to 8 7.99 after 
iodination due to the negative inductive effect of iodine. The broad singlet seen for 
NH also shifted from 8 7.71 to 8 8.52.
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After N-methylsulfonylation, the singlet for SO2CH3 appeared at 8 3.00 between the 
methyl and methoxy group at 5 2.68 and 8 3.80. H-4 is shifted back upfield at 8 6.84. 
The methylsulfonyl group is known to be electron-withdrawing but its position 
triggered the deactivation of the Whole pyrrole ring, presumably overcoming any 
magnetic effect from the iodine on the fused benzene ring. The H-6 signal came at 8 
6.95 and H-7 was observed downfield compared to its previous position, at 8 7.85, 
illustrating the deshielding effect of the N-methylsulfonyl group.
The following step involved the coupling of the iodine derivative with selected 
acetylene derivatives. The choice of the latter was based on the observations made 
during the different attempts to attach the indoledione trigger 11 to the selected drugs. 
Propargyl bromide was thought to be a good choice for future nucleophilic sub­
stitutions together with propargyl alcohol for its versatility. The former would lead to 
an indoledione unit with a reactive electrophile, whereas the indoledione-propargyl 
alcohol would be a useful component of a Mitsunobu coupling. Coupling experiments 
proved that propargyl bromide was unreactive under the coupling conditions used. 
Sakamoto et al140 reported the inertness of propargyl alcohol in this kind of coupling 
experiments with indoles.
Alternative acetylenes were selected, introducing the desired versatile functional 
groups: 2-methyl-3-butyn-2-ol and trimethylsilylacetylene140. 2-Methyl-3-butyn-2-ol 
would potentially afford an alcohol derivative, as it was desired, but the introduction 
of steric hindrance with the two methyl groups would also be a potential toxicity- 
limiting factor to observe in the case of in vivo studies. The TMS derivative would be 
easily transformed into other types of leaving groups and was therefore a convenient 
starting point.
Coupling reaction were carried out under strong basic conditions in the presence of a 
mixture of the acetylene, 110, Cut and Pd(PPh3)2Cl2. The reaction with trimethylsilyl­
acetylene afforded 111 in 60% yield (Scheme 36).
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Scheme 36: Heck-Castro coupling of 3-iodo-5-methoxy-2-methyl-l-methylsulfonyl- 
indole with 2-methyl-3-butyn-2-ol and trimethylsilylacetylene. Reagents-, i, 
Cul, Pd(PPh3)2Cl2, DMF, Et3N, trimethylsilylacetylene, Ar; ii, Cul, Pd(PPh3)2Cl2, 
DMF, Et3N, 2-methyl-3 -butyn-2-ol, Ar.
]H NMR analysis brought evidence for the formation of the compound. For compound 
111, H-7 was seen as a doublet at 8 7.83, followed by H-4, a narrow multiplet, at 8 
7.05, and H-6 (8 6.94) as a doublet of doublets, for it is coupled to H-4 and H-7 
(coupling constants are typical of ortho and meta coupling, 7 =  9.1 and 2.5 Hz). The 
methoxy, methylsulfonyl and 2-methyl groups were observed as singlets at 8 3.88, 8 
3.01, and 8 2.69, respectively. The singlet expected for the nine protons of the 
trimethylsilyl group was observed at 8 0.3 due to the deshielding effect of the triple 
bond.
Compound 112, obtained in 60% yield, showed similar splitting patterns and chemical 
shifts in the NMR spectrum. The six protons of the geminal dimethyl unit were 
observed at 8 1.69 as a single peak.
The following steps planned for both compounds were the deprotection of the nitrogen 
atom, N-methylation and building of the paraquinone on the 6-membered ring by 
nitration, reduction to the amine, and oxidation to the paraquinone.
Deprotection of 2,3-substituted-N-alkylsulfonylindoles was reported by Yasuhara and 
Sakamoto141 and involved the use of one equivalent of tetrabutylammonium fluoride 
(TBAF) in THF under reflux from 30 to 90 min. The method is mild and fast, 
compared to the more commonly used basic hydrolysis. The yields reported ranged 
from 38% to 100%. Other methods are known, such as five equivalents of K2CO3 in
x?
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refluxing aqueous methanol142 and 5 M NaOH in methanol,143 or reductive conditions 
like Na-Hg in NaH2P 04-buffered EtOH.143
Sundberg and Laurino142 used 5% methanolic potassium carbonate and 18 hours 
reflux to deprotect a series of indoles monosubstituted on the 6-membered ring with a 
variety of substituents. The reported yields were high, ranging between 85% and 98%. 
The methods used are thus generally harsh, and the yields are not always as good as 
the ones given as examples above. The nature of the substituent on the sulfonyl 
influences the ease of deprotection. Substituents on the pyrrole ring are certainly 
determining the degree of lability of those groups, especially at position 2.
The first attempt of deprotection of 111 by the Yasuhara and Sakamoto141 failed and 
the starting material was recovered. Increased TBAF concentrations together with 
increased temperature and reaction time did not influence the cleavage of the 
methylsulfonyl group. The method involving five equivalents of potassium carbonate 
also proved to be unsuccessful. The reaction was repeated since Ravikanth et allu 
reported that such conditions would have cleaved the *TMS group at the same time to 
afford a terminal alkene. No cleavage of the TMS group was observed.
Treatment of 111 with methanolic potassium hydroxide gave a new compound 
detected by TLC analysis (Scheme 37). Proton NMR showed a broad peak integrating 
for 1 H at 8 8.40 recognised as the NH group. The indole H-4 was detected at 8 7.60, 
followed by H-7 at 8 7.21 and H-6 at 8 6.85. Three single peaks integrating for three 
protons were found at 8 3.88, 8 2.73, and 8 2.71, respectively. The first and the last 
peaks were assigned as the methoxy and the methyl group initially present on 111. No 
sign of the nine Si(CH3)3 protons was observed. Mass spectrometry confirmed the 
reduction in mass of the compound and showed a fragment corresponding to a methyl 
carbonyl (acetyl) group. Calculation of the mass with this fragment integrating the 
groups identified on the proton NMR gave the mass found for the unknown compound 
on the mass spectrum. The chemical shift of the unidentified peak on the proton NMR 






Scheme 37: Reaction of 111 under refluxing basic conditions. Reagents: KOH, MeOH.
Hydration of an aromatic alkyne to obtain a methyl ketone is a known reaction taking 
place under a c i d i c  conditions, catalysed by mercury(II) sulfate, or mercury(II) 
oxide.145,146 Bobek e t  a l u l  reported the deprotection of an heteroaromatic alkyne, 
namely l-(2,3,5-tri-0-acetyl-P-D-arabinofuranosyl)-5-[2-(trimethylsilyl)ethynyl]- 
cytosine, from its trimethylsilyl protecting group by using anhydrous potassium 
carbonate in methanol at 20°C for 5 hours. The deprotection proved to be successful 
but 5-acetyl-1-p-D-arabinofuranosylcytosine was also detected (Scheme 38). 
Speculations on the eventual hydration of the ethynyl group were the only explanation 
for this reaction.




Scheme 38: Basic deprotection of l-(2,3,5-tri-Oacetyl-P-D-arabinofuranosyl)-5-[2- 
(trimethylsilyl)ethynyl]cytosine reported by Bobek e t  a l u l . R eagen ts. 
K2CO3, MeOH, 5 h.
The alcohol analogue 112 was subjected to the same deprotection methods as was 
111. The potassium carbonate, potassium hydroxide and TBAF methods were run in
Results and Discussion
parallel and the first two runs did not lead to deprotection. Repeating the reactions 
with increased temperature and reaction time led to the first deprotection via the 
TBAF method (Scheme 39). 5-Methoxy-2-methyl-3-(3-hydroxy-3-methyl-1 -butynyl)- 
indole 117 was afforded in 50% yield. TLC analysis and proton NMR proved the 
presence of the compound, backed up by mass spectrometric analysis.





Scheme 39: Deprotection reaction of 112 under refluxing basic conditions. R ea g en ts: 
TBAF, THF, Ar.
In the absence of the strong deshielding effect from the methylsulfonyl group, the 
chemical shift of H-7 was observed further upfield at 5 7.15, H-4 at 8 7.03 and H-6 at 
8 6.79 were not affected. The broad single signal for NH came at 8 8.16. No change in 
the chemical shift of the aliphatic protons was noted. The methylsulfonyl singlet was 
not present in the spectrum.
The reaction proved to be non-repeatable; under similar conditions, the reactions 
would either work and give very variable yields and most of the time not work at all 
for reasons that are still unclear.
The last approach was to try and build the paraquinone before deprotection. 
Speculation were made on the deshielding effect of the para carbonyl group that could 
have, eventually rendered the sulfonyl protecting group more labile. Sulfonyl 
protecting groups are strong electron-withdrawing groups, as it has been mentioned 
above. The sulfonyl group at position 1 of the indole deactivates the pyrrole ring, 
making it fairly unreactive to electrophilic attack and oxidation104. It may affect the 
fused benzene ring104. Further investigation would be necessary to find a suitable
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deprotecting system for the N-methylsulfonyl. The study of other electron- 
withdrawing protecting groups could also be a different way of solving the problem.
A series of indoledione based potential prodrugs have been synthesised. The synthesis 
of a new trigger containing an 3-alkene substituent was not achieved. However, some 
interesting aspects of indole chemistry have been highlighted. The diversity of the 
structure of those seven targets (difference in the linkage unit, drug substitution effect) 
was expected to be reflected in the results of the release studies.
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8. NITROTHIOPHENE TRIGGER
Nitrothiophene was selected as a trigger for its ease of reduction, its structural 
similarity with nitroimidazole and because it was shown to be very efficiently 
activated under reductive conditions in vitro in the study reported by Threadgill et 
al
Literature about nitroimidazoles80,82 and nitrofurans83,84 used as triggers suggested two 
main ways of approaching the synthesis of the potential prodrugs. The first one was 
via the use of (5-nitro-2-thienyl)methanol as a nucleophile to attack electrophilic drug 
derivatives, the second was by preparing derivatives of (5-nitro-2-thienyl)methanol for 
it to act as an electrophile. Alternatively, the thiophene could be introduced without 
the nitro group, which could be attached later in the synthetic sequence.
The drugs used were the ones selected for the indoledione trigger, namely, 
prednisolone-21-hemisuccinate, isoquinolin-l-one and its 5-substituted analogues. 
Aspirin was also chosen as a drug moiety for nitrothiophene triggers and reactions 
with nifedipine were investigated.
8.1 P r e p a r a t io n  o f  (5-n it r o -2 -thienyl) m e th a n o l  a n d  it s  c h l o r o d e r iv a t iv e
(5-Nitro-2-thienyl)methanol 119 was obtained by reduction of 5-nitrothiophene-2- 
carboxaldehyde 118 with sodium borohydride 140. Different reduction conditions were 
described in the literature but they mainly used an excess of sodium borohydride in 
ethanol or methanol149,150. Compound 119 was afforded in good yield. The proton 
NMR spectrum showed the appearance of peaks for H-3 and H-4, observed as 
doublets at 8 6.94 and 8 7.81, respectively, in the aromatic region. The aliphatic 
region contained a singlet for the methylene protons at 8 4.88 and another singlet 
integrating for 1 H at 8 2.03 and disappearing in the presence of D2O, was identified 
as the OH peak.
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2-Chloromethyl-5-nitrothiophene 120 was synthesised by treatment of 119 with 
thionyl chloride. The compound was obtained in 52% yield (Scheme 40).148 Proton 
NMR analysis expectedly did not show any important change in the chemical shifts. 
TLC analysis confirmed the formation of 120.
118 H 119 120
Scheme 40: Synthesis o f (5-nitro-2-thienyl)methanol and 2-chloromethyl-5-nitro­
thiophene. Reagents: i, NaBH,, MeOH, H20; ii, SOCl2.
8.2 Re a c t io n s  w ith  (5-n it r o -2 -thienyl) m e th a n o l .
(5-Nitro-2-thienyl)methanol was first used as a nucleophile. Deprotonation of the 
hydroxyl group with a base would give the alkoxide anion which could then displace a 
leaving group on a drug derivative.
Trahanovsky et al,151 in their study of the pyrolysis of a series of methyl 
furfurylbenzoates, reported the synthesis of 3-methylfurfurylbenzoate from benzoyl 
chloride and 3-methylfurfuiylmethanol in the presence of pyridine in ether. 
Compound 119 was similarly treated with acetylsalicyloyl chloride in the presence of 
pyridine. TLC analysis indicated the presence of a new substance in the mixture. 
Proton NMR analysis showed each fraction to contain a mixture of three compounds. 
Further attempts to purify and isolate the fractions proved to be vain. Distillation led 
to the decomposition of the thiophene ring.
It was suggested from the complex proton NMR spectra that two of the three 
compounds present were: the expected target and the dimer o f the starting alcohol 
(Scheme 41). The reaction was repeated using triethylamine as a base instead of 
pyridine. TLC indicated the presence of a newly formed substance. Isolation gave the 









Scheme 41: Chemical pathway to the ester 42. Reagents: i, DCM, Et3N; ii, DCM, pyridine.
Proton NMR confirmed the formation of 42. The chemical shifts and splitting pattern 
allowed to assign the peaks as follows: the doublet of doublets at 8 8.04 was identified 
as being H-6’, further downfield than other protons since it bore the effect of the ortho
1.9 Hz). H-4 was observed at 8 7.83 as a doublet (J — 4.3 Hz), deshielded by the 
vicinal nitro group at position 5 of the thiophene ring. H-5’ followed at 8 7.61 
resonating as a triplet of doublets due to coupling with H-6’ and H-4’ (coupling 
constants J=  7.8 and 1.2 Hz). H-4’ at 8 7.33 also resonated as a triplet of doublets due
seen at 8 7.12 as a doublet of doublets, since it was coupled to H-4’ and meta coupled 
to H-5’ ( /=  8.2 and 1.2 Hz). Finally, H-3 came at 8 7.07 as a doublet, coupled to H-4. 
The singlet expected for the methylene protons, previously at 8 4.88, was observed at 
8 5.41 due to the deshielding effect of the ester carboxy group CO2. The acetate 
protons were seen as a singlet at 8 2.31.
carbonyl group. H-6’ was coupled to H-5’ and meta coupled with H-4’ (J  = 8.2 and
to ortho coupling with H-5’ and H-3’ (same coupling constants as H-5’). H-3’ was
RQ
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The structure of this first nitrothiophene-based target contained a weakness, which 
was the nature of the linkage. The ester bond between the trigger and the drug could 
be a problem for the release studies; under the model reductive conditions, this bond 
could easily be hydrolysed to give the thiophene alcohol and salicylic acid. This 
structural characteristic would also be an indicator, during the release studies, of 
whether the trigger moiety of the potential prodrug was reductively activated and the 
drug released by electron transfer, or if the ester linkage was hydrolysed.
8.3 R e a c t io n s  w it h 2 -ch lo r o m e th yl-5-n itr o th io ph e n e .
The use of 2-chloromethyl-5-nitrothiophene 120 involved the action of a nucleophilic 
species generated from the selected drug moieties to displace the chlorine atom. 2- 
Chloromethyl-5-nitrothiophene 120 was selected to react, first, with prednisolone. The 
reaction was carried out in the presence of lithium bis(trimethylsilyl)amide. Increasing 
reaction time and temperature did not give the expected conjugate. Prednisolone was 
recovered but no traces of the aromatic were detected by proton NMR analysis. It was 
speculated that nitrothiophene could be temperature-sensitive and decompose when 
harsher temperature conditions were applied.
It has been noted in the case of the reaction between 3-(chloromethyl)-l,2-dimethyl-5- 
methoxyindole-4,7-dione 63 and prednisolone that steric hindrance was an important 
factor in the non-reactivity of the reagents. The alternative had been to introduce a 
long carbon chain (a hemisuccinate) as a linker.
A similar reaction of prednisolone hemisuccinate anion was attempted under the 
conditions described for the formation of 65 but using 120 as the electrophile. The 
reaction failed to work. The base effect was investigated and sodium hydride was 
chosen as an alternative base but the reaction proved to be unsuccessful. The 
thiophene trigger was not always recovered and temperature did not seem to be the 
only factor.
Nitrothiophenes are known to be prone to undergo ring-opening reactions. Also, the 
presence of the nitro group at position 5, combined with the electronegativity of the
QO
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sulfur atom make the methylene protons at position 2 very acidic. The presence of 
strong bases can lead to the removal of one of those protons rather than to the attack at 
the carbon atom thus displacing the halogen. After deprotonation, electron-transfer is 
thought to induce the ring opening15? 153.
l,8-Diazabicyclo[5,4,0]-undec-7-ene (DBU) was also used as an alternative base. Ono 
et al154 reported a method for the esterification of carboxylic acids with alkyl halides 
(Figure 22). This method was designed for acid- or base-sensitive compounds or 
sterically hindered acids. Successful esterification of a series of sterically hindered 
acids, heterocyclic carboxylic acids, thermally unstable acids and N-protected amino 
acids make this method very interesting and noteworthy.
^  _ TT ^  DBU
RiCOOH + R2X -------------► RjCOOR2 + DBU.HX
C6H6
Figure 22: Reaction of an acid with an alkyl halide in the presence of DBU following 
Ono et aVs protocol154.
The principle of this esterification reaction using DBU resembles that of the ion pair 
extractive alkylation or the crown ether method. In this particular case, the complex is 
not a pair of free ions but the proton forms a hydrogen-bonded bridge between DBU 
and the carboxylate (Figure 23).
Q  .N * 0 * n ~H ~O C R
U  j
123
Figure 23: DBU-acid complex.
The complex is a strong nucleophile but a weak base; therefore, although the free 
carboxylate ions could attack both the carbon and the hydrogen of alkyl halides, the
Q1
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hydrogen-bonded complex attacks preferably the carbon atom. This method is highly 
selective, compared to the ion pair extraction method.
The method proved to be unsuitable for the proposed type of synthesis. Although 
prednisolone and prednisolone-21-hemisuccinate were not successfully linked to the 
nitrothiophene, further investigations were necessary.
Other drug moieties were selected, such as isoquinolinone and nifedipine mentioned 
earlier. Two model reactions showed precedents in conditions that, so far, had not 
been used with the nitrothiophene trigger. Benzyl chloride reacted with nifedipine in 
the presence of lithium bis(trimethylsilyl)amide to give conjugate 103. Berry et a P  
obtained 2-(5-nitrofuran-2-ylmethyl)isoquinolin-l-one by deprotonation of iso- 
quinolin-l-one with sodium hydride and treatment with 2-(tosyloxymethyl)-5-nitro- 
furan.
Varying the reaction conditions, i.e. the base and the solvent together with changing 
the chlorine atom for a better leaving group might have led to the expected conjugates. 
Reaction between isoquinolinone or nifedipine with 120 in the presence of lithium 
bis(trimethylsilyl)amide did not give any positive results.
Reactions of the nitrothiophene alcohol 119 with phosgene gave the chloroformate 
derivative. Similarly, reactions with ethyl chloroformate and with 1-chloroethyl 
chloroformate 124 under basic conditions produced the carbonate derivatives. TLC 
analysis and proton NMR brought evidence for the formation of the carbonates. These 
compounds were treated with isoquinolinone and nifedipine under the two different 




8.4 A l t e r n a t iv e  a p p r o a c h e s  to  th e  1-(5-n it r o -2 -thienylm ethyl) -4 -  
(p r e d n iso l o n -21 -yl)  b u t a n e d io a t e  c o n ju g a te .
A new strategy was developed based on “building” the linker or spacer chain, that is 
to say the hemisuccinate subunit, from the nitrothiophene starting material.
Wang and Wong155 reported the reaction between succinic anhydride and benzyl 
alcohol in the presence of pyridine and DMAP to yield monobenzyl succinate in 63% 
yield. The same protocol was applied to 119 and succinic anhydride to yield the acid 
derivative 126 in 76% yield. NMR analysis showed the thiophene H-4 and H-3 as 
doublets at 6 7.25 and 6 7.03, respectively, with a coupling constant of 5.0 Hz. The 
thiophene-CH2 protons were observed as a single peak at 5 5.27 due to the deshielding 
effect of the adjacent CO2 group. The (CH2)2 came at 8 2.70 as a multiplet, for the 
overlapping two triplets that were expected.
The next logical step was to produce the acid chloride derivative, making the 
substance more reactive for nucleophilic attack (Scheme 42). Carboxylic acid 126 was 
treated with oxalyl chloride. The compound was used in the next step with 
prednisolone under basic conditions but gave no reaction. Further runs of those two 
steps gave no positive results and mass spectrometry analysis did not show the 
presence of the acid chloride. An alternative to the acid chloride was used: the 
pentafluorophenyl active ester156.
The ester 128 was generated by treatment of 126 with pentafluorophenol and 
dicyclohexylcarbodiimide. Proton NMR showed no changes in the aromatic region. 
The methylene protons at position 2 of the thiophene ring were still observed at 8 
5.29. Now the strongly electron-deficient pentafluorophenyl group is present at one 
end of the system, the signals for the two contiguous CH2 groups were observed at 
different chemical shifts (8 3.04 and 8 2.84) with a coupling constant of 6.2 Hz. The 
signals for the 6 carbons of the pentafluorobenzene ring expected in the 13C NMR 
spectrum were not observed. The peak height observed for quaternary carbons is 
usually weak, and the additional 13C-I9F coupling splits these signals into complex
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multiplets owing to Vc-f, 2Jc-f and Vc-f, reducing the peak height further. The mass 
spectrometric analysis gave further evidence for the formation of the active ester.
0 2n ^ 0H + ----- ~— 0 2N'
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o
Scheme 42: Synthesis of l-[(5-nitro-2-thienyl)methyl]-4-(prednisolon-21-yl)
butanedioate 129. Reagents: i, pyridine, DMAP; ii, (COCl)2, THF; iii, PFP, DCC, 
EtOAc; iv, prednisolone, DMF, DMAP, HC1.
Reaction between 128 and prednisolone under basic conditions afforded conjugate 
129 in good yield by displacement of the phenolate by the alkoxide ion generated by 
deprotonation of prednisolone. Although the !H NMR spectrum showed the 
characteristic peaks of the nitrothiophene in the aromatic region together with those of 
prednisolone and, although the integrations were matching, the aliphatic region was 
too complex, therefore no conclusions could be drawn on whether the conjugate was 
formed or if the spectrum was showing a one-to-one mixture of the starting materials. 
Mass spectrometry was the main technique that could be used. Mass and accurate 




This second target 129 offered an important element of comparison with target 65 for 
the release studies. The drug and linker unit being the same, the trigger effect could 
therefore be studied. The choice of this strategy afforded the target with a limited 
number of steps and offered a reasonable overall yield.
8.5 N it r o t h ie n y lm e t h yl e n e -iso q u in o l in -1 -o n e  c o n ju g a te s .
The next type of nitrothiophene-based potential prodrugs that were to be synthesised 
were bearing the PARP inhibitors. The synthesis of indoledione-based potential 
prodrugs bearing an isoquinolin-l-one moiety has been described in part 6.3.3. The 
synthesis of two potential prodrugs possessing the same drug moiety but having a 
different trigger counterpart, for which the mechanism of bioreduction is different, 
offered the possibility to compare two systems for the most efficient drug delivery in 
future in vitro and in vivo testing.
Nucleophilic attack from the deprotonated isoquinolinone (or nifedipine) on 2- 
chloromethyl-5-nitrothiophene or the ethyl and chloroethyl carbonate derivatives gave 
no sign of reaction. The nitro group at position 5 of the thiophene ring deactivates the 
ring markedly but is also thought to render the methylene protons at position 2 acidic, 
as discussed previously. The alternative use of 2-chloromethylthiophene as a trigger 
unit, followed by nitration of the thiophene ring after the drug linking reaction was 
investigated.
Thiophene-2-carboxaldehyde 130 was reduced with aqueous formaldehyde and 
sodium hydroxide, following the method reported by Dunn and Dittmer157, to give 2- 
hydroxymethylthiophene 132 in 48% yield, in a process that is related to the 
Cannizzaro reaction. The 2-chloromethyl derivative 133 was obtained by reaction of 
132 with thionyl chloride in the presence of pyridine in 64% yield (Scheme 43).
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Scheme 43: Synthesis of 2-hydroxymethyl- and 2-chloromethyl-thiophene. Reagents: i, 
MeOH, NaOH; ii, SOCl2, DCM, pyridine.
The proton NMR. spectra of those two compounds were very similar in their splitting 
pattern and chemical shifts. H-5 was seen as a doublet due to its H-4 neighbour at 8 
7.31, 8 7.09 showed H-3 as a doublet as well since it was also coupled to H-4. H-4 
arose at 8 6.95 as a doublet of doublets as a consequence of the noted couplings. The 
methylene protons were seen as a single peak at 8 4.80. In the case of 132, the peak 
for OH was observed at 8 2.03 as a singlet.
Following the procedures described earlier, isoquinolin-l-one 28 was deprotonated 
with lithium bis(trimethylsilyl)amide and the resulting anion reacted with 2-chloro- 
methylthiophene 133 to give the conjugate 135 in 45% yield. The proton NMR 
spectrum matched the structure, with shifting of the methylene protons downfield to 8 
5.34 and of H-3 in the isoquinolin-l-one to 8 7.50. H-4 of the isoquinoline resonated 
upfield at 8 6.49, confirming that the thienylmethyl unit was attached at the nitrogen 
of the isoquinolin-l-one.
A similar reaction was investigated using nifedipine 101 as the drug moiety. The 
conjugate, 136 was obtained in 10% yield (Scheme 44).
The successful course of those reactions provided the evidence that the nitro group 













Scheme 44: Synthesis of 2-(2-thienylmethyl)isoquinolin-l-one and dimethyl 2,6- 
dimethyl-4-(2-nitrophenyl)-1 -(2 -thienylmethyl)-1,4-dihydropyridine- 
3,5-dicarboxylate. Reagents: i, UN(SiMe3)2, THF, Ar.
The yields obtained for those two conjugates were relatively low but the following 
nitration steps were critical and suspected to be difficult in terms of regioselectivity. 
For that reason, optimisation of the previous reaction was considered as being of 
second order and more attention was focused on the nitration.
It is known that electrophilic substitutions are favoured at position 2 of the thiophene 
nucleus. When a substituent is present at the 2-position, electron-donating substituents 
will favour nitration at position 5, whereas electron-withdrawing substituents will be 
equally 5- and 4-directing. Berry et a f 3 worked on the nitration of 2-(furan-2- 
ylmethyl)isoquinolin-l-one and reported that mild nitration conditions such as acetyl 
nitrate, or nitric acid in acetic acid as well as other mild nitrating systems 
systematically gave the dinitrated product 4-nitro-2-(5-nitrofuran-2-ylmethyl)- 
isoquinolin-l-one. Studies on substitution of isoquinolinones showed that the principal 
site of reaction of a range of electrophiles is position 4. However, Berry et a f 3 
exploited the fact that treatment of isoquinolin-l-one with potassium nitrate in 
concentrated sulfuric acid triggered nitration at positions 5 and 7, due to the 
deactivation of the heterocyclic ring by protonation. Therefore, treatment of 2-(furan- 
2-ylmethyl)isoquinolin-l-one in trifluoroacetic acid (TFA) with nitric acid or
07
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copper(II) nitrate at low temperature lead to the selective mononitration of the furan 
ring at position 5, thus affording their target compound. Traces of the dinitro­
compound were detected and the parent isoquinolin-l-one was also isolated resulting 
from dealkylation under acidic conditions.
Based on those observations and results, 135 was treated with concentrated nitric acid 
in TFA. Work up after one hour at room temperature gave the dinitro-compound, 137. 
Work up after only 30 min at -10°C gave the mono-nitrated derivative 138 (Scheme
Scheme 45: Nitration of 2-(2-thienylmethyl)isoquinolin-l-one. Reagents: i, HN03, TFA, 
-10°C, >lh; ii, HN03, TFA, - 10 °C, < lh, HN03, AcOH, A c02, -10°C or Cu(N03)2, 
TFA.
The 4-nitro compound 138 was also obtained in 40% yield by using nitric acid and 
acetic acid in acetic anhydride at -10°C. Products of dealkylation were observed as 
minor components of the final mixture. Copper(II) nitrate in TFA gave mono-nitration 
at position 4 of the isoquinolin-l-one ring. The selective nitration of the 
isoquinolinone moiety was achieved but none of the systems used afforded selective 
nitration of the thiophene ring.
Attempts to nitrate the thiophene/nifedipine conjugate 136 under various conditions 





The next option available after the success with the indoledione trigger was to use the 
Mitsunobu reaction124. 2-Hydroxymethyl-5-nitrothiophene was treated with 
isoquinolin-l-one 28, and with 5-iodo- and 5-bromo-isoquinolin-l-ones 34,35 in the 
presence of the Mitsunobu complex triphenylphosphine / diethyl azodicarboxylate to 
afford the conjugates 139, 140 and 141. The yield for those reactions ranged from 
30% to 40% (Scheme 46).
For each of these compounds, TLC indicated that the mixture was composed of the 
target compound, an eventual dimer of the parent thiophene, the two starting materials 
and triphenylphosphine oxide. For the isolated products, proton NMR analysis showed 
an important downfield shifting of the isoquinoline H-3, H-4 and H-5, as in the case of 
compound 97, demonstrating that the nitrothienylmethyl group had attached to the 
exocyclic oxygen.
Formation of conjugate 139 was proved by the change in chemical shift o f the CH2 
group, seen in the NMR spectrum at 8 5.74. The thiophene H-4 was observed as a 
doublet at 5 7.12, coupled to H-3 also a doublet at 8 7.8, identified by their mutual 
coupling constant of 4.0 Hz. The isoquinoline H-4 was observed as a doublet at 5 7.3 
and had a coupling constant o f 6.0 Hz which matched the one of the doublet at 8 8.0 
thus identified as H-3. A pseudo triplet followed at 8 7.55 for H-7; H-6 resonated at 8 
7.7 also as a pseudo triplet with a coupling constant corresponding to the one of H-7 
of 7.7 Hz. H-5 was seen as a doublet at 8 7.75. H-8 was the most deshielded proton on 




28 R = H
34 R = I
35 R = Br
139 R = H
140 R = I
141 R = Br
Scheme 46: Synthesis of l-(5-nitro-2-thienylmethoxy)isoquinoline 139 and its 5-iodo 
and 5-bromo analogues. Reagent: i, PPh3, DEAD, THF.
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The deshielded character of the CH2 group in the molecule observed in the ]H NMR 
and the comparison between the 13C NMR shift of the CH2 group in 140 and in the 
furan analogue of 139 reported by Beriy et a l83 suggested that attachment took place 
at the oxygen rather than at the nitrogen atom of the isoquinolinone as observed in the 
case of compounds 93 and 99. No concomitant N-alkylation was observed for any of 
the compounds. The presence or absence of substituents at position 5 of the 
isoquinolinone ring did not affect the outcome of the reactions.
Proton NMR analyses for the following 5-substituted analogues were slightly 
different. Proton shifts for H-8, the thiophene H-3 and H-4 and the methylene protons 
were similar to the ones observed for the first conjugate. For both analogues, H-6 and 
H-3 resonated at similar chemical shifts. In the case of 140, H-6 was observed after H- 
8 at 6 8.22 followed by H-3 at 6 8.10. In the case of the bromo derivative, H-3 was 
seen first at 6 8.12 followed by H-6 at 6 7.97. This could be a consequence o f the 
different negative inductive effect applied by iodine compared to bromine on the ring. 
H-4 was also noticed in both conjugates to appear downfield compared to H-7, which 
was the opposite of what was observed in the parent drug moiety and in the first 
conjugate. In 140 H-4 was seen at 6 7.49 followed by the pseudo triplet of H-7 at 6 
7.27. Similarly for 141, the doublet of H-4 came at 5 7.65 and the pseudo triplet o f H- 
7 came at 6 7.42.
The Mitsunobu method enabled the synthesis of three conjugates, bringing the total 
number of nitrothiophene-based conjugates to five.
It was demonstrated that 2-hydroxymethyl-5-nitrothiophene 119 could be used to 
generate the nucleophilic alkoxide anion and attack an electrophilic centre on a drug 
derivative to yield the corresponding conjugate. However, as an electrophile, the 5- 
nitro derivative 119 did not react as expected due to the electron-withdrawing effect of 
the nitro group, presumably rendering the methylene protons too acidic. The 
Mitsunobu alternative was used to overcome this problem. The apparent selective 
formation of the ether raises more questions concerning the mechanism leading to the 
formation of the potential prodrugs.
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8.6  A ttem pted  s y n t h e sis  o f  1-[3-(5-n itro -2 -thienyl)-2 -pr o p y n -1 -ylJ-4- 
(p r e d n iso l o n -2 1 -yl)  b u t a n e d io a t e  142.
In order to study as many dimensions of the problem as possible, it was planned to 
synthesise an analogue of 129, namely l-[3-(5-nitro-2-thienyl)-2-propyn-l-yl]-4- 
(prednisolon-21-yl) butanedioate 142, by introducing a triple bond conjugated to the 
thiophene ring. By increasing the conjugated system, especially by introducing a 
multiple bond, a another parameter was introduced that was expected to influence the 
release efficiency, by analogy with the 3-alkynylindolediones.
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Scheme 47: Proposed mechanism for the bioreductively triggered release of drugs 
from 5-nitro-2-thienylpropynyl potential prodrugs.139






Scheme 48: Retrosynthetic analysis of synthetic target 142.
The major step that is highlighted by this retrosynthetic study is the coupling of the 
terminal alkyne 146 to the 2-substituted-5-nitrothiophene (Scheme 48). The creation 
of such a carbon-carbon bond has already been studied in the present work, in the case 
of the indole trigger.
Palladium-catalysed coupling reactions on thiophenes have previously been reported; 
Rossi et a /158,159 , in their work on naturally occurring acetylenic thiophenes, used 5- 
substituted-2-iodothiophene derivatives in the presence of tetrakis(triphenyl- 
phosphine)palladium, Cul as catalyst and 2.5 N sodium hydroxide as a base. Further 
work on the synthesis of acetylenic thiophenes published by van den Hoven and
10?
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Alper160 described a similar method for coupling reaction between 2-iodothiophene 
and a series of acetylenes bearing different functionalities (including simple terminal 
alkynes, propargyl ethers, alcohols, or esters, phenylacetylenes and enynes) in the 
presence of Pd(PPh3)4 and Cul. Relatively good yields were reported, ranging from 
65% to 90%. Wu et alm , in their study of push-pull type chromophores prepared from 
nitrothiophene-induced Michael-type reaction of alkynes reported the synthesis of 
nitrothienylalkynes from terminal alkynes and 2-bromo-5-nitrothiophene via 
Sonogashira coupling catalysed by bis(triphenylphosphine)palladium dichloride and 
copper(I) iodide.
Those examples seemed to offer the possibility to couple either the 2-halothiophene or 
the 5-nitro-2-halothiophene with the terminal alkyne chosen.
The synthesis of the required acetylene was based on the method used for compound 
128 (Scheme 42). Reaction between propargyl alcohol and succinic anhydride under 
basic conditions afforded acid 147 in 64% yield (Scheme 49). Proton NMR data 
matched the structure o f the compound formed: the methylene protons of the 
propargyl moiety were shifted to 8 4.71, due to the carboxy group. The two CH2 
groups of the succinic subunit were observed as a multiplet at 8 2.88 due to the 
overlapping of the two triplets expected. Finally, the methine proton was observed at 8 
2.49. The active ester of 147 was prepared following the protocol described for 128, 
affording 146 in 100% conversion.
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Scheme 49: Synthesis of 4-oxo-4-(prop-2-ynyloxy)butanoic acid 147 and 1- 
(pentafluorophenyl)-4-(prop-2-ynyl) butanedioate 146. Reagents: i, pyridine, 
DMAP; ii, PFP, DCC, EtOAc.
im
Results and Discussion
The proton NMR showed no change in chemical shift for the CH2 group a  to the triple 
bond and for the methine proton but the multiplet observed for the two CH2 groups 
changed into two distinct triplets at 6 2.80 and 8 3.03, respectively.
2-Iodothiophene 149 was commercially available but 2-iodo-5-nitro-thiophene 150 
was synthesised following the method used by D ’Auria et al162. 2-Iodothiophene 149 
was nitrated with acetic anhydride and nitric acid at low temperature to give derivative 
150 in 70% yield.
Coupling reactions between 149 and 150 (thiophene and nitrothiophene) and 146 
(alkyne) were carried out in parallel, following the general protocol described by van 
den Hoven and Alper160 using Pd(PPh3)4 as the palladium catalyst (Scheme 50).
o
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Scheme 50: Coupling reaction of 2-iodothiophene and its 5-nitro analogue to 1- 
(pentafluorophenyl)-4-(prop-2-ynyl) butanedioate. Reagents, i, Pd(PPh3)4, 
Cul, Ar, Et3N, CgHfi.
Only the non-nitrated thiophene 149 coupled successfully to the alkyne affording 151 
in 52% yield.
Nitration of 151 was attempted but, even under mild conditions (nitric acid in acetic 
acid or trifluoroacetic acid at low temperature or copper(II) nitrate in trifluoroacetic 
acid), gave a complicated mixture in which could be identified the 5-nitrated
104
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thiophene derivative but the ester bond to the succinic subunit seemed to be 
hydrolysed.
The nature of the catalyst and of the halogen on the thiophene are known to be factors 
influencing the reaction. To investigate their effect on this coupling reaction, the 
method published by Wu et al161 was used. 2-Bromo-5-nitrothiophene was prepared 
according to the method used for 2-iodothiophene and gave the derivative in 60% 
yield.
Both 2-iodo- and 2-bromo-5-nitrothiophene 150 and 152 were treated, in parallel, with 
acetylene 146, in the presence of Pd(PPh3)2Cl2. No sign of reaction was observed 
(Scheme 51).
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Scheme 51: Coupling reaction following the Wu method161. Reagents: i, Pd(PPh3)2 Cl2 , Cul, 
Ar, 'Pr2NH.
The last approach for the synthesis of the target proposed was to exploit the fact that 
coupling of the alkyne to 2-iodothiophene was successful, it was then proposed to 
couple propargyl alcohol to 2-iodothiophene, nitrate the resulting compound and react 
the nitrated derivative with succinic anhydride, followed by the expected preparation 
of the active ester and reaction with prednisolone (Scheme 52).











Scheme 52: Coupling reaction of 2-iodothiophene with propargyl alcohol and 
nitration of the product. Reagents: i, Pd(pph3)4, Cul, Ar, Et3N, CeHg, ii, HN03, 
TFA, - 10 °C.
153 was obtained in 67% yield. Nitration of 153 in TFA and nitric acid did not give 
the nitrated compound 154. Stronger conditions led to the decomposition of the ring.
Although the coupling reaction gave the expected compound, the nitration step was a 
critical reaction and no appropriate system was found to overcome the problem so far.
Results and Discussion
9. SYNTHESIS OF NITROTHIOPHENE-BASED NEW TRIGGERS.
The synthesis of new thiophene triggers was also considered. The role of these new 
triggers was to compare and optimise the ease of reduction and release the drug non- 
reversibly. The introduction of a cyclopropane ring a  to the thiophene ring was 
another idea to modify the thiophene trigger in an interesting way (Figure 24). 
Reductive activation of the proposed trigger and electron transfer would result in the 
ring opening of the cyclopropane leading to the eventual irreversible delivery of the 
drug moiety (Scheme 53).
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Scheme 53: Proposed mechanism for the bioreductively triggered release of drugs 
from 5-nitro-2-thienylcyclopropylmethyl potential prodrugs.
Figure 24: Structure of the proposed trigger.
Retrosynthetic analysis indicated a possible chemical pathway to the thienylcyclo- 
propane 155 via the Knoevenagel condensation reaction of 5-nitro-2-thiophene- 
carboxaldehyde and malonic acid reported by King and Nord163.
The condensation reaction between aldehyde 118 and acid 156, in the presence of 
pyridine gave acrylic acid 157 in high yield. Its methyl ester 158, was obtained by 
treatment with methanol in the presence of sulfuric acid. Proton NMR data matched 
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Scheme 54: Synthesis of 5-nitro-2-thienylpropenoic acid and its methyl ester. Reagent: 
i, pyridine, piperidine; ii, MeOH, H2S 0 4.
Cyclopropanation could be tried directly on this last intermediate, but it could also be 
used to produce a simpler trigger. The double bond is conjugated to the ring similarly 
to the triple bond in the proposed target 142. By reducing either the acid or the ester to 
the alcohol, a simple model of nitrothiophene trigger with a conjugated multiple bond 
would be obtained (Figure 25).
Figure 25: Structure of the proposed trigger 3-(5-nitro-2-thienyl)prop-2-enol 159.
alcohols and finally to their acetates. The starting acrylic acids were treated with ethyl 
chloroformate in the presence of triethylamine in THF. The resulting ethyl esters were 
then treated with sodium borohydride in THF and methanol at low temperature to 
afford the corresponding allylic alcohol.
5-Nitro-2-thienyl-3-propenoic acid 157 was converted into its ethyl ester 158, 
according to the method described, in 80% yield. However, the attempted reduction 
with sodium borohydride was unsuccessful. Reduction under harsher conditions, such 
as use of lithium aluminium hydride, resulted in the decomposition of the starting 
ester.
159
Pontikis et all6A converted a series of heterocyclic acrylic esters into the allylic
ins
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D’Auria and Ferri165 used thiophenepropenoic acid to produce the allyl alcohol, but 
without the nitro group at position 5. Lithium aluminium hydride was used in THF at 
low temperature. The multiple attempts resulted in decomposition of the starting 
material. More attention was then given to the cyclopropyl trigger.
The formation of cyclopropane rings from vinylthiophenes can be achieved by 
different methods. Simmons and co-workers166,167 reported a method using 
diiodomethane and a zinc-copper couple (Simmons-Smith reaction).
LeGoff168 suggested a method for the preparation of the zinc-copper couple (as a 
granular form or as a dust) before the reaction of cyclopropanation. Rawson et al169 
proposed a one-pot reaction using zinc dust and a cuprous halide. The protocol 
involved the preparation of a mixture of zinc dust and cuprous chloride in ether heated 
under reflux and nitrogen atmosphere. The olefin was then added followed by 
diiodomethane and the mixture was boiled for 24 h.
Paulissen et alm  reported a palladium-catalysed cyclopropanation of olefins using 
palladium acetate in the presence of ethyl diazoacetate or diazomethane. The model 
reactions were carried out under mild thermal conditions and were thought to proceed 
via a carbene-metal-olefin complex.
The method of Simmons166,167 was studied first. Reactions were carried out using the 
acid 157 and the ester 158. The starting material was recovered in each case without 
any sign of reaction. To prove that the electron-withdrawing effect of the nitro group 
had no effect on the reactivity of the alkene, the same reactions were carried out using 
2-thienylacrylic acid 160 and the corresponding ester 161 but no cyclopropanation 
occurred.
Paulissen’s170 method was then used. The four starting materials, that is to say the 
nitrated and non nitrated thienyl acrylic acids 157 and 160 and their methyl esters 158 
and 161 were investigated in parallel. Treatment of these alkenes with ethyl 




171Vallgarda et al synthesised and studied a range of /ra^v-2-arylcyclopropylamine 
derivatives from substituted arylpropenoate esters; methyl 2-thienylpropenoate was 
converted to methyl rraw-2-thienylcyclopropane-1 -carboxylate by the action of 
palladium acetate on a saturated ethereal diazomethane solution. The relative 
concentration of palladium catalyst was of 0.005 equivalents strictly, as higher 
concentrations led to the precipitation of palladium (0) with consequent termination of 
the reaction.
Application of this method to 158 and 161 required the preliminary generation of 
diazomethane. Diazomethane was prepared by treatment of Diazald® with potassium 
hydroxide. Reaction of 158 and 161 in the presence of Pd(OAc)2 (10 mol%) and 
diazomethane gave 162 in high yield. The corresponding nitro derivative was not 
obtained and no trace of the starting material was detected by proton NMR analysis.
NMR analysis of compound 162 showed a complicated splitting pattern in the 
aliphatic region. The four protons of the cyclopropyl ring were split into multiplets. 
The CH2 protons were, as expected, inequivalent. The three-membered ring 
conformation involves a highly strained structure causing the protons to resonate 
upfield from a usual alkane position. Each proton of the three-membered ring was 
influenced by three inequivalent neighbours, explaining the splitting pattern observed. 
The four multiplets were observed at 8 2.7, 8 1.9, 8 1.6 and 8 1.3. The methoxy 
protons were seen at 8 3.7 as a single peak. The aromatic protons of the thiophene ring 
were observed as three doublets of doublets at 8 7.09 for H-5, 8 6.89 for H-4 and 8 
6.81 for H-3 suggesting V  coupling between H-3 and H-5. The coupling constants 
accompanying the signal of those protons were respectively 3.5 and 1.3 Hz and 5.3 





Scheme 55: synthesis of methyl 2-(5-nitro-2-thienyl)cyclopropane-l-carboxylate.
Reagents: i, pyridine, piperidine; ii, MeOH, H2S04; iii, CH2N2, ether, Pd(OAc)2; iv, 
TFA, H N03; v, DffiAL-H or UAIH4 .
Regioselective nitration of 162 led to the next intermediate 163 (Scheme 55). The 
final step towards the new trigger was the reduction of the ester derivative to the 
alcohol. Reduction of the ester to the alcohol required methods involving 
diisobutylaluminium hydride or lithium aluminium hydride. Both reagents were 
investigated and gave disappointing results: DIBAL-H gave no reaction, the starting 
cyclopropyl ester was recovered from each attempt and LLAIH4 was suspected to 
trigger the cyclopropane ring-opening. The proton NMR data obtained after reaction 
were unclear and did not allow the proper identification of the compounds obtained. 
Further studies are required on that final step that would lead to a new interesting 
trigger.
In addition to the nitrothiophene-based targets, the design of two new triggers was 
proposed, but although the synthesis of the compounds was not achieved, some 
interesting aspects of the thiophene chemistry were highlighted.
Results cmd Discussion
10. RELEASE STUDIES
10.1 IN D O L E D IO N E -B A S E D  PO T E N T IA L  P R O D R U G S
A number of method have been reported for mimicking the reductive activation of 
quinone systems: e.g. electrochemistry, catalytic hydrogenation, Cr(II), sodium 
dithionite. Radiolytic reduction methods have also been reported by Naylor, Everett 
and co-workers50'52. They allowed the quantification of the efficiency of the leaving 
group elimination by studying the kinetic properties of the radical intermediates 
generated (semiquinone radical reactivity towards oxygen, effect of oxygen on leaving 
group release).
Sodium dithionite had been used to activate mitomycin C and proved to be a 
convenient method that was therefore used by Naylor et al51. The reduction 
experiment was carried out on a series of l,2-dimethyl-4,7-dioxo-5-methoxyindole-3- 
methylene potential prodrugs and models, using sodium dithionite as a reducing agent 
in the presence of a thiol to trap the electrophilic iminium intermediate. The role of the 
thiol was determined by its nucleophilic properties in mimicking the scavenging 
cellular thiols such as glutathione. The series of indolequinones was reduced with a 
large excess of sodium dithionite and five equivalents of thiol, in aqueous degassed 
THF. Naylor et al 151reported the elimination of the (model) drugs from position 3 by 
detecting both the (model) drugs and the thiol-trapped indolediones.
Tin(II) chloride has been used in the case of the nitroaromatic bioreductive triggers 
and proved to be a selective reducing agent of the nitro group80,83. The use of tin(II) 
chloride with selected indolequinone derivatives synthesised in the present study led 
to the release of the drug counterpart. TLC analysis was first used to prove the 
efficiency of the method. HPLC analysis was then required to bring further evidence 
for the reductive activation of the potential prodrug and subsequent release of the 
drug. The wavelength of maximum absorption was determined for each target to allow 
efficient UV detection.
Treatment of the potential prodrug 97 with SnCL in methanol gave two fully resolved 
peaks with retention times (Rt) of 4.3 and 4.9 min. HPLC analysis of the starting
n?
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indole 11 in the same conditions gave a peak with Rt= 4.6 min. The isoquinolin-l-one 
counterpart 28 gave a peak at Rt= 4.9 min which matched the second peak observed 
after addition of the reductive agent and the results described by Parveen et alm after 
reduction of their nitroimidazole-based potential prodrug (identical reduction system, 
HPLC instrument and operator). In the same HPLC system, the parent potential 
prodrug 97 was detected as a single peak with a retention time of 6.0 min, which was 
not observed after addition of tin(II) chloride. (Appendix 1A)
The reductively triggered release of drugs from their indoledione potential prodrugs 
was then monitored directly by proton NMR. The potential prodrugs were dissolved in 
deuterated chloroform due to their limited solubility in deuterated methanol. A tin(II) 
chloride solution was prepared in deuterated methanol. A proton NMR spectrum of 
each sample was run, a known quantity of SnCL in deuterated methanol was then 
added and the proton NMR of the new mixture was run immediately. Further 
additions of the reducing agent were carried out in the same conditions.
Compound 96 (Appendix 2) was the first potential prodrug of the indoledione series 
to be studied by HPLC and was therefore the first one subjected to the NMR study as 
an element of comparison. Following the addition of SnCL, changes in the chemical 
shifts of some of the peaks were observed. 3-H and 5-H were shifted upfield from 8
8.0 and 8 7.7, respectively, to 8 7.37 for 5-H and 8 6.88 for 3-H. Similarly 4-H moved 
from 8 7.2 to 8 6.4 after reduction. 8-H remained unchanged, 6-H and 7-H were 
slightly shifted upfield by approximately 0.1 ppm. The methylene group at position 3 
of the indole ring, which was also the linking point between the 2 subunits, shifted 
from 8 5.72 to 8 4.4, which was the final evidence that release of the drug moiety 
occurred. The chemical shifts observed after reduction corresponded to the ones of an 
equimolar mixture of isoquinolin-l-one 28 and l,2-dimethyl-3-(hydroxymethyl)-5- 
methoxyindole-4,7-dione 11. These results suggest that the electrophilic species 
produced after reduction and drug release was quenched by water and reoxidised to 
the quinone. (Appendices 3 and 4)
Results and Discussion
The methyl, N-methyl and methoxy protons of the indole showed a slight difference in 
chemical shift compared to the starting material and potential prodrug which was 
attributed to the effect of the solvent mixture (deuterated chloroform and methanol). 
Evidence for that phenomenon was obtained by running a proton NMR spectrum of a 
mixture of 28 and 11 in the same solvent mixture.
It was postulated that tin(II) chloride, being a Lewis acid, may have catalysed the 
cleavage o f the carbon-nitrogen bond instead of the expected quinone reduction 
triggering the release of the drug moiety. As a control, a similar NMR-monitored 
experiment was then carried out using SnCU, which is a stronger Lewis acid but 
exhibits no reductive properties. No cleavage was observed.
The generation of paramagnetic compounds, possessing an unpaired electron {i.e. 
radicals) causes peak broadening and changes in chemical shifts in proton NMR 
spectra. No such effects were observed at any time during the release studies.
A preliminary experiment carried out on 97 contaminated with diethyl hydrazine-1,2- 
dicarboxylate showed complete release of the drug after the addition of 0.1 equivalent 
of SnCb. In contrast, the pure potential prodrug 97 did undergo stoichiometric 
reductively triggered release; spectra taken after the addition of 0.1, 0.2, 0.5 and 1 
equivalents showed the appropriate molar ratios of 97 and the products 11 and 28. 
These observations are consistent with a stoichiometric reduction and subsequent drug 
release caused by the Sn(II) in the latter experiment. In the former experiment, it is 
likely that the Sn(IV) produced in the reaction is reduced back to Sn(E) by the diethyl 
hydrazine-1,2-dicarboxylate, making the process apparently catalytic in tin. Tin(IV) 
has not previously been reported to oxidise hydrazine- 1,2-dicarboxylates but this 
oxidation has been carried out with Pb(IV)172.
The 5-substituted analogues of 97, namely 39, 40 and 99 were treated with SnCk 
under the same conditions. The results observed were somewhat different.
Addition of one equivalent SnCb to the N-linked 5-bromoisoquinolin-l-one 40 
(Appendix 5) did not show any effects on the compound. Further addition of up to 
five equivalents did not trigger the release of the 5-bromoisoquinolinone. After 24 h,
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two sets of new peaks were observed in a 1:10 ratio with the target peaks. The number 
of peaks and the splitting pattern suggested that they were isoquinolinones; No other 
peaks were detected in the aliphatic region. Speculations were made on the possibility 
that, under reductive conditions, the bromine atom at position 5 could be cleaved 
reductively (Appendices 6 and 7). Parveen et alm reported that, under other reductive 
conditions, (sodium borohydride and palladium on charcoal) reductive debromination 
of the 5-bromoisoquinolinone occurred after its release from the initial 
nitroimidazolylmethyl potential prodrug.
The N-linked 5-iodo analogue 39, when submitted to the same reductive conditions, 
also did not show any signs of release of the 5-iodoisoquinolin-l-one 34 or of the free 
indoledione-methanol 11 (Appendix 8).
In contrast, when the O-linked 5-iodoisoquinoline 99 (Appendix 9) was subjected to 
similar reductive conditions and monitored by proton NMR, the addition of one 
equivalent of SnCl2 led to the complete release of the drug. Significant shifting of 3-H 
and 4-H was observed from 8 8.08 to 8 7.12 and 8 7.40 to 8 6.76, respectively. The 3- 
CH2 protons of the indole shifted from 8 5.71 to 8 4.52, as observed in the case of 97, 
confirming complete release of the drug 34 and regeneration of the indoledione 11 
(Appendix 10). This NMR approach to studying release of drugs and other moieties 
from their 4,7-dioxoindole-3-methylene derivatives is the first report of evaluation of 
potential bioreductively activated prodrugs in this way.
Subjection of the indoledione-prednisolone potential prodrug 65 (containing the 
succinate linker) (Appendix 11) to the same conditions gave surprising results. The 
side-reaction, hydrolytic/methanolytic cleavage of the ester, was not observed by the 
proton NMR spectrum. Moreover, the overall chemical shifts were not modified when 
either the tin(H) chloride or sodium dithionite reductive system was used, suggesting 
that no release of the drug moiety occurred. (Appendices 12 and 13).
Treatment of analogous pentamethylmelamine potential prodrug 94 (Appendix 14) 
with excess SnCl2 gave complex and largely uninterpretable results. The spectrum 
obtained after addition of tin(II) chloride in deuterated methanol was composed of
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broad peaks masking all signals. The addition of deuterium oxide allowed the partial 
reduction of some of the broad peaks, presumably due to complexes formed between 
the tin and the drug moieties; the addition of deuterated water allowed the transfer of 
the tin and of a fraction of the methanol in the aqueous phase. Although the peaks of 
the starting material could still be identified, a second set of peaks corresponding to 
the free drug were also identified together with H-6 and CH2 from the indoledione 11 
at 8 5.5 and 8 4.60, respectively. Some of the drug moiety appeared to be release from 
94. However, the presence of remaining broad peaks together with only an apparent 
partial release of the pentamethylmelamine in the presence of an excess of reductant 
do not allow one to draw conclusions (Appendices 15 and 16). The deuterated 
analogue 96 (Appendix 17) gave similar results (Appendix 18).
Some general trends could be drawn from the release studies of the series of indole- 
dione-based potential prodrugs. Firstly, the observation o f release from the 0-(indolyl- 
methoxy)isoquinolines but no release from the N-(indolylmethyl)isoquinolin-1 -ones is 
consistent with the potentially greater leaving group ability of the oxyanion, compared 
to the nitrogen anion. When the indoledione is reduced to the corresponding 4,7- 
dihydroxyindole, the latter has only two possible fates: expulsion of the drug or 
reoxidation back to the indoledione potential prodrug. Thus the drug moiety has to be 
a sufficiently good leaving group to be expelled rapidly during the lifetime of the 
reduced indole unit. Clearly, the carboxylate of prednisolone-21-hemisuccinate, 
although predicted to be a better leaving group than the isoquinolinone nitrogen 
anions, is still not sufficiently powerful. Naylor et a l51 report efficient expulsion of a 
range of different model leaving groups (carboxylates, phenolates and hydroxide) 
from this indoledione trigger but their experiments were conducted using ten 
equivalents of sodium dithionite as reductant and in the presence of ethyl xanthate as a 
trapping agent, conditions which are much more vigorous that those in the present 
study. The larger excess of the more powerful reductant would prolong the effective 
lifetime of the 4,7-dihydroxyindole initial intermediate, whereas the thiolate-trapping 




10.2 N it r o t h io p h e n e -b a s e d  p o t e n t ia l  p r o d r u g s
The methods available to reduce selectively an aromatic / heteroaromatic nitro group 
are numerous. Everett et a t 2 reported the reduction of the 2-nitroimidazole to the nitro 
radical anion using pulse radiolysis and y-radiolysis. Other methods include catalysed 
hydrogenation, although this has been reported to trigger hydrogenolysis at the 
“benzylic” position, that is to say the linking ArCHk-O or A1CH2N bonds.
Sodium borohydride in the presence of palladium on charcoal, but also tin(II) chloride 
and titanium trichloride have been used successfully to reduce aromatic nitro groups 
selectively and thus to trigger release of the drug moieties. Beny et a t 3 reported the 
release of the drug counterpart from nitrofuran-based prodrugs following reduction to 
the aminofuran intermediate using sodium borohydride in the presence of palladium 
on and using tin(D) chloride. Parveen et a t 0 used zinc dust in the presence of 
ammonium chloride in aqueous methanol, the sodium borohydride method described 
by Berry et a t 3, and tin(II) chloride in methanol to achieve the reduction of a 
nitroimidazole-based prodrug.
The effects of reduction on nitrothiophene-based potential prodrug series were 
initially studied by HPLC. Injection of a solution of the nitrothienylmethyl aspirin 
compound 42 gave a single peak at Rt = 3.4 min. The nitrothiophenemethanol 119 and 
the salicyloyl counterpart (aspirin) under the same conditions were detected at Rt =
3.1 and 3.9 min, respectively. Potential prodrug 42 was then treated with zinc powder 
in the presence of NH4CI and the mixture was analysed at regular time intervals. After 
1 min, two peaks were observed at Rt = 3.1 and 3.7 min. These results suggested rapid 
ester hydrolysis, rather than reduction of the nitrothiophene.(Appendix IB)
The analogous nitrothienylmethyl prednisolone hemisuccinate compound 129 was 
subjected to treatment with SnC^ in methanol. No reaction was observed at 20°C. On 
warming, two new peaks with retention times 3.7 and 3.9 min were formed (the less 
polar potential prodrug had Rt = 4.1 min). These retention times corresponded with 
the retention times for prednisolone-21-hemisuccinate and 5-nitro-2-thienylmethanol,
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respectively. As in the case of 42, hydrolysis of an ester was strongly 
suspected. (Appendix 1C).
The nitrothienylmethyl potential prodrugs of the isoquinolin-1 -ones 139-141 were too 
insoluble in methanol for this reductive system to be investigated. Thus a different 
approach was considered for the release studies on the potential prodrugs.
The success o f the NMR-monitored release studies for the indoledione-based 
compounds was not transferred to the case of the nitrothiophene-based analogues. 
Tin(II) chloride in deuterated chloroform and methanol at room temperature did not 
induce the reduction and release of the drug counterpart for any of the nitrothienyl­
methyl potential prodrugs.
The method used for the release studies on nitrofuran prodrugs83 seemed to be a more 
appropriate system to use. Each nitrothienylmethyl potential prodrug was treated with 
sodium borohydride in the presence of palladium on carbon in aqueous isopropanol. 
TLC analysis indicated the disappearance of the potential prodrugs and the presence 
of the free drugs after 30 min. Proton NMR analysis was carried out for each mixture 
after reaction. The spectra obtained showed complicated patterns. In each case, the 
aliphatic region was complicated and few interpretations could be obtained. The peaks 
corresponding to the nitrothiophene had disappeared in each case.
In these NMR studies, after reduction of 139, the free isoquinolinone was detected, 
giving a doublet for 8-H at 8 8.23, followed by the pseudo triplet of H-7 at 8 7.62, the 
doublet of H-5 at 8 7.48, the pseudo triplet of H-6 at 8 7.41 and the two doublets of H- 
3 and H-4 at 8 7.19 and 8 6.59, respectively. These signals were identical to those of 
isoquinolin-l-one 28 recorded under the same conditions but were distinct from those 
o f the isoquinoline unit in the potential prodrug (Appendix 19). Reduction of 140 
(Appendix 20)and 141 (Appendix 22) also gave the free 5-iodo- and 5-bromo- 
isoquinolin-l-ones 34 (Appendix 21), 35 (Appendix 23).
Results and Discussion
!H NMR analysis of the product of reduction of the aspirin potential prodrug 42 
(Appendix 24) showed two sets of peaks in the aromatic region. It was suspected that 
one set corresponded to salicylic acid and the other to aspirin, implying that hydrolytic 
deacetylation took place, either before or after release. The absence of nitrothiophene 
peaks suggested that the trigger subunit was efficiently reduced, but it is not known 
whether the drug was released following potential prodrug activation or whether the 
ester cleavage preceded the trigger reduction (Appendices 25 and 26).
Complex results were also obtained after reduction of prednisolone potential prodrug 
129 (Appendix 27). Aliphatic protons from the steroid could be identified amongst 
the multiple signals of the aliphatic region. However, the steroid alkene protons, 
namely H -l, H-2 and H-4, were not found. The reductive conditions could have led to 
reduction of the two double bonds of the steroid A-ring. The two CH2 groups of the 
hemisuccinate linker were masked by another signal rendering impossible to tell 
whether the two ester bonds present in the molecule were affected by the environment. 
Therefore no conclusion could be drawn on whether the drug moiety was released 
after prodrug activation or ester cleavage took place first (Appendix 28).
Successful reduction of each of the nitrothiophene-based potential prodrugs was 
achieved. Release of the drug moiety was observed for in the case o f 139, 140 and 
141, the isoquinoline potential prodrug analogues. However in the case of the two 
target compounds containing ester bonds 42 and 129, the order of events could not be 
determined, i.e. there was no evidence for the specific release of the drug moieties 
after reduction, the reductive ester cleavage before reduction of the trigger was just as 
probable.
In contrast to the reversible reduction of the indoledione potential prodrugs, the 
reduction of the nitrothiophenes is essentially irreversible, since aminothiophenes 
often undergo rapid ring-opening reactions. Thus the effective lifetime of the reduced 




Two series of potential prodrugs, designed for bioreductive activation and release of 
anti-inflammatory and anti-arthritic drugs, have been synthesised for the selective 
delivery of these drugs to areas of inflammation characterised by low oxygen 
concentrations.
One series is based on l,2-dimethyl-5-methoxyindole-4,7-dione unit. The synthesis of 
the first potential prodrug was achieved by nucleophilic attack from the steroidal drug 
moiety on the trigger. The introduction of a spacer proved to be necessary due to steric 
hindrance. The drug counterpart for the four following potential prodrugs were PARP 
inhibitors, namely isoquinolin-l-one and its 5-substituted analogues. Trigger and 
effector were linked via the Mitsunobu reaction. The site of attachment of the trigger 
on the drug varied with the analogue used, the ether derivative was obtained for 
isoquinolin-l-one, N-alkylation took place in the case of 5-bromo and of the Boc- 
protected 5-aminoisoquinolinones. 5-Iodoisoquinolinone gave both derivatives 
separately. There is some evidence that the nature of the 5-substituent and the precise 
reaction conditions have a major effect on the regioselectivity of the reaction.
The second series was based on the 5-nitrothiophene-2-ylmethylene unit. The 
influence of the nitro group at position 5 influenced the chemistry of the thiophene 
119 considerably. Reactions involving 119 as the electrophile failed due to the acidity 
of the methylene protons and consequently the risk of ring opening. The nucleophilic 
species derived from 119, however, reacted with 2-acetoxybenzoyl chloride to give 
potential prodrug 42. Coupling of the nitrothienylmethyl succinate active ester 128 
with prednisolone generated potential prodrug 129. Three potential prodrugs were 
obtained from Mitsunobu reaction between trigger 119 and the isoquinolinone 
analogues. Each analogue reacted with 119 to give the ether derivatives. No N- 
alkylation was observed, adding a possible alcohol effect to the speculations made 
above for the indoledione series.
The release studies were carried out using chemical systems to represent the in vivo 
reductive conditions. The indoledione-isoquinoline ethers released the drug moiety 
under reductive conditions (tin(II) chloride). The reduction observed proved to be
i?n
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stoichiometric, no Lewis acid seemed involved. The N-alkylated derivatives and the 
steroid potential prodrug did not give any signs of release. Although the quinone 
seemed to be reduced, the half-life of the reduced form was suspected to be short. The 
release of drugs from 11 is reversible and a leaving group effect was probably at the 
origin of the lack of reactivity observed in the case of 65,39 and 40.
The nitrothiophene series was reduced with sodium borohydride in the presence of 
palladium on carbon. Reduction of the nitrothiophene trigger was observed for each 
target, and release of the isoquinolinone effector moiety was detected for 139,140 and 
141. The weakness of potential prodrugs 42 and 129 relied on the presence of ester 
bonds as linkers. The results obtained by proton NMR analysis together with HPLC 
data suggested that the ester bond between the trigger and effector unit was 
hydrolysed under the conditions before reductive trigger activation.
Finally, this study showed that nitrothiophene- and indoledione-based potential 
prodrugs could be used as potential bioreductively activatable prodrugs. Release of the 
drug moiety was observed for each series for some of the potential prodrugs. 
However, testing of the compounds in hypoxic cell culture and in vivo is necessary to 
draw further conclusions on the hypoxia and enzyme selectivity and potential toxicity 




M a t e r ia l s  a n d  g e n e r a l  p r o c e d u r e s
Chemicals were purchased from the Aldrich, Fluka, Lancaster and Sigma chemical 
companies and were used without further purification. All solvents were either GPR 
or HPLC grade purchased from BDH. Anhydrous solvents were purchased in 
anhydrous form, or prepared by standard procedures (THF was used freshly distilled 
from Na/benzophenone). Water refers to singly distilled water. All solvent ratios are 
given as volume/volume. When anhydrous reagents were used, all glassware was first 
dried at 120°C, in vacuo. !H and 13C NMR spectra were recorded on JEOL GX270 or 
VARIAN EX400 spectrometers. Chemical shifts (8) are reported in parts per million 
downfield from tetramethylsilane as internal standard. Coupling constants (J) are in 
Hertz and multiplicities are indicated as follows: s (singlet), d (doublet), t (triplet), dd 
(doublet of doublets), q (quartet), m (multiplet) and br (broad signal). Assignments of 
13C NMR spectra were assisted by the use of 135- and 90-DEPT experiments. Thin 
layer chromatography (TLC) was performed routinely to monitor reaction progress 
and chemical purity. TLC was performed on pre-coated plates (Merck TLC 
aluminium sheets 60 F254, Art no. 5554). The spots were visualised using UV light 
(254 nm or 366 nm). Flash column chromatography was performed according to the 
method of Still et al (1978) using Sorbasil C60-H silica gel purchased from BDH. 
Columns were packed as a slurry in the eluting solvent and pressure was applied with 
a Hy Flo pxw-430-T one piston pump. High performance chromatography, for the 
release studies, was performed using a semi-preparative column Kromasil 10C18, a 
Jasco PU-986 preparative pump and Jasco UV-975 detector. Methanol was used as the 
eluant with a flow rate of 5 mL min'1, the injection volume was kept at 20 pL. Melting 
points (mp) were determined using a Reichert-Jung Thermo Galen Kopfler block and 
are uncorrected. Infra red spectra were recorded either as a thin liquid film or as a KBr 
disc using a Perkin Elmer 782 instrument. Ultra Violet spectra were obtained from 
solutions in chloroform using a Perkin Elmer Lambda 3 spectrometer. Mass spectra 
were obtained using VG autospec spectrometer. Electron impact ionisation (El) 
spectra were recorded typically using an ionising potential of 70 eV. Positive and 
negative FAB mass spectra were recorded using 3-nitrobenzyl alcohol as the matrix.
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In vacuo refers to the use of a water pump, at a pressure typically 15-30 mmHg. For 
the removal of solvents in vacuo, a Btichi rotary evaporator was used and for chying of 
solids in vacuo, a Gallenkamp vacuum oven was used with P2O5 as the drying agent, 
unless otherwise stated. Experiments were conducted at room temperature, unless 





Method 1: to 54 (3.4 g, 12.3 mmol) in CHCI3 (370 ml) and EtOH (125 ml) was added 
a solution of sodium dithionite (25.0 g) in water (160 ml). The mixture was stirred 
vigorously overnight. The organic layer was separated, washed with brine, dried and 
concentrated to give 55 as a buff solid that was used directly. To a stirred suspension 
of 55 in toluene (500 ml) under N2 at -30°C, was added DIBAL-H (1 M solution in 
toluene; 13.9 g, 97.9 mmol) dropwise during 5 min. The mixture was stirred at this 
temperature for 2 h. The reaction was quenched by dropwise addition of iron(HI) 
chloride solution (1 M FeC^/0.1 M HC1, 125 ml) while keeping the temperature 
below -30°C. The mixture was filtered (Celite®) and the solid was washed with hot 
CH2CI2. The organic layer was separated, washed with saturated aq. NH4CI and dried. 
Evaporation and chromatography (EtOAc/CFhC^ 4:1) yielded 11 (0.20 g, 6.4%) as an 
orange-red crystalline solid: R f 0.3 (EtOAc/CH2Cl2 4:1); mp 200-201°C (lit.51 mp 
199-200°C); ]H NMR (CDC13) 8 5.60 (1 H, s, 6-H), 4.59 (2 H, d, J  = 7.0 Hz, 
CH2OH), 3.87 (1 H, t, J  = 6.7 Hz, OH), 3.88 (3 H, s, OCH3), 3.81 (3 H, s, NCH3), 
2.21 (3 H, s, 2-CH3).
Method 2: to LiAM* (0.13 g, 3.3 mmol) in THF (20 ml) at 0°C was added 53 (0.22 g, 
0.84 mmol) in THF (10 ml). The mixture was allowed to warm to 20°C and was 
stirred for 30 min. It was then cooled to 0°C and the reaction was quenched by 
addition of water (0.1 ml), 1 M NaOH (0.1 ml) and silica gel (1.0 g). The granular 
precipitate was filtered off (Celite®). The filtrate was dried and evaporation yielded 56 
(0.15 g, 80%) as an off-white powder which was used directly in the next step without 
further purification: lH NMR (CDC13) 8 6.86 (1 H, d, J  = 8.7 Hz, 6-H), 6.59 (1 H, d, J  




To 56 (0.2 g, 0.91 mmol) in acetone (40 ml) was added potassium nitrosodisulfonate 
(0.9 g, 3.6 mmol) in phosphate buffer (0.3 M, pH 6.7,40 ml). The mixture was stirred 
for lh. The acetone was evaporated in vacuo. The resulting residue was extracted with 
CH2CI2 and washed with water. The organic layer was dried. Evaporation, chromato­
graphy (EtOAc/CTECE 4:1) and recrystallisation (CTECE/hexane) yielded 11 (0.16 g, 
75%) as an orange-red solid (characterisation above).
Method 3: to a suspension of 62 (0.10 g, 0.43 mmol) in MeOH (40 ml, degassed) was 
added NaBHU (0.16 g, 4.3 mmol) under dry Ar. The solution was stirred for 1 h and 
aerated prior to the addition of water (20 ml). The mixture was extracted with CH2CI2 
(3 x 50 ml) and dried. Evaporation, chromatography (EtOAc) and reciystallisation 




Compound 86 (0.15 g, 0.8 mmol) in EtOH (12 ml) and conc. HC1 (0.4 ml) was stirred 
under H2 in the presence of palladium on charcoal (0.1 g) for 1 h. The suspension was 
filtered through Celite®. The Celite® pad and residue were heated in water (200 ml). 
The resulting hot suspension was filtered through a second Celite® pad. Evaporation 
of the solvent from the combined filtrates gave 33’ (0.12 g, 95%) as off-white crystals: 
mp >230°C (lit.111 mp >230°C); lHNMR (D20 )  5 8.29 (1 H, d,7  = 8.0 Hz, 8-H), 7.77 
(1 H, d, 7 =  8.0 Hz, 6-H), 7.63 (1 H, t, 7 =  8.0 Hz, 7-H), 7.42 (1 H, d ,7 =  7.5 Hz, 3-H),







Compound 82 (0.3 g, 1.1 mmol) was added to a solution of 2-methoxyethanol (50 ml) 
saturated with ammonia. The solution was boiled under reflux for 24 h, with periodic 
cooling and re-saturation with ammonia. Evaporation yielded 34 as beige crystals (0.2 
g, 68%): mp 239-242°C (lit.83 mp 238-244°C); !H NMR (CDC13) 8 11.20 (1 H, s, 
NH), 8.35 (1 H, dd, J  = 7.5, 1.1 Hz, 8-H), 8.15 (1 H, dd, J = 7.5, 1.1 Hz, 6-H), 7.17 (1 




Compound 83 (0.3 g, 1.1 mmol) was added to a solution o f 2-methoxyethanol (50 ml) 
saturated with ammonia. The solution was boiled under reflux for 24 h, with periodic 
cooling and re-saturation with ammonia. Evaporation yielded 35 (0.2 g, 71%) as beige 
crystals: mp 240-243°C (lit.113 mp 242-244°C); 'H  NMR (CDC13) 8 11.17 (1 H, s. 
NH), 8.21 (1 H, d, 7 =  8.0 Hz, 8-H), 8.05 (1 H, d ,J =  8.0 Hz, 6-H), 7.41 (1 H, d ,J  = 





Diethyl azodicarboxylate (0.12 ml, 0.7 mmol) was added dropwise to 5- 
iodoisoquinolin-l-one 34 (0.1 g, 0.4 mmol) and PPI13 (0.19 g, 0.7 mmol) in dry THF 
(20 ml) under dry Ar. The mixture was stirred for 15 min and 11 (0.085 g, 0.4 mmol) 
was added. The mixture was stirred overnight. Evaporation and chromatography 
(EtOAc) afforded 39 (63 mg, 36%) as a purple powder: R f 0.46 (EtOAc); mp >230°C; 
m  3096,2923, 1702, 1470, 1380 cm"1; 'H NMR (CDCI3) 5. 8.38 (1 H, d, J=  8.2 Hz, 
8-H), 8.11 ( H, dd, ./ = 7.9, 1.1 Hz, isoquinoline 6-H), 7.80 (1 H, d, J  = 7.9 Hz, 
isoquinoline 3-H), 7.12 (1 H, t, J — 7.8 Hz, isoquinoline 7-H), 6.66 (1 H, d ,J — 7.9 Hz, 
isoquinoline 4-H), 5.62 (1 H, s, indole 6-H), 5.29 (2 H, s, CH2), 3.88 (3 H, s, CH30),
3.81 (3 H, s, CH3N), 2.47 (3 H, s, CH3); 13C NMR (CDC13) 8 178.1 (indole 7-CO),
161.1 (indole 4-CO), 159.0 (isoquinoline 1-CO), 142.5 (indole 5-C), 138.9 (iso­
quinoline 8a-C), 138.7 (isoquinoline 3-CH), 134.1 (isoquinoline 6-CH), 128.7 (iso­
quinoline 4a-C), 128.0 (indole 7a-C), 127.2 (isoquinoline 7-CH and indole 2-C), 126.7 
(isoquinoline 8-CH), 121.1 (isoquinoline 5-C and indole 3a-C), 109.1 (isoquinoline 4- 
CH and indole 3-C), 106.5 (indole 6-CH), 56.5 (CH30), 42.2 (CH3N), 32.6 (CH2),





Diethyl azodicarboxylate (0.07 ml, 0.4 mmol) was added dropwise to 5- 
bromoisoquinolin-l-one 35 (0.05 g, 0.2 mmol) and PPI13 (0.11 g, 0.4 mmol) in dry 
THF (20 ml) under dry Ar. The mixture was stirred for 15 min and 11 (0.05 g, 0.2 
mmol) was added. The mixture was stirred overnight. Evaporation and 
chromatography (EtOAc) afforded 40 (38 mg, 40%) as a purple powder: R f 0.35 
(EtOAc/hexane 10:1); mp 278-280°C; IR 3070, 2999, 1695, 1693, 1676, 1465, 1399 
cm 'H NMR (CDCI3) 5 8.36 (1 H, d. J  = 7.8 Hz, isoquinoline 8-H), 7.84(1 H, dd, J  
= 7.3, 0.9 Hz, isoquinoline 6-H), 7.82 (1 H, d, J  = 8.0 Hz, isoquinoline 3-H), 7.27 (1 
H, t, J=  8.2 Hz, isoquinoline 7-H), 6.77 (1 H, d, J=  8.0 Hz, isoquinoline 4-H), 5.62 (1 
H, s, indole 6-H), 5.30 (2 H, s, CH2), 3.88 (3 H, s, CH30), 3.81 (3 H, s, CH3N), 2.47 
(3 H, s, indole 2-CH3); 13C NMR (CDC13) 5 178.2 (indole 7-CO), 161.2 (indole 4- 
CO), 159.3 (isoquinoline 1-CO), 138.8 (isoquinoline 8a-C), 136.3 (indole 5-C), 135.6 
(isoquinoline 3-CH), 134.1 (isoquinoline 6-CH), 128.8 (isoquinoline 4a-C), 128.5 
(indole 2-C), 128.1 (indole 7a-C), 127.4 (isoquinoline 7-CH), 126.8 (isoquinoline 8- 
CH), 121.2 (isoquinoline 5-C), 120.4 (indole 3a-C), 116.1 (indole 3-C), 106.6 
(isoquinoline 4-CH), 104.3 (indole 6-CH), 56.5 (CH30), 42.2 (CH3N), 32.6 (CH2),
10.2 (CH3); MS (FAB +ve) m/z 441.0443 (M+H), (C2iH18N204Br requires 441.0449).
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5-N itrothien-2-ylmethy 1 2-acetoxybenzoate (42)
Triethylamine was added (0.65 ml, 4.7 mmol) to 119 (0.5 g, 301 mmol) in CH2CI2 (5 
ml) at 0°C. The mixture was stirred for 10 min at 0°C. 2-Acetoxy benzoyl chloride 
(0.62 g, 3.1 mmol) in CH2CI2 (5 ml), was added. The resulting mixture was stirred at 
20°C for 1.5 h, and the solvent was evaporated. The residue in CH2CI2 was washed 
with HC1 3 M, aqueous NaHC03, and brine. It was then dried and the solvent was 
evaporated. Chromatography (hexane/EtOAc 1:1) yielded 42 (0.36 g, 35%) as a 
yellow oil: R f 0.5 (hexane / EtOAc 1:1); IR 3100, 2960, 1715, 1750, 1600, 1500, 
1450, 1370, 740, 700 c m 1; lU NMR (CDC13) 8 8.04 (1H, dd, J = 1.5, 7.8 Hz, Ph 6-H), 
7.83 (1 H, d, 3.9 Hz, thiophene 4-H), 7.61 (1H, ddd, J=  1.5, 7.4, 8.2 Hz, Ph 4-H), 
7.33 (1H, ddd, J  = 1.1, 7.4, 7.8 Hz, Ph 5-H), 7.12 (1 H, dd, J = 1.1, 8.2 Hz, 3-H), 7.07 
(1 H, d, J  = 3.9 Hz, thiophene 3-H), 5.41 (2 H, s, CH2), 2.31 (3 H, s, CH3); 13C NMR 
(CDCI3) 5 169.3 (CO), 163.4 (CO), 150.8 (thiophene 5-C), 145.4 (Ph 2-C), 134.4 
(thiophene 2-C), 131.6 (Ph 4-CH and thiophene 4-CH), 128.0 (Ph 6-CH), 126.7 
(thiophene 3-CH), 126.0 (Ph 1-C), 123.8 (Ph 5-CH), 122.0 (Ph 3-CH), 60.8 (CH2),
21.0 (CH3); MS (FAB +ve) m/z 322.0385 (M+H) (Ci4H12N0 6S requires 322.0385). 
Anal. C 52.28%, H 3.42%, N 4.35% (Ci4HnN 0 6S requires C 52.33%, H 3.42%, N 
4.36%).
Ethyl l,2-dimethyl-5-methoxymdole-3-carboxylate (49)
Ethyl 5-hydroxy-2-methylindole-3-carboxylate (48) (6.0 g, 27.5 mmol) in dry DMF 
(50 ml) was added under N2 to a stirred suspension of KH (3.3 g, 82.5 mmol) in dry 
DMF (200 ml) at 0°C. The mixture was stirred for 45 min. Iodomethane (11.7 g, 82.4
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mmol) was added dropwise at 0°C and the mixture was allowed to warm to 20°C 
during 4 h. Saturated aqueous NH4CI was added and the mixture was extracted with 
EtOAc (3x75 ml). The EtOAc solution was washed twice with water and dried. 
Evaporation and chromatography (EtOAc) gave 49 as a white solid (5.4 g, 80 %): Rf 
0.5 (EtOAc); mp 119-120°C (lit.51 mp 119-121°C); NMR (CDCI3) 8 7.66 (1 H, d, J  
= 2.5 Hz, 4-H), 7.17 (1 H, d, J=  8.8 Hz, 7-H), 6.87 (1 H, dd, 8.8, 2.5 Hz, 6-H), 
4.39 (2 H, q, J=  7.1 Hz, CH2), 3.88 (3 H, s, OCH3), 3.66 (3 H, s, NCH3), 2.74 (3 H, s,
2-CH3), 1.45 (3 H, t, 7.1 Hz CH2C//3).
Ethyl l,2-dimethyl-5-methoxy-6-nitroindoIe-3-carboxyIate (51) and ethyl 1,2- 
dimethyl-5-methoxy-4-nitroindole-3-carboxy!ate (52).
To 51 (5.1 g, 20.6 mmol) in AcOH (80 ml), cooled to -10°C, was added a mixture of 
conc. HNO3 (11 ml) and AcOH (41 ml). The mixture was stirred for 2 h, while 
warming to 20°C. The yellow suspension was poured onto an ice/water mixture and, 
after 15 min, the solid was collected by filtration, and dried. Chromatography 
(EtOAc/light petroleum 1:1) yielded 51 (0.8 g, 14%): R f 0.6 (EtOAc); mp 138-139°C 
(lit.45 mp 139-141°C); lK  NMR (CDC13) 8 7.96 (1 H, s, 7-H), 7.79 (1 H, s, 4-H), 4.40 
(2 H, q, J  = 7.0 Hz, CH2), 4.02 (3 H, s, OCH3), 3.73 (3 H, s, NCH3), 2.79 (3 H, s, 2- 
CH3), 1.46 (3 H, t, J  = 7.0 Hz CH2C//3). Further elution gave 52 (3.8 g, 63%): R f 0.4 
(EtOAc); mp 187-188°C (lit.51 mp 189-192°C); NMR (CDCl3) 8 7.30 (1 H, d, J  =
9.1 Hz, 7-H), 6.93 (1 H, d, J=  9.1 Hz, 6-H), 4.29 (2 H, q, J = 7.1 Hz, CH2), 3.91 (3 H, 






To 52 (2.18 g, 7.5 mmol) in EtOH (190 ml) were added HC1 (conc., 10ml) and tin 
powder (4.0 g, 33.6 mmol). The mixture was heated under reflux for 30 min. Upon 
cooling, the solution was decanted from the excess of tin and was neutralised with 
aqueous NaHCXb. The suspension was added to an equal volume of water, was stirred 
overnight with CH2CI2 (200 ml) and filtered (Celite). The organic layer was dried 
(MgSCU) and concentrated. Evaporation and chromatography (EtOAc) yielded 53 as a 
light yellow crystalline solid (1.56 g, 80%): R f 0.6 (EtOAc); mp 96-97°C (lit.51 mp 
96-98°C); lU NMR (CDCI3) 8 6.88 (1 H, d, 8.7 Hz, 7-H), 6.52 (1 H, d, J=  8.7 Hz,
6-H), 5.68 (2 H, br s, NH2), 4.36 (2 H, q, J  = 7.0 Hz, CH2), 3.87 (3 H, s, OCH3), 3.58 





To 53 (3.2 g, 12.2 mmol) in Me2<X> (400 ml) was added potassium nitrosodisulfonate 
(5 g, excess) in phosphate buffer (NaH2P04/Na2HP04) (0.3 M, 400 ml, pH 6.0). The 
mixture was stirred for 1 h. The excess Me2<30 was removed in vacuo. The residue 
was extracted with CH2CI2 (3x75 ml) which was washed with water and dried. 
Evaporation and recrystallisation (CXbCyiight petroleum, 2:3) gave 54 (3.3 g, 97%) 
as an orange-yellow crystalline solid: R f 0.4 (EtOAc); mp 202-203°C (lit.51 mp 202- 
204°C); *H NMR (CDC13) 8 5.64 (1 H, s, 6-H), 4.36 (2 H, q, 7.1 Hz, CH2), 3.91 (3 








5-Methoxy-2-methylindole 57 (0.1 g, 0.62 mmol) was added slowly under diy Ar to a 
stirred suspension of NaH (0.027 g of a 60% dispersion, 0.68 mmol) in DMF (15 ml). 
The suspension was heated at 45°C for 10 min and cooled to 20°C. Mel (0.33 ml, 5.3 
mmol) was added during 5 min. The solution was then heated at 60°C for 1 h, cooled, 
poured onto cold (0°C) NaHSC>4 (aqueous, 10%, 5 ml), extracted with EtOAc (3x15 
ml), dried and evaporated. Chromatography (EtOAc/hexane 3:97) gave 58 (0.09 g, 
80%) as a pale buff solid: R f 0.5 (EtOAc/hexane 3:97); mp 70-73°C (lit.50 mp 73- 
74°C); *H NMR (CDC13) 8 7.06 (1 H, d, J=  8.8 Hz, 7-H), 6.93 (1 H, d, J=  2.4 Hz, 4- 
H), 6.73 (1 H, dd, J=  2.4, 8.8 Hz, 6-H), 6.16 (1 H, s, 3-H), 3.82 (3 H, s, OCH3), 3.59 
(3 H, s, NCH3), 2.37 (3 H, s, 2-CH3).
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l,2-Dimethyl-5-methoxyindole-3-carboxaldehyde (59)
Anhydrous DMF (0.088 ml, 1.1 mmol) was added to 58 (0.1 g, 0.57 mmol) in CH2CI2 
(3 ml), was added and the mixture was stirred for 5 min. POCI3 (0.1 ml, 1.1 mmol) 
was then added dropwise. The solution was heated under reflux for 2 h and cooled, 
aqueous NaOAc (1.0 M, 10 ml) was added and the solution was stirred for 2.5 h. The 
solution was extracted with EtOAc and dried. Evaporation and chromatography 
(EtOAc/hexane 1:1) gave 59 (0.05 g, 43%) as an off-white solid: R f 0.5 (EtOAc); mp 
115-117°C (lit.50 mp 108-110°C); *HNMR (CDC13) 5 10.1 (1 H, s, CHO), 7.80 (1 H, 
d, J  = 2.3 Hz, 4-H), 7.17 (1 H, d, J  = 8.9 Hz, 7-H), 6.89 (1 H, dd, J  = 2.3, 8.9 Hz, 6- 




Compound 59 (0.70 g, 3.4 mmol) in acetic acid (55 ml) was cooled to 5°C and yellow 
fuming nitric acid (2.0 ml) in AcOH (8.2 ml) was added dropwise during 5 min. The 
temperature was allowed to rise to 20°C during 3 h, the mixture was poured onto 
crushed ice and the precipitate was collected by filtration. Chromatography 
(EtOAc/hexane 2:1) gave 60 (0.43 g, 60%) as a pale yellow solid: R f 0.42 (EtOAc); 
mp 235-237°C (lit.50 mp 236-238°C); NMR (DMSO) 5 9.90 (1 H, s, CHO), 7.75 (1 
H, d, J=  9.0 Hz, 7-H), 7.25 (1 H, d ,J=  9.0 Hz, 6-H), 3.89 (3 H, s, OCH3), 3.76 (3 H, 
s, NCH3), 2.71 (3 H, s, 2-CH3).
W  CHO
4-Amino-l ,2-dimethyl-5-methoxyindole-3-carboxaIdehyde (61)
Powdered tin (0.35 g, 2.9 mmol) was added to 60 (0.15 g, 0.60 mmol) in EtOH (15 
ml), followed by aqueous HC1 (3.0 M, 5 ml), and the solution was heated under reflux 
for 1 h. Water (45 ml) was added and the solution neutralised with aqueous NaHC03, 
extracted with CHC13 (3 x 100 ml), dried and evaporated. Chromatography 
(EtOAc/Hexane 1:1) gave 61 (0.10 g, 62%) as a pale yellow solid: R f 0.6 (EtOAc); 
mp 155-157°C (lit.50 mp 152-153°C); *H NMR (DMSO) 5 9.71 (1 H, s, CHO), 6.85 (1 
H, d, J = 9.0. Hz, 6-H), 6.56 (1 H, d, J  = 9.0 Hz, 7-H), 6.0 (2 H, s, NH2), 3.75 (3 H, s, 





To compound 61 (0.15 g, 0.68 mmol) in acetone (30.5 ml) was added potassium 
nitrosodisulfonate (0.92 g, 3.4 mmol) in NaH2P04/Na2HPC>4 buffer (30.5 ml, 0.3 M, 
pH 6) and the solution was stirred for 1 h. The acetone was evaporated at 30°C. The 
precipitate was collected by filtration and was washed with H2O and cold MeOH to 
give 62 (0.12 g, 75%) as an orange solid: R f 0.5 (EtOAc); mp 240-242°C (lit.50 mp 
239-242°C); ]H NMR (DMSO) 8 10.37 (1 H, s, CHO), 5.89 (1 H, s, 6-H), 3.88 (3 H, 
s, OCH3), 3.82 (3 H, s, NCH3), 2.50 (3 H, s, 2-CH3).
3-(Chloromethyl)-1^2-dimethyl-5-methoxyindole-4,7-dione (63)
Compound 11 (0.5 g, 2 mmol) was stirred with SOCI2 (5 ml) for 30 min. The solution 
was then evaporated in vacuo, dissolved in EtOAc (25 ml), and evaporated to dryness. 
This procedure was repeated twice. Reciystallisation (EtOAc) gave 63 (0.42 g, 79 %) 
as an orange solid: Rf 0.25 (EtOAc); mp 203-204°C (lit.51 mp 204-205°C); ]H NMR 
(CDC13) 8 5.62 (1 H, s, 6-H), 4.86 (2 H, s, CH2), 3.89 (3 H, s, OCH3), 3.80 (3 H, s, 




(1,2-Dimethy I-4,7-dioxo-5-methoxy indoI-3-y I)methy 14-n itropheny 1 carbonate 
(64)
4-Nitrophenyl chloroformate (0.085 g, 0.42 mmol) in THF (10 ml) was added slowly 
to 11 (0.1 g, 0.42 mmol) and pyridine (0.033 ml, 042 mmol) in THF (15 ml) under Ar. 
The mixture was stirred for 2 d. The evaporation residue in EtOAc was washed with 
water and brine and dried. Evaporation and chromatography (EtOAc) yielded 64 (0.13 
g, 78%) as a yellow oil: R f 0.52 (EtOAc); *H NMR (CDCI3) 5 8.15 (2 H, d, J =  9.1 
Hz, Ph 3V5’-H2), 6.94 (2 H, d , / = 9.1 Hz, Ph 2’/6’-H2), 5.66 (1 H, s, indole 6-H), 5.46 





butanedioate or 4-(l,2-dimethyl-4,7-dioxo-5-methoxyindol-3-ylmethoxy)-21-0-(4- 
oxobutanoyl)predniso!one (65)
Compound 63 (0.20 g, 0.79 mmol) was dissolved in DMF (50 ml). Prednisolone-21- 
hemisuccinate sodium salt (0.38 g, 0.79 mmol) was added. The mixture was heated 
under reflux for 24 h. The solution was allowed to cool and the solvent was
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evaporated. Chromatography (EtOAc/CtkCh 4:1) gave 65 as a bright orange glassy 
material (0.21 g, 40%): IR (KBr) 3450, 2920, 1730, 1650, 1490, 1220, 1150, 1110, 
1050 c m 1; *H NMR (DMSO) S 7.32 (1 H, d, J=  10.5 Hz, steroid 2-H), 6.17 (1 H, d, J  
= 10.6 Hz, steroid 1-H), 5.92 (1 H, s, steroid 4-H), 5.77 (1 H, s, indole 6-H), 5.16 (2 
H, s, CH2), 5.04(1 H, d, J =  17.5 Hz) and 4.71 (1 H, d, J  = 17.5 Hz) (steroid 21-H2), 
4.27 (1 H, s, steroid 11-H), 3.98 (3 H, s, OCH3), 3.85 (3 H, s, NCH3), 3.65 (2 H, m, 
steroid 6-H2), 2.8 (4 H, m, butanedioate CH2CH2), 2.4 (2 H, m, steroid I6-H2), 2.24 (3 
H, s, indole 2-CH3), 2.15 (2 H, m, steroid 15-H2), 2.05 (1 H, m, steroid 9-H), 1.75 (2 
H, m, steroid I2-H2), 1.45 (2 H, m, steroid 7-H2), 1.38 (3 H, s, steroid 19-CH3), 1.13 
(1 H, m, steroid 8-H), 1.05 (1 H, m, steroid 14-H), 0.76 (3 H, s, steroid 18-CH3); 13C 
NMR (CDC13) 5 204.9 (steroid 20-CO), 186.1 (steroid 3-CO), 178.0 (indole 7-CO), 
172 (ester CO), 170.9 (ester CO), 159.7 (indole 4-C), 157.1 (steroid 1-CH), 138.2 
(indole 5-C), 129.3 (indole 2-C), 127.7 (indole 3a-C), 122.3 (steroid 2-CH), 121.8 
(steroid 4-CH), 115.7 (indole 3-C), 106.8 (indole 6-CH), 89.92 (steroid 17-C), 70.3 
(steroid 11-CH), 68.5 (steroid 21-CH2), 57.3 (CH30), 56.7 (steroid 9-CH), 55.8 
(steroid 5-CH2), 51.7 (steroid 14-CH), 48.0 (steroid 13-C), 44.6 (steroid 10-C), 39.8 
(steroid I2-CH2), 34.6 (steroid I6-CH2), 34.0 (steroid 8-CH), 32.5 (NCH3 and steroid
7-CH2), 31 (steroid 6-CH2), 29.4 (butanedioate 2-CH2 and 3-CH2), 24.3 (steroid 15- 
CH2), 21.4 (steroid 19-CH3), 17.7 (steroid 18-CH3), 9.9 (indole 2-CH3); MS (FAB 




SOCI2 (6.84 ml, 0.9 mmol) was added dropwise to 2-methyl-3-nitrobenzoic acid 75 
(10.0 g, 0.55 mmol) in MeOH (200 ml) and the mixture was boiled under reflux 
overnight. Evaporation gave 76 as a beige solid (9.0 g, 83%): mp 63-65°C (lit.114 mp 
64-65°C); lH NMR (CDC13) 5.8.00 (1 H, d,J =  7.8 Hz, 4-H), 7.85 (1 H, d, J=  7.8 Hz,





5-Nitroisocoumarin (78) and 3-methoxy-5-nitro-3,4-dihydroisocoumarin (79)
Dimethylformamide dimethyl acetal (21.5 ml, 160 mmol) was added to 76 (9.0 g, 46 
mmol) in DMF (30 ml) and the mixture was boiled under refluxed for 20 h. 
Evaporation and chromatography (hexane/EtOAc 10:1) gave 78 (2.82 g, 32%) as 
yellow crystals: mp 171-172°C (lit.108 mp 173-174°C); ]H NMR (CDC13) 8 8.64 (1 H, 
ddd, J = 7.8, 1.5, 0.8 Hz, 8-H), 8.51 (1 H, dd, J  = 8.2, 1.5 Hz, 6-H), 7.68 ( l H , t , J  =
8.2 Hz, 7-H), 7.44 (1 H, d, /  = 5.8 Hz, 3-H), 7.39 (1 H, d, J  = 5.8, 0.8 Hz, 4-H). 
Further elution gave 79 (0.90 g, 10%) as yellow crystals: mp 111-112°C (lit.110 mp
111.5-112.5°C); !H NMR (CDC13) 8 8.48 (1 H, d, J = 8.0 Hz, 6-H), 8.28 (1 H, d, J  = 
8.0 Hz, 8-H), 7.59 ( 1 H , U =  8.0 Hz, 7-H), 5.52 (1 H, t, J  = 3.1 Hz, 3-H), 3.59 (2 H, 




2 M aqueous HC1 (4 ml) was added to 78 (1.67 g, 8.7 mmol) in dry THF (40 ml). 
Palladium on charcoal (0.25 g) was added and the flask was exposed to hydrogen for 1 
h after which the solution was filtered (Celite®). The evaporation residue in CH2CI2 
was washed with aq. NaHCC>3. The aqueous layer was re-extracted with CH2CI2. The 
combined organic phases were dried. Evaporation yielded 80 (1.12 g, 80%) as pale 
yellow crystals: mp 191-192°C (lit.114 mp 194-195°C); !HNMR (CDC13) 8 7.76 (1 H, 
d, J = 8.1 Hz, 8-H), 7.32 (1 H, t, J  = 8.1 Hz, 7-H), 7.25 (1 H, d, J  = 6.1 Hz, 3-H), 7.04 






HC1 was passed through 80 (0.15 g, 0.9 mmol) in CHCI3 (50 ml) for 1 h. The solid 
formed was filtered off to give 80* (0.17 g, 95%) as white ciystals: mp 161-164°C; 
NMR (CDCI3) 5 8.14 (1 H, d, J=  8.2. Hz, 8-H), 7.88 (1 H, t, J=  8.2. Hz, 7-H), 7.53 (1 
H, t, J  = 7.7 Hz, 6-H), 7.39 (1 H,d, J  = 6.7 Hz, 3-H), 6.98 (1 H, d, J  = 6.7 Hz, 4-H), 




A solution of NaN02 (2.6 g, 37.3 mmol) in water (200 ml) was added to a solution of 
80 (7.0 g, 43.4 mmol) in HC1 (50 % solution, 250 ml) at 0°C, maintaining the 
temperature of the solution below 5°C. A chilled solution of KI (10.0 g, 60 mmol) and 
Cul in water (250 ml) was added slowly. The solution was stirred for 2 h before 
extraction with EtOAc. Evaporation and chromatography (hexane/EtOAc 4:1) yielded 
82 (8.3 g, 70%) as off-white crystals: mp 155-156 °C (lit.83 mp 160-161°C); !HNMR 
(DMSO) 5 8.31 (1 H, d, J=  7.9 Hz, 8-H), 8.22 (1 H, d, J=  7.6 Hz, 6-H), 7.75 (1 H, d, 






Compound 80 (2.5 g, 15.4 mmol) was dissolved in 2 M aq. H2SO4 (80 ml). The 
solution was cooled to 0°C. A solution of NaNC>2 (1.05 g, 15.4 mmol) in water (5 ml) 
was added maintaining the temperature below 5°C. KBr (3.6 g, 31 mmol) and CuBr 
(4.4 g, 30.9 mmol) were added slowly to the solution. The reaction mixture was stirred 
for 2 h and extracted with EtOAc. Evaporation and chromatography (hexane/EtOAc 
6:1) gave 83 (1.4 g, 37%) as off white crystals: mp 135-137°C (lit.113 113-115°C); 
NMR (CDCI3) 6 8.31 (1 H, d, J=  8.1 Hz, 8-H), 7.95 (1 H, d, J=  8.1 Hz, 6-H), 7.41 (1 
H, t9J=  8.1 Hz, 7-H), 7.36 (1 H, d, J  = 6.2 Hz, 3-H), 6.85 (1H, d, J=  6.2 Hz, 4-H).
O
5-(l,l-DimethyIethoxycarbonylamino)isocoumarin (84)
To 80 (0.11 g, 0.8 mmol) in CH2CI2 (20 ml) was added DMF (1.5 ml) and Et3N (50 
pi). The solution was cooled to 0°C and di-ter/-butyl dicarbonate (0.30 g, 1.4 mmol) 
in CH2CI2 (1 ml) was added in small quantities over 4 d. The evaporation residue in 
EtOAc was washed with water and brine and dried. Evaporation and chromatography 
(EtOAc/hexane 1:4) gave 84 (0.12 g, 60%) as a yellow powder: mp 190-192°C (lit.113 
mp 188-190°C); ]H NMR (CDC13) 6 8.10 (1 H, d, J  = 8.0 Hz, 8-H), 8.05 (1 H, d, J  = 
6.9 Hz, 6-H), 7.50 (1 H, t ,J =  8.0 Hz, 7-H), 7.30 (1 H, d, 6.0 Hz, 3-H), 6.53 (1 H, 







EtsN (1.56 ml, 0.1 mmol) was added to 33* (0.6 g, 3.7 mmol) in DMF (40 ml) and the 
solution was cooled to 0°C. Di-terf-butyl dicarbonate (2.45 g, 0.1 mmol) was added in 
small quantities over 2 d. The evaporation residue in EtOAc was washed with water 
and brine and dried. Evaporation and chromatography (EtOAc/hexane 1:4) gave 85 
(0.57 g, 60%) as a yellow powder: R f 0.23 (EtOAC/hexane 1:1); mp >230°C (lit.113 
mp >230°C); ]H NMR (CDC13) 5.11.17 (1 H, s, NH), 8.22 (1 H, d, J=  7.8 Hz, 8-H),
8.03 (1 H, m, 6-H), 7.48 (1 H, t, J  = 7.8 Hz, 7-H), 7.18(1 H, d, J  = 6.2 Hz, 3-H), 6.67 




Compound 78 (0.5 g, 2.6 mmol) was boiled under reflux for 4 h in 2-methoxyethanol 
(50ml) saturated with ammonia. The solution was cooled eveiy 30 min and re­
saturated with ammonia. The solvent was then removed in vacuo until 10 ml 
remained. The cloudy solution was stored at 4°C overnight. The precipitate was 
collected, washed (water, ethanol) and dried to yield 86 (0.2 g, 60%) as yellow 
crystals: mp 247-249°C (lit.94 mp 250°C); ]H NMR (CDC13) 8.11.8 (1 H, s, NH), 8.58 
(1 H, d, / =  7.7 Hz, 8-H), 8.46 (1 H, d,J =  7.7 Hz, 6-H), 7.66 (1 H, t, / =  7.7 Hz, 7-H), 
7.45 (1 H, d, J  = 7.7 Hz, 3-H), 6.97 (1 H, d, J  = 7.7 Hz, 4-H). MS (FAB +ve) m/z 




H3C <> ° \ < - CH3
h’c1 h3 * t « *
5-(N,N-Bis(l ,l-dimethylethoxycarbonyI)ammo)isoquinoIin-l-one (87)
EtsN (50 pi) and DMAP (5 mg) were added to 33' (0.15 g, 0.9 mmol) in DMF (20 ml) 
and the solution was cooled to 0°C. Di-terf-butyl dicarbonate (0.6 g, 2.8 mmol) was 
added in small quantities over 4 d. The evaporation residue in EtOAc was washed 
with water and brine and dried. Evaporation and chromatography (EtOAc/Hexane 1:4) 
gave 87 as a yellow powder (0.2 g, 60%): R f 0.34 (EtOAC/hexane 1:1); mp 178- 
180°C; !H NMR (CDC13) 6 11.61 (1 H, s, NH), 8.41 (1 H, d9J  = 7.8 Hz, 8-H), 7.51 (2 
H, m, 6/7-H2), 7.27 (1 H, d, J=  7.8 Hz, 3-H), 6.56 (1 H, d, J  = 7.0 Hz, 4-H), 1.56 (18 
H, s, 2 Bul); MS (FAB +ve) m/z 361.1762 (M+H), (Q 9H25N2O5 requires 361.1763).
Cl
N ^ N
(H3C)2Nx ^ N x ^N (C H 3)2
2,4-Bis(dimethylamino)-6-chloro-l^,5-triazine (89)
2,4,6-Trichloro-l,3,5-triazine 88 (2.0 g, 11 mmol) in acetone (20 ml) was added to 
crushed ice (50 g) and dimethylamine (22 ml, 43 mmol) was added all at once with 
stirring. The mixture was stirred at 40°C and then allowed to cool. Filtration and 
recrystallisation (propanol/water) yielded 89 (1.3 g, 59%) as a white crystalline solid: 
R f 0.5 (EtOAc/hexane 1:1); mp 62-64°C (lit.119 mp 66-68°C); 'H NMR (CDC13) 5 





Compound 89 (1.0 g, 4.9 mmol) was added to methylamine (4.3 ml, 49 mmol) in 
water (7.5 ml). The mixture was boiled under reflux until it became homogeneous. 
Aqueous NaOH (1 ml, 0.2 g, 4.9 mmol) was added slowly. Reflux was maintained for 
another 20 minutes. The solution was filtered hot. Evaporation gave an oil which 
solidified on cooling. The solid was triturated with cold water (50 ml), filtered and 
dried. Reciystallisation (ethanol/water) gave 90 (0.61 g, 63%) as a white crystalline 
solid: R f 0.3 (EtOAc/hexane 1:1); mp 104-105°C (lit.120 mp 98-103°C); 'H NMR 
(CDCI3) 5 3.09 (12 H, s, 4 x CH3), 2.90 (3 H, s, CH3).
2,4-Bis(dimethylamino)-6-trideuteromethylamino-l,3,5-triazine (91)
Compound 89 (2.0 g, 9.9 mmol) was added to CD3NH2.HCI (0.35 g, 4.9 mmol) in 
water (15 ml). The mixture was boiled under reflux until it became homogeneous. 
Aqueous NaOH (4 mi, 0.4 g, 9.9 mmol) was added slowly. Reflux was maintained for 
another 20 minutes. The solution was filtered hot. Evaporation gave an oil which 
solidified on cooling. The solid was triturated with cold water (50 ml), filtered and 
dried. Recrystallisation (ethanol/water) gave 91 (1.18 g, 60%) as a white crystalline 
solid: R f 0.3 (EtOAc/hexane 1:1); mp 94-95°C; IR 3090, 2933, 2073 cm”1; NMR
(CDCI3) 6 3.07 (12 H, s, 4 x CH3), 4.89 (1 H, s, NH); 13C NMR (CDC13) 6 166.5 (1- 





Diethyl azodicarboxylate (0.06 ml, 0.4 mmol) was added dropwise to isoquinolin-1- 
one 28 (0.05 g, 0.3 mmol) and PPI13 (0.09 g, 0.4 mmol) in dry THF (20 ml) under dry 
Ar. The mixture was stirred for 15 min and benzyl alcohol 92 (0.04 ml, 0.3 mmol) was 
added. The mixture was stirred overnight. Evaporation and chromatography (EtOAc) 
afforded 93 (31 mg, 39%) as a colourless oil: R f 0.63 (EtOAc/hexane 1:1); *H NMR 
(CDCI3) 6.8.31 (1 H, d, J  =  8.5 Hz, isoquinoline 8-H), 8.00 (1 H, d, J  = 6.2 Hz, 
isoquinoline 3-H), 7.7 (1 H, d, J =  8.2 Hz, isoquinoline 5-H), 7.66 (1 H, t, J=  8.2 Hz, 
isoquinoline 6-H), 7.55 (1 H, t, J=  8.2 Hz, isoquinoline 7-H), 7.36 (5 H, m, Ph), 7.25 
(1 H, d, J  = 6.2 Hz, isoquinoline 4-H), 5.58 (2 H, s, CH2); 13C NMR (CDC13) 8 147.2 
(isoquinoline 1-C), 137.8 (Ph 1-C), 137.2 (isoquinoline 8a-C), 130.3 (Ph 276’-CH),
129.4 (isoquinoline 4a-C), 128.3 (Ph 4CH and isoquinoline 6-CH and 7-CH), 127.7 
(Ph 375’-CH), 126.5 (isoquinoline 3-CH and 8-CH), 125.9 (isoquinoline 5-CH), 124.1 






Diethyl azodicarboxylate (0.05 ml, 0.3 mmol) was added dropwise to compound 90 
(0.060 g, 0.3 mmol) and PPI13 (0.080 g, 0.3 mol) in dry THF (15 ml) under dry Ar.
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The mixture was stirred for 15 min and 11 (0.070 g, 0.3 mmol) was added. The 
mixture was stirred overnight. Evaporation and chromatography (EtOAc) afforded 94 
(49 mg, 40%) as an orange solid: Rf 0.36 (EtOAc); IR 3090, 2980, 1680, 1690, 1470 
cm-1; 'H  NMR (CDC13) 5 5.61 (indole 1 H, s, 6-H), 5.12 (2 H, m, CH2), 3.88 (3 H, s, 
CH3O), 3.81 (3 H, s, indole CH3N), 3.11 (12 H, s, 2 x N(CH3)2), 2.94 (3 H, s, 
meiamine CH3N), 2.21 (3 H, s, indole 2-CH3); 13C NMR (CDCI3) 5 178.6 (indole 7- 
CO), 165.2 (indole 4-CO, meiamine 2-C), 159.4 (meiamine 4/6-C), 137.8 (indole 7a-C 
and indole 5-C), 122.5 (indole 2-C and indole 3a-C), 120.3 (indole 3-C), 106.6 (6- 
CH), 56.4 (CH30), 39.6 (CH2), 35.9 (N(CH3)2), 32.8 (indole N-CH3), 29.8 (meiamine 
CH3N), 9.9 (indole 2-CH3); MS (FAB +ve) m/z 414.2253 (M+H) C ^ H ^ O s  requires 
414.2256).
(H3Q 2N N N(CHj>2Y Y
1,2-Dimethyl 3-{N-[[4,6-bis(dimethylamino)-l^,5-triazin-2-yI]-N-(trideutero)- 
methylamino]methyl}-5-methoxyindole-4,7-dione (96)
Diethyl azodicarboxylate (0.07 ml, 0.45 mmol) was added dropwise to compound 91 
(0.1 g, 0.4 mmol) and PPh3 (0.12 g, 0.45 mol) in dry THF (15 ml) under diy Ar. The 
mixture was stirred for 15 min and 11 (0.085 g, 0.4 mmol) was added. The mixture 
was stirred overnight. Evaporation and chromatography (EtOAc) afforded 96 (35 mg, 
20%) as an orange solid: R f 0.5 (EtOAc); IR 3090, 2980, 2780, 1680, 1690, 1470 
c m 1; 'H  NMR (CDC13) 8 5.61 (1 H, s, indole 6-H), 5.14 (2 H, m, CH2), 3.88 (3 H, s, 
CH3O), 3.81 (3 H, s, indole CH3N), 3.11 (12 H, s, 2 x N(CH3)2), 2.21 (3 H, s, indole
2-CH3); 13C NMR (CDCI3) 5 178.6 (indole 7-CO), 165.2 (indole 4-CO, meiamine 2- 
C), 159.8 (meiamine 4/6-C), 138.1 (indole 7a-C and indole 5-C), 122.5 (indole 2-C 
and indole 3a-C), 120.3 (indole 3-C), 106.8 (indole 6-CH), 56.6 (CH30), 39.8 (CH2),
36.1 (N(CH3)2), 32.8 (indole N-CH3), 10.1 (indole 2-CH3), the CD3 signal was too 






Diethyl azodicarboxylate (0.13 ml, 0.85 mmol) was added dropwise to isoquinolin-1- 
one 28 (0.06 g, 0.4 mmol) and PPh3 (0.22 g, 0.85 mmol) in dry THF (20 ml) under dry 
Ar. The mixture was stirred for 15 min and 11 (0.1 g, 0.4 mmol) was added. The 
mixture was stirred overnight. Evaporation and chromatography (EtOAc) afforded 97 
(59 mg, 40%) as a red powder: R f 0.47 (EtOAc); mp >230°C; IR 3042, 2991, 1725, 
1694/1671.7, 1465/1399 cm"1; ‘H NMR (CDC13) 5. 8.17 (1 H, d, J  = 8.6 Hz, iso- 
quinoline 8-H), 8.00 (1 H, d, J=  5.8 Hz, isoquinoline 3-H), 7.70 (1 H, d, J  — 8.2 Hz, 
isoquinoline 5-H), 7.61 (1 H, td, 7  = 8.2, 1.1 Hz, isoquinoline 6-H), 7.45 (1 H, td, 7  = 
8.2, 1.1 Hz, isoquinoline 7-H), 7.20 (1 H, d, 7  = 5.8 Hz, isoquinoline 4-H), 5.72 (2 H, 
s, CH2), 5.62 (1 H, s, indole 6-H), 3.89 (3 H, s, CH30), 3.80 (3 H, s, CH3N), 2.38 (3 
H, s, indole 2-CH3); l3C NMR (CDCI3) 8 178.9 (indole 7-CO), 177.6 (indole 4-CO),
160.3 (indole 5-C), 159.7 (isoquinoline 1-C), 142.4 (isoquinoline 8-CH), 139.6 (iso­
quinoline 3-CH), 138.0 (isoquinoline 4a-C), 137.9 (isoquinoline 6-CH), 130.3 (indole
2-C), 129.0 (indole 7a-C), 126.4 (isoquinoline 7-CH), 125.9 (isoquinoline 5-CH),
124.4 (isoquinoline 8a-C), 122.0 (indole 3a-C), 119.8 (indole 3-C), 117.3 (iso­
quinoline 4-CH), 114.8 (indole 6-CH), 56.4 (CH30), 53.4 (CH2), 50.8 (CH3N), 9.8 







Diethyl azodicarboxylate (0.12 ml, 0.7 mmol) was added dropwise to 5-iodo- 
isoquinolin-l-one 34 (0.1 g, 0.4 mmol) and PPh3 (0.19 g, 0.7 mmol) in dry THF (20 
ml) under dry Ar. The mixture was stirred for 15 min and 11 (0.085 g, 0.4 mmol) was 
added. The mixture was stirred overnight. Evaporation and chromatography (EtOAc) 
afforded 99 (69 mg, 39%) as a purple powder R f 0.46 (EtOAc); mp >230°C; IR 3096, 
2923, 1702, 1470, 1380 cm-1; ’H NMR (CDCI3) 8. 8.20 (1 H, d, J =  8.3 Hz, iso­
quinoline 8-H), 8.15 (1 H, dd, J=  7.4, 1.0 Hz, isoquinoline 6-H), 8.08 (1 H, d, .7 = 6.1 
Hz, isoquinoline 3-H), 7.40 (1 H, d, J=  6.1 Hz, isoquinoline 4-H), 7.16 (1 H, t, J  = 8.0 
Hz, isoquinoline 7-H), 5.71 (2 H, s, CH2), 5.62 (H, s, indole 6-H), 3.89 (3 H, s, 
CH3O), 3.80 (3 H, s, CH3N), 2.37 (3 H, s, indole 2-CH3); 13C NMR (CDCI3) 8 178.9 
(indole 7-CO), 177.6 (indole 4-CO), 160.5 (indole 5-C), 159.7 (isoquinoline 1-C),
141.1 (isoquinoline 4a-C), 139.5 (isoquinoline 3-CH), 138.0 (indole 7a-C), 134.5 (iso­
quinoline 6-CH), 128.9 (indole 2-C), 127.5 (isoquinoline 8-CH), 125.1 (isoquinoline
7-CH), 120.6 (indole 3a-C and isoquinoline 8a-C), 118.5 (indole 3-C), 117.0 (indole
4-CH), 106.6 (isoquinoline 4-CH and 5-C), 58.6 (CH30), 56.4 (CH2), 32.4 (CH3N), 







Diethyl azodicarboxylate (0.12 ml, 0.8 mmol) was added dropwise to 85 (0.10 g, 0.4 
mmol) and PPI13 (0.20 g, 0.8 mmol) in dry THF (20 ml) under dry Ar. The mixture 
was stirred for 15 min and 11 (0.090 g, 0.4 mmol) was added. The mixture was stirred 
overnight. Evaporation and chromatography (EtOAc) afforded 100 (22 mg, 12%) as 
an orange solid: R f 0.51 (EtOAc); *H NMR (CDCI3) 5 8.21 (1H, d, /  = 8.0 Hz, iso­
quinoline 8-H), 7.47 (2 H, m, isoquinoline 3-H and 6-H), 7.27 ( l H , t , / =  8.0 Hz, iso­
quinoline 7-H), 6.57 (1 H, d, J=  8.0 Hz, isoquinoline 4-H), 5.62 (1 H, s, indole 6-H), 
5.25 (2 H, s, CH2), 3.88 (3 H, s, CH30), 3.81 (3 H, s, CH3N), 2.47 (3 H, s, indole 2- 
CH3), 154 (9 H, s, Bul).
Dimethyl l-benzyl-2,6-dimethyl-4-(2-nitrophenyl)-l,4-dihydropyridine-3,5- 
dicarboxylate (103)
LiN(SiMe3)2 (1.0 M in THF) (7.8 ml, 7.8 mmol) and nifedipine 101 (1.35 g, 3.9 
mmol) were stirred together in DMF (10 mi) for 2 h under dry Ar. Benzyl chloride 
(0.5 g, 3.9 mmol) was added followed by Nal (5 mg). The mixture was stirred for 2 d. 
The evaporation residue in EtOAc was washed with water and brine and dried. 
Evaporation and chromatography (hexane/EtOAc 1:1) yielded 103 (0.68 g, 40%) as a
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yellow glass: Rf 0.43 (EtOAc/hexane 1:1); ]H NMR (CDC13) 5 7.65-7.20 (9 H, m, Ar, 
ArN02), 5.70 (1 H, s, 4-H), 4.93 (2 H, s, CH2), 3.63 (6 H, s, 2 x OCH3), 2.4 (6 H, s, 2 





Method 1: IC1 (0.71 ml, 6.2 mmol) and 1,4-dioxane (0.8 ml) were added to 57 (0.1 g,
6.2 mmol) in pyridine (5 ml) at 0°C. The solution was stirred overnight. The solvents 
were evaporated. The residue, in CH2Cl2,was washed with aq. Na2C 03 (10%), aq. HC1 
(2 M), aq. NaHC03 (saturated) and water and was dried. Evaporation gave 109 (0.089 
g, 50%) as a buff solid: R f 0.27 (EtOAc); 'H  NMR (CDC13) 8 8.52 (1 H, s, NH), 7.99 
(1 H, s, 4-H), 7.18 (1 H, d, J  = 9.3 Hz, 7-H), 6.73 (1 H, m, 6-H), 3.80 (3 H, s, CH30),
2.37 (3 H, s, 2-CH3).
Method 2: KOH (1.3 g, 23 mmol) was added to 57 (1.0 g, 6.2 mmol) in DMF (4.0 ml) 
and the mixture was stirred 5 min. I2 (1.57 g, 6.2 mmol) in DMF (4.0 ml) was added 
dropwise. The mixture was stirred for 10 min and was poured into a mixture of 
Na2S2C>5, (0.91 g, 4.8 mmol) and 25 % aqueous NH3 (8.53 ml) in water (150 ml). The 
precipitate was filtered off to give 109 (1.07 g, 60%) as a buff solid which was used 





M eS02Cl (1.72 g,15 mmol) in benzene (15ml) was added dropwise under vigorous 
stirring to 109 (1.0 g, 3.5 mmol), BiLjNBr (0.2 g, 0.62 mmol), NaOH (5.0 g), benzene
148
Experimental
(15 ml) and water (25 ml). Stirring was continued for 1 h, the organic layer was 
washed with water and dried. Evaporation, chromatography (toluene) and reciystall- 
isation yielded 110 (0.24 g, 19%) as an off-white solid: Rf 0.7 (EtOAc); mp 146- 
147°C; IR 3090, 2970, 1600, 1470 cm'1; !H NMR (CDC13) 6 7.85 (1 H, d, J=  9.1 Hz, 
7-H), 6.95 (1 H, dd, J=  9.1, 2.5 Hz, 6-H), 6.84 (1 H, d, J=  2.5 Hz, 4-H), 3.93 (3 H, s, 
CH30), 3.00 (3 H, s, S02CH3), 2.68 (3 H, s, 2-CH3); 13C NMR (CDC13) 6 157.3 (5-C),
138.0 (2-C), 132.8 (3a-C), 130.4 (7a-C), 115.1 (7-CH), 114.1 (6-CH), 104.1 (4-CH), 
73.1 (3-C), 55.7 (OCH3), 40.6 (SCH3), 16.4 (CH3); MS (FAB+ve) m/z 365.9678 
(M+H) (Cn H]3IN03S requires 365.9660); Anal. C 36.60%, H 3.39%, N 3.86% 




A mixture of 110 (0.50 g, 1.3 mmol), trimethylsilylethyne (0.14 g, 1.4 mmol), 
Pd(PPh3)2Cl2 (32 mg, 0.045 mmol), Cul (16 mg, 0.084 mmol) and DMF (10 ml) was 
stirred under Ar for 10 min and triethylamine (1.22 ml, 8.7 mmol) was added. The 
mixture was stirred for 3 d. The mixture was diluted with water (20 ml) and extracted 
with diethyl ether ( 3 x 1 0  ml). The ether extracts were washed with water and dried. 
Evaporation, chromatography (EtOAc/hexane 1:1) and reciystallisation (pentane) 
yielded 111 (0.25 g, 60%) as a light yellow solid: R f 0.6 (EtOAc/hexane 1:1); mp 98- 
102°C; IR (KBr) 3090, 2970, 2260, 1610, 1470, 1260, 850, 780 cm-1; *H NMR 
(CDC13) 5 7.83 (1 H, d, J=  9.1 Hz, 7-H), 7.05 (1 H, d , / =  2.6 Hz, 4-H), 6.94 (1 H, dd, 
J  = 9.1, 2.6 Hz, 6-H), 3.88 (3 H, s, CH30), 3.00 (3 H, s, S 02CH3), 2.68 (3 H, s, 2- 
CH3), 0.30 (9 H, s, Si(CH3)3); 13C NMR (CDC13) 6 157.2 (5-C), 142.2.0 (2-C), 130.9 
(7a-C), 130.0 (3a-C), 115.0 (7-CH), 113.7 (6-CH), 105.6 (alkyne 1-C), 102.8 (4-CH),
101.6 (3-C), 96.4 (alkyne 2-C), 56.3 (CHsO), 41.0 (S02CH3), 14.0 (CH3), -0.1 






A mixture of 110 ( 0.08 g, 0.21 mmol), 2-methyl-3-butyn-2-ol (0.02 g, 0.23 mmol), 
Pd(PPh3)2Cl2 (32 mg, 0.045 mmol), Cut (16 mg, 0.084 mmol) and DMF (10 ml) was 
stirred under Ar for 10 min and triethylamine (0.18 ml, 1.3 mmol) was added. The 
mixture was stirred for 3 d. The mixture was diluted with water (20 ml) and extracted 
with diethyl ether (3 x 10 ml). The ether extracts were washed with water and dried. 
Evaporation, chromatography (EtOAc/hexane 1:1) and recrystallisation (pentane) 
yielded 112 (0.04 g, 60%) as an off-white powder: R f 0.5 (EtOAc/hexane 1:1); mp 
110-115°C; IR (KBr) 3090, 2970, 2260, 1610, 1470, 1260, 850, 780 cm-1; !H NMR 
(CDCI3) 6 7.85 (1 H, d, J=  8.9 Hz, 7-H), 7.01 (1 H, d, 2.3 Hz, 4-H), 6.90 (1 H, dd, 
J  = 8.9, 2.3 Hz, 6-H), 3.88 (3 H, s, CH3O), 3.01 (3 H, s, S 02CH3), 2.69 (3H, s, 2- 
CH3), 1.69 (6 H, s, CH3); l3C NMR (CDC13) 5 156.9 (5-C), 141.1 (2-C), 130.6 (3a-C),
129.8 (7a-C), 114.7 (7-CH), 113.0 (6-CH), 104.6 (alkyne 1-C), 102.2 (4-CH), 100.7 
(3-C), 73.3 (alkyne 2-C), 65.8 (alkyne 3-C), 55.7 (OCH3), 40.7 (S02CH3), 31.7 
((CH3)2), 14.2 (CH3); MS (FAB +ve) m/z 322.1081 (M+H) (Cl6H20NO3SSi requires 
322.1113).
SO2CH3
3- Acetyl-5-methoxy-2-methy 1-1-methylsulfonylindole (113)
Compound 111 (0.1 g, 0.39 mmol) in methanolic KOH (5 % w/v 10 ml) was boiled 
under reflux for 20 h. It was cooled, diluted with water (20 ml) and extracted with 
ether (3 x 10 ml). The ether fractions were washed with water and dried. Evaporation
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yielded 113 (0.056 g, 71%) as a yellow powder: Rf 0.1 (EtOAc/hexane 1:1); mp 219- 
221°C; IR (KBr) ) 3450, 3090, 2970, 1860, 1650, 1600, 1470 c m 1; !H NMR (CDC13) 
6 8.40 (1 H, s, NH), 7.60 (1 H, d,J=  2.4 Hz, 4-H), 7.21 (1 H, d, J=  8.7 Hz, 7-H), 6.85 
(1 H, dd, / =  8.7, 2.4 Hz, 6-H), 3.88 (3 H, s, CH30), 2.73 (3 H, s, CH3CO), 2.71 (3 H, 
s, 2-CH3); 13C NMR (CDC13) 6 194.0 (CO), 155.6 (5-C), 144.5 (2-C), 129.9 (7a-C),
128.0 (3a-C), 114.2 (7-CH), 111.6 (3-C), 111.3 (6-CH), 103.7 (4-CH), 55.8 (OCH3),




Compound 112. (0.07g, 0.22 mmol) in dry THF (10 ml) was boiled under reflux with 
B114NF (0.05g, 0.22 mmol) under Ar overnight. The solvent was evaporated. Water (5 
ml) was added. The mixture was extracted with diethyl ether and dried. Evaporation 
and recrystallisation (acetone/hexane) gave 117 (53 mg, 50%) as a yellow solid: R f 
0.2 (EtOAc); IR (KBr) 3276, 2982, 1623, 1453-1366, 1210, 1168 c m 1; lH NMR 
(CDC13) 5 8.16 (1 H, br s, NH), 7.15 (1 H, d, / =  7.8 Hz, 7-H), 7.03 (1 H, d ,J =  2.7 
Hz, 4-H), 6.79 (1 H, dd, J  = 2.7, 7.8 Hz, 6-H), 3.88 (3 H, s, CH30), 2.33 (3 H, s, 2- 
CH3), 1.71 (6 H, s, 2 x CH3); 13C NMR (CDC13) 5 156.3 (5-C), 134.0 (2-C), 129.8 
(7a-C), 127.8 (3a-C), 114.5 (7-CH), 111.6 (6-CH), 103.3 (alkyne 1-C), 100.7 (4-CH),
97.9 (3-C), 70.1 (alkyne 2-C), 65.0 (alkyne 3-C), 55.3 (CH30), 30.9 ((CH3)2), 11.7 (2- 





NaBH4 (0.96 mg, 2.5 mmol) was added slowly to 5-nitro-2-thienaldehyde 118 (0.1 g, 
0.63 mmol) in absolute MeOH (5 ml) at 0°C. The mixture was stirred at 20°C for 20 
min. Water was added (15 ml), and the mixture was extracted with diethyl ether (3 x 
15 ml). The ether extracts were washed with water and brine and the solvent was 
evaporated. Chromatography (EtOAc/hexane 1:1) gave 119 (0.071 g, 70%) as a 
yellow oil: ( li t148 bp3 130-133°C); 'H NMR (CDC13) 5 7.81 (1 H, d, 7  = 4.1 Hz, 
4-H), 6.94 (1 H, d ,.7=4.1 Hz, 3-H), 4.88 (2 H, s, CH2), 2.03 (1 H, s, OH).
2-Chloromethyl-5-nitrothiophene (120)
Thionyl chloride (0.091 ml, 1.25 mmol) was added to 119 (0.1 g, 0.63 mmol) at 0-5°C 
over 4 h. The mixture was stirred at 5°C for a further hour, water was added (15 ml), 
and the mixture was extracted with diethyl ether ( 3 x 1 5  ml). The ether extracts were 
washed with water and brine and the solvent was evaporated. Chromatography 
(EtOAc/hexane 1:1) gave 119 (0.052 g, 52%) as a yellow oil: (lit.148 bp3 mm 105- 
107°C); ]H NMR (DMSO) 8 7.31 (1 H, d, J=  4.1 Hz, 4-H), 7.07 (1 H, d, J=  4.1 Hz,
3-H), 4.72 (2 H, s,CH2).
l-Chloroethyl (5-nitro-2-thienyl)methyl carbonate (124)
Pyridine (5 ml) was added to 119 (0.3 g, 1.9 mmol) in dry THF (10 ml), and the 




added dropwise and the mixture was stirred overnight. The evaporation residue in 
CH2CI2 was washed with saturated aqueous K2CO3 and water and dried. Evaporation 
and chromatography (hexane/EtOAc 1:1) yielded 124 (0.27 g, 54%) as a yellow oil: 
R f 0.5 (EtOAc/hexane 1:1); lH NMR (CDCI3) 8 7.82 (1 H, d, J  = 4.3 Hz, 4-H), 7.11 (1 
H, d, J  = 4.3 Hz, 3-H), 6.44 (1 H, q, J  = 5.8 Hz, CH), 5.37 (1 H, d, J = 12.5 Hz) and 
5.31 (1 H, d,«/= 12.5 Hz) (CH2), 1.82 (3 H, d,J=  5.8 Hz, CH3).
O
4-(5-Nitro-2-thienylmethoxy)-4-oxobutanoic acid (126)
Compound 119 (1.0 g, 6.3 mmol) was added to a mixture of succinic anhydride (0.63 
g, 6.3 mmol) and DMAP (5 mg) in pyridine (5 ml) and the mixture was stirred for 8 h 
at 50 °C. After cooling and evaporation, the residue in EtOAc, was washed with water 
and dried. Evaporation and chromatography (EtOAc) gave 126 (1.23 g, 76%) as an 
off-white solid: R f 0.4 (EtOAc); mp 93-95°C; IR 3090, 2970,1730, 1690, 1470 c m 1; 
'H  NMR (CDClj) 6 7.25 (1 H, d, /  = 5.0 Hz, 4’-H), 7.03 (1 H, d,J =  5.0 Hz, 3’-H), 
5.27 (2 H, s, CH2), 2.70 (4 H, m, 2 x CH2); 13C NMR (CDClj) 8 173.9 (1-CO), 171.9 
(4-CO), 146.3 (5’ and 2’-C), 128.3 (4’-CH), 126.7 (3’-CH), 60.4 (CH2), 28.9 (3/2- 
CH2); MS (FAB +ve) m/z 260.0230 (M+H) (C9H,0NO6S requires 260.0228). Anal. C 




Compound 126 (0.22 g, 0.85 mmol) was stirred in EtOAc (5 ml) at 0°C for 15 min. 
Pentafluorophenol (0.15 g, 0.85 mmol) in EtOAc (3 ml) was added, followed by 1,3- 
dicyclohexylcarbodiimide (0.17 g, 0.85 mmol) in EtOAc (3 ml). The mixture was
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stirred for 5 h and was left at 4°C overnight Filtration and evaporation gave 128 (0.35 
g, 98%) as a buff oil: R f 0.6 (EtOAc); 1R 3090, 2970, 2260, 1770, 1730, 1470 cm'1; 
'H NMR (CDCIj) 8 7.81 (1 H, d, J  = 4.2 Hz, 4-H), 7.04 (1 H, d , . /=  4.2 Hz, 3-H), 5.29 
(2 H, s, CH20), 3.04 (2 H, t, J  = 6.2 Hz, COCH2), 2.84 (2 H, t, J  = 6.2 Hz, CH2CO); 
l3C NMR (CDClj) 5 170.8 (ester CO), 168.1 (ester CO), 145.3 (thiophene 2 and 5-C),
128.1 (thiophene 4-CH), 126.9 (thiophene 3-CH), 60.8 (CH2), 28.7 and 28.2 
(CH2CH2); Owing to multiple C-F coupling and to the quaternary nature of these 
carbons, the signals for the C6F5 carbons were too weak to be observed; MS (FAB 
+ve) m/z 426.0078 (M+H) (C15H9F5NO6S requires 426.0070).
(5-Nitro-2-thienyl)methyl prednisolon-21-yl butanedioate (129)
Compound 128 (0.22 g, 0.52 mmol) was stirred with prednisolone (0.18 g, 0.52 
mmol) and DMAP in dry DMF (10 ml) for 2 days. The evaporation residue in CH2CI2 
was washed with aq. HC1 (1 M), water and was dried. Evaporation yielded 129 as a 
yellow-orange glass (0.233 g, 75%): IR (KBr) 3450, 3090, 2970, 1740, 1650, 1600, 
1470 c m 1; 'H  NMR (CDClj) 8 7.81 (1 H, d, 7  = 4.3 Hz, thiophene 4-H), 7.29 (1 H, d, 
J  = 10.5 Hz, steroid 2-H), 7.04 (1 H, d ,J =  4.3 Hz, thiophene 3'-H), 6.27 (1 H, d , J  =
10.5 Hz, steroid 1-H), 6.00 (1 H, s, steroid 4-H), 5.28 (2 H, s, CH2), 5.00 (1 H, d ,./  =
17.5 Hz) and 4.90 (1 H, d, J  = 17.5 Hz) (steroid 21-H2), 4.49 (1 H, s, steroid 11-H), 
2.80 (4 H, m, butanedioate CH2CH2), 2.6-2.0 (4 H, m, steroid 6 and I6-H4), 1.95-1.45 
(5 H, m, steroid 9, 12 and 15-HS), 1.45 (3 H, s, steroid 19-CH3), 1.2-1.0 (5 H, m, 
steroid 7, 8 and 14-H5), 0.95 (3 H, s, steroid 18-CH3); °C  NMR (CDC13) 8 206.1 
(steroid 21-CO), 186.1 (steroid 3-CO), 172.0 (2 x ester CO), 171.0 (steroid 5-C),
157.0 (steroid 1-CH), 148.0 (thiophene 5-C and 2-C), 125.0 (thiophene 4-CH and 3- 
CH and steroid 2-CH), 122.2 (steroid 4-CH), 89.5 (steroid 17-C), 69.9 (steroid 11- 
CH), 68.3 (steroid 21-CH2), 67.2 (CH2), 55.4 (steroid 9-CH), 51.4 (steroid 14-CH), 47
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(steroid 13 and 10-C), 39.5 (steroid I2-CH2), 34.6 (steroid I6-CH2), 34.1 (steroid 7- 
CH2), 32.0 (steroid 6-CH2), 31.3 (butanedioate 2 and 3-CH2), 23.9 (steroid 15-CH2),
21.1 (steroid 19-CH3), 17.0 (steroid I8-CH3); MS (FAB +ve) m/z 602.2084 (M+H) 
(C30H36NO10S requires 602.2059). ,
2-Hydroxy methyl thiophene (132)
2-Thiophene carboxaldehyde 130 (0.83 ml, 8.9 mmol), MeOH (5 ml) and 
formaldehyde 131 (1.33 ml, 17.8 mmol) were heated together at 65°C aq. NaOH (2.0 
g in 2 ml of H2O) was added. Heating was continued for 30 min and the solution was 
refluxed for a short time. The mixture was extracted with benzene and dried. 
Evaporation and chromatography (EtOAc/hexane 1:1) yielded 132 (0.48 g, 48%) as an 
orange oil: R f 0.57 (EtOAc); (lit.176 bpj _  130-133°C); 'H NMR (DMSO) 8 7.50 (1 
H, dd,J =  5.0,1.1 Hz, 5-H), 7.10 (1 H, d, .7= 3.5, 1.1 Hz, 3-H), 7.00 (1 H, dd, J=  3.5,
5.0 Hz, 4-H), 5.20 (2 H, s, CH2), 2.03 (1 H, s, OH).
2-Chloromethylthiophene (133)
To 132 (0.5 g, 4.4 mmol) in CH2CI2 (5 ml) at 0°C was added SOCI2 (0.64 ml, 8.8 
mmol) followed by the addition of pyridine (0.42 ml, 5.3 mmol). The mixture was 
stirred at 20°C for 30 min and concentrated. The brown oil was filtered through a 
silica gel pad to yield 133 (0.37g, 64%) as an orange oil: R f 0.65 (EtOAc/hexane 1:1); 
(lit.177 bps mm 105-107°C); ■H NMR (CDClj) 8 7.31 (1 H, dd, J =  5.1, 1.1 Hz, 5-H),
7.09 (1 H, d, J=  3.5 Hz, 3-H), 6.95 (1 H, dd, J = 5.1,3.5 Hz, 4-H), 4.72 (2 H, s, CH2).
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1-ChloroethyI 2-thienyImethyl carbonate (134)
Pyridine (5 ml) was added to 132 (0.2 g, 1.7 mmol) in dry THF (10 ml), and the 
mixture was stirred for 15 min. 1-Chloroethyl chloroformate (0.18 ml, 1.7 mmol) was 
added dropwise and the mixture was stirred overnight. The evaporation residue in 
CH2CI2 was washed with saturated aqueous K2CO3 and water and dried. Evaporation 
and chromatography (hexane/EtOAc 1:1) yielded 134 (0.24 g, 63%) as a yellow oil: 
R f 0.66 (EtOAc/hexane 1:1); *H NMR (CDCI3) 8 7.31 (1 H, d, J=  5.1 Hz, 5-H), 7.09 
( l H , d , J =  3.5 Hz, 3-H), 6.95 (1 H, dd, J = 5.1, 3.5 Hz 4-H), 6.44 (1 H, q, J = 5.8 Hz, 
CH), 5.40 (1 H, d, J=  12.5 Hz) and 5.33 (1 H, d, 12.5 Hz) (CH2), 1.82 (3 H, d , J =
5.8 Hz, CH3).
2-(2-Thienylmethyl)LsoquinoIin-l-one (135)
LiN(SiMe3)2 (2.8 ml, 2.8 mmol) and isoquinolin-l-one (0.2 g, 1.4 mmol) were stirred 
together in DMF (10 ml) for 2 h under dry Ar. Compound 133 (0.27 g, 1.4 mmol) was 
added together with Nal (5 mg). The mixture was stirred for 2 d. The evaporation 
residue in EtOAc was washed with water and brine and dried. Evaporation and 
chromatography (hexane/EtOAc 1:1) afforded 135 (0.15 mg, 45%) as a light orange 
glass: R f 0.6 (EtOAc); IR (KBr) 3090, 2950, 1640, 1600, 1610, 1430 cm '1; ‘H NMR 
(CDCI3) 8 8.45 ( l H , d , / =  7.5 Hz, isoquinoline 8-H), 7.62 (1 H, t , 7 =  7 .4 Hz, iso­
quinoline 6-H), 7.50 (2 H, m, isoquinoline 3-H and 7-H), 7.24 (1 H, dd, J  = 5.2, 1.4 
Hz, thiophene 5-H), 7.14 (1 H, d, J  = 7.4 Hz, isoquinoline 5-H), 7.11 (1 H, d, J=  3.5 
Hz, thiophene 3-H), 6.95 (1 H, dd , . / =  5.2, 3.5 Hz, thiophene 4-H), 6.49 (1 H, d, J  = 
7.3 Hz, isoquinoline 4-H), 5.34 (2 H, s, CH2); ,3C NMR (CDCI3) 8 161.9 (CO), 138.8 
(thiophene 2-C), 136.9 (isoquinoline 3-CH), 132.3 (isoquinoline 4a-C), 130.6 (iso­
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quinoline 6-CH), 128.0 (thiophene 4-CH and 5-CH), 127.3 (isoquinoline 8-CH), 126.9 
(isoquinoline 5-CH), 126.8 (isoquinoline 7-CH), 126.1 (isoquinoline 8a-C), 125.9 
(isoquinoline 3-CH), 106.6 (isoquinoline 4-CH), 46.5 (CH2); MS (FAB +ve) m/z 
242.0635 (M+H) (CuHi2NOS requires 242.0639).
Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-l-(2-thienyImethyl)-l,4-dihydro- 
pyridine-3,5-dicarboxylate (136)
LiN(SiMe3)2 (1.0 M in THF) (3.0 ml, 3.0 mmol) and nifedipine 101 (0.52 g, 1.5 
mmol) were stirred together in DMF (10 ml) for 2 h under dry Ar. 133 (0.2 g, 1.5 
mmol) was added followed by Nal. The mixture was stirred for 2 d. The evaporation 
residue in EtOAc was washed with water and brine and dried. Evaporation and 
chromatography (hexane/EtOAc 1:1) yielded the 136 (0.060 g, 10%) as a light orange 
glass: R f 0.4 (EtOAc/hexane 1:1); IR 3090, 2970, 1730, 1690, 1470 cm '1; ‘H N M R 
(CDC13) 6 7.65-7.00 (7 H, m, thiophene, ArN02), 5.64 (1 H, s, 4-H), 5.06 (2 H, s, 
CH2), 3.61 (6 H, s, 2 x OCH3), 2.53 (6 H, s, 2 x CH3); 13C NMR (CDC13) 5 168.1 (2 x 
CO), 149.7 (2’-C), 146.9 (2/6-C), 140.9 (2-C), 137.1 (5’-CH), 136.2 ( l ’-C), 132.4 (5- 
CH/4’-CH), 128.2 (4-CH), 127.3 (3’-CH), 126.3 (3-CH), 124.7 (3/5-C), 52.1 (CH2),





Cone. HNO3 (0.05 ml, 0.8 mmol) was added to 135 (0.050 g, 0.2 mmol) in TFA (1 
ml) at -10°C and the mixture was stirred at 20°C for 16 h. The pH of the mixture was 
adjusted to 5 with 2 M aq. NaOH and the mixture was extracted with EtOAc. The 
organic layer was washed with water, 10% aq. NaHC03, brine and dried. Evaporation 
and chromatography (EtOAc/hexane 1:1) afforded 137 (28 mg, 42%) as an off-white 
solid: R f 0.3 (EtOAc/hexane 1:1); mp 70-73°C; IR 3090, 2963, 1638, 1598, 1570, 
1392 cm'1; NMR (CDCI3) 8 8.70 (2 H, m, isoquinoline 8-H and 3-H), 8.51 (1 H, d, 
J=  7.5 Hz, isoquinoline 5-H), 7.89 (1 H, t, «/= 7.5 Hz, isoquinoline 6-H), 7.80 (1 H, d, 
J  = 4.1 Hz, thiophene 4-H), 7.65 (1 H, t, J  = 7.5 Hz, isoquinoline 7-H), 7.18 (1 H, d, J  
= 4.1 Hz, thiophene 3-H), 5.4 (2 H, s, CH2); ,3C NMR (CDCh) S 183.3 (CO), 160.9 
(thiophene 2-C and 5-C), 143.9 (isoquinoline 3-CH), 135.4 (isoquinoline 6-CH and 
4a-C), 134.6 (thiophene 4’-CH and isoquinoline 8a-C), 130.1 (isoquinoline 7-CH),
128.8 (isoquinoline 8-CH), 128.2 (isoquinoline 5-CH), 127.3 (isoquinoline 4-C),
123.8 (thiophene 3-CH), 48.6 (CH2); MS (FAB +ve) m/z 332.0340 (M+H) 
(C14H10O5N3S requires 332.0341).
4-Nitro-2-(2-thienylmethyI)isoquinoIin-l-one (138)
Cone. HNO3 (65 pi, 1.0 mmol) was added to a mixture of 135 (0.05 g, 0.2 mmol) in 
A c20  (94 pi, 1.0 mmol) and AcOH (5 ml) at -10°C. The mixture was stirred for 40 
min at -10°C. Water was added and the solution was extracted with EtOAc. The 
organic layer was washed with 10% aq. Na2C03 and dried. Evaporation and 
chromatography (EtOAc/hexane 1:1) yielded 138 (20 mg, 40%) as an off white solid:
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R f 0.5 (EtOAc/hexane 1:1); mp 75-77°C; IR 3090, 2925, 1670, 1630, 1508, 1408 
c m 1; ‘H NMR (CDC13) 8 8.67 (2 H, m, isoquinoline 8-H and 3-H), 8.53 (1 H, d, J  =
6.8 Hz, isoquinoline 5-H), 7.85 (1 H, t, J=  7.2 Hz, isoquinoline 6-H), 7.64 ( l H , t , /  =
7.2 Hz, isoquinoline 7-H), 7.33 (1 H, d, / =  4.6 Hz, thiophene 5-H), 7.22 (1 H, d, /  =
3.8 Hz, thiophene 3-H), 7.01 (1 H, m, thiophene 4-H), 5.43 (2 H, s, CH2); l3C NMR 
(CDClj) 5 160.8 (CO), 136.0 (thiophene 2-C), 135.8 (isoquinoline 3-CH), 134.1 (iso- 
quinoline 6-CH), 128.8 (isoquinoline 4a-C), 128.6 (isoquinoline 8a-C), 128.3 
(thiophene 5-CH), 127.0 (isoquinoline 7-CH), 126.4 (isoquinoline 8-CH and 5-CH),
125.7 (4-CH), 124.1 (4-C), 123.5 (3’-CH), 47.3 (CH2); MS (FAB +ve) m/z 287.0488 
(M+H) (Ci4H „03N2S requires 287.0490).
l-(5-nitro-2-thienyImethoxy)isoquinoline (139)
Diethyl azodicarboxylate (0.20 ml, 1.2 mmol) was added dropwise to isoquinolin-1- 
one 28 (0.09 g, 0.6 mmol) and PPh3 (0.33 g, 1.2 mmol) in diy THF (20 ml) under dry 
Ar. The mixture was stirred for 15 min and 119 (0.1 g, 0.6 mmol) was added. The 
mixture was stirred overnight. Evaporation and chromatography (EtOAc/hexane 1:1) 
afforded 139 (67 mg, 38%) as a yellow oil: R f 0.51 (EtOAc/hexane 1:1); IR 3061, 
2970, 1735, 1631, 1439, 1398 cm-1; ]H NMR (CDCI3) 8.8.25 (1 H, d, ./ = 8.2 Hz, iso- 
quinoline 8-H), 8.00 (1 H, d, J=  6.0 Hz, isoquinoline 3-H), 7.8 (1 H, d, / =  4.0 Hz, 
thiophene 4-H), 7.75 (1 H, d, J  = 7.7 Hz, isoquinoline 5-H), 7.7 (1 H, t, J  = 7.7 Hz, 
isoquinoline 6-H), 7.55 (1 H, t, J=  7.7 Hz, isoquinoline 7-H), 7.3 (1 H, d, J=  6.0 Hz, 
isoquinoline 4-H), 7.12 (1 H, d, J  = 4.0 Hz, thiophene 3-H), 5.74 (2 H, s, CH2); 13C 
NMR (CDC13) 8 165.6 (CO), 158.9 (thiophene 5-C), 148.2 (thiophene 2-C), 131.8 
(isoquinoline 3-CH), 131.5 (isoquinoline 4a-C), 132.3 (isoquinoline 6-CH),. 132.1 
(thiophene 4-CH), 130.0 (isoquinoline 5-CH), 128.5 (isoquinoline 7-CH), 128.1 (iso­
quinoline 8a-C), 127.4 (isoquinoline 8-CH), 126.1 (thiophene 3-CH), 116.1 (iso­





Diethyl azodicarboxylate (0.12 ml, 0.7 mmol) was added dropwise to 5-iodoiso- 
quinolin-l-one 34 (0.1 g, 0.4 mmol) and PPI13 (0.19 g, 0.7 mmol) in dry THF (20 ml) 
under diy Ar. The mixture was stirred for 15 min and 119 (0.06 g, 0.4 mmol) was 
added. The mixture was stirred overnight. Evaporation and chromatography (EtOAc/ 
hexane 1:1) afforded 140 (45 mg, 30%) as a yellow powder: R f 0.54 (EtOAc/hexane 
1:1); mp 78-82°C; IR 3066,2968, 1618,1459,1387 cm-1; 'H NMR (CDCI3) 5 8.27 (1 
H, d, J  = 8.5 Hz, isoquinoline 8-H), 8.22 (1 H, d, J  = 7.4 Hz, isoquinoline 6-H), 8.10 
(1 H, d, J  = 6.2 Hz, isoquinoline 3-H), 7.83 (1 H, d, / =  3.9 Hz, thiophene 4-H), 7.49 
(1 H, d, J  = 6.2 Hz, isoquinoline 4-H), 7.27 (1 H, t, J  = 8.2 Hz, isoquinoline 7-H), 7.12 
(1 H, d, J  = 3.9 Hz, thiophene 3-H), 5.74 (2 H, s, CH2); l3C NMR (CDCI3) 8 158.9 
(isoquinoline 1-C), 147.6 (thiophene 5-C), 141.7 (isoquinoline 4a-C and 6-CH), 140.5 
(thiophene 2-C), 139.6 (isoquinoline 3-CH), 127.9 (isoquinoline 7-CH and 8-CH),
125.9 (thiophene 4-CH), 124.3 (isoquinoline 8a-C), 120.0 (thiophene 3-CH), 119.7 
(isoquinoline 4-CH), 96.9 (isoquinoline 5-C), 62.8 (CH2); MS found (El) m/z 
411.9360 (M) (C14H9IN2O3S requires 411.9378). Anal. C 40.70%, H 2.09%, N 6.43% 
(C14H9IN2O3S requires C 40.87%, H 2.18%, N 6.80%).
5-Bromo-l-(5-nitro-2-thienylmethoxy)isoquinoline (141)
Diethyl azodicarboxylate (0.2 ml, 1.2 mmol) was added dropwise to 5-bromoiso- 
quinolin-l-one 35 (0.14 g, 0.6 mmol) and PPI13 (0.33 g, 1.2 mmol) in diy THF (20 ml) 
under dry Ar. The mixture was stirred for 15 min and 119 (0.1 g, 0.6 mmol) was 
added. The mixture was stirred overnight. Evaporation and chromatography (EtOAc/ 
hexane 1:1) afforded 141 (94 mg, 41%) as a yellow powder: R f 0.5 (EtOAc/hexane
160
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1:1); mp 128-130°C; IR 3098,2968, 1616, 1459,1399 cm-1; ]H NMR (CDCI3) 5 8.25 
(1 H, d, J  = 8.2 Hz, isoquinoline 8-H), 8.12 (1 H, d, J  = 6.0 Hz, isoquinoline 3-H), 
7.97 (1 H, d, /  = 7.8 Hz, isoquinoline 6-H), 7.84 (1 H, d, J  = 4.2 Hz, thiophene 4-PI), 
7.65 (1 H, d, J=  6.0 Hz, isoquinoline 4-H), 7.42 (1 H, t, J =  7.7 Hz, isoquinoline 7-H), 
7.13 (1 H, d, /  = 4.2 Hz, thiophene 3-H), 5.75 (2 H, s, CH2); 13C NMR (CDC13) 8
158.9 (isoquinoline 1-C), 147.8 (thiophene 5-C), 140.6 (isoquinoline 3-CH), 139.0 
(thiophene 2’-C and isoquinoline 4a-C), 134.7 (isoquinoline 6-CH), 128.2 (thiophene
4-CH), 127.5 (isoquinoline 7-CH), 126.1 (isoquinoline 8a-C), 123.7 (isoquinoline 8- 
CH), 121.5 (thiophene 3-CH), 120.1 (isoquinoline 4-CH), 115.2 (isoquinoline 5-C),
62.9 (CH2); MS (FAB +ve) m/z 366.9575 (M+H) (Ci481BrHioN20 3S requires 
366.9589), 365 (M+H for Ci479BrHioN20 3S).
o  F
F
Pentafluorophenyl prop-2-ynyl butanedioate (146)
Compound 147 (0.50 g, 3.2 mmol) in EtOAc (10 ml) was stirred at 0°C for 15 min. 
Pentafluorophenol (0.59 g, 3.2 mmol) in EtOAc (5 ml) was added to the solution 
followed by 1,3-dicyclohexylcarbodiimide (0.66 g, 3.2 mmol) in EtOAc (5 ml). The 
mixture was stirred for 5 h and was allowed to stand at 4°C overnight. Filtration and 
evaporation gave 146 (1.12 g, 100%) as a light yellow oil: R f 0.6 (EtOAc/hexane 1:1); 
IR 3250,2960, 1760-1720,1500,1000 cm- '; 'H  NMR (CDC13) 8 4.74 (2 H, s, CH20 ),
3.03 (2 H, t, J  = 6.6 Hz, COCH2), 2.80 (2 H, t, J  = 6.6 Hz, CH2CO), 2.50 (1 H, s, 
CsCH); I3C NMR (CDC13) 8 170.8 (1-CO), 167.9 (4-CO), 76.8 (2’-C), 75 ( l ’-CH),
52.1 (CH2), 28.5 (2 and 3-CH2); owing to multiple C-F coupling and to the quaternary 
nature of these carbons, the signals for the C6F5 carbons were too weak to be 







Succinic anhydride 125 (1.78 g, 18 mmol) was stirred with pyridine (15 ml, 185 
mmol), DMAP (5 mg) and propargyl alcohol 148 (1.0 g, 18 mmol) overnight. The 
evaporation residue in EtOAc was washed with water and dried. Evaporation yielded 
147 (1.87 g, 67%) as a light yellow oil: R f 0.1 (EtOAc/hexane 1:1); IR, 3500, 3250,
76.7 (O CH ), 75.0 (C=CH), 52.6 (CH2), 29.2 (CH2CH2); MS (FAB +ve) m/z 
157.0511 (M+H) (C7H9O4 requires 156.0500).
2-Iodo-5-nitrothiophene (150)
60% nitric acid (0.42 ml, 9.5 mmol) was added to acetic anhydride (2.0 ml, 0.21 
mmol) at -5°C. The mixture was cooled to -10°C and 2-iodothiophene 149 (1.0 g, 4.7 
mmol) in acetic anhydride was added dropwise. The mixture was stirred at -10 °C for 
2 h and poured into an ice water mixture. The precipitate was recrystallised (MeOH) 
to yield 150 (0.9 g, 60%) as buff shiny crystals: R f 0.5 (EtOAc/hexane 1:1); mp 60- 
61°C (lit.162 mp 70-75°C); 'H NMR (CDClj) 5 7.55 (1 H, d , J  = 4.3 Hz, 4-H), 7.30 (1 
H, d, / =  4.3 Hz, 3-H).
2960, 1700 cm '1; ■h NMR (CDClj) 5 8.35 (1 H, s, OH), 4.71 (2 H, s, CH20), 2.88 (4 








EtsN (0.59 ml, 4.3 mmol) was added to 146 (0.2 g, 0.6 mmol), benzene (5 ml), 2- 
iodothiophene (0.09 ml, 0.4 mmol), Pd(PPti3)4 (20 mg) and Cul (10 mg) under dry Ar. 
The mixture was stirred for 24 h. MeOH (5 ml) was added, the solvent was evaporated 
and diethyl ether (20 ml) was added to the residue leading to the precipitation of 
Et^NH* T. This mixture was filtered, washed with 10% aq. HC1, water, brine and 
dried. Evaporation and chromatography (hexane/EtOAc 1:1) yielded 151 (0.09 g, 
52%) as a yellow oil: Rf 0.7 (EtOAc/hexane 1:1); IR (KBr) 3091, 2962, 1669, 1059, 
1404, 1326, 1262 cm'1; ‘H NMR (CDCI3) 8 7.28 (1 H, dd, J  = 5.4, 1.1 Hz, thiophene
5-H), 7.24 (1 H, dd, J  = 3.5, 1.2 Hz, thiophene 3-H), 6.97 (1 H, dd, J  = 5.4, 3.5 Hz, 
thiophene 4-H), 4.97 (2 H, s, CH20), 3.03 (2 H, t, J  = 6.6 Hz, CH2CO), 2.85 (2 H, t, J  
= 6.6 Hz, COCH2); 13C NMR (CDCI3) 8 170.0 (CO), 167.9 (CO), 132.9 (thiophene 3- 
CH), 128.5 (thiophene 4-CH), 127.5 (thiophene 5-CH), 121.7 (thiophene 2-C), 86.4 
(C=CCH2), 80.1 (C=CCH2), 53.4 (C=CCH2), 28.4 (3 and 2-CH2); owing to multiple 
C-F coupling and to the quaternary nature of these carbons, the signals for the C6F5 
carbons were too weak to be observed; MS (FAB +ve) m/z 405.0214 (M+H) 
(C17H10F5O4 requires 405.0219).
2-Bromo-5-nitro thiophene (152)
HNO3 (15.5 M) (5.06 ml, 79 mmol) in Ac20  at 0°C was added dropwise to 2-bromo- 
thiophene (5.0 g, 0.36 mmol) in Ac20  (10 ml) at -5°C during 45 min. Stirring was 
continued for another 30 min. The mixture was kept at 4°C overnight and was poured 
over crushed ice with stirring. Chromatography (EtOAc) yielded 152 (3.8 mg, 60%)
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as a shiny buff crystalline solid: R f 0.61 (EtOAc); mp 42-44°C (lit.178 mp 45-46°C); 
‘HNMR(CDCI3)6 7.70 (1 H, d, 7=4 .3  Hz, 4-H), 7.12 (1 H, d,J =  4.3 Hz, 3-H).
3-(2-Thienyl)prop-2-yn-l-ol (153)
EtjN (6.6 ml, 47 mmol) was added to propargyl alcohol 148 (0.41 ml, 7.1 mmol), 
benzene (50 ml), 2-iodothiophene 149 (0.6 ml, 4.7 mmol), Pd(PPh3)4 (200 mg) and 
Cul (100 mg) under dry Ar. The mixture was stirred for 24 h. MeOH (50 ml) was 
added, the solvent was evaporated and diethyl ether (20 ml) was added to the residue 
leading to the precipitation of Et3NH+ T. This mixture was filtered off, washed with 
10% aq. HCi, water, brine and dried. Evaporation and chromatography (hexane/ 
EtOAc 1:1) yielded 153 (0.43 g, 67%) as a yellow oil: R f 0.4 (EtOAc/hexane 1:1); ]H 
NMR (CDCI3) 6 7.24 (1 H, d, J  = 5.0 Hz, thiophene 5-H), 7.20 (1 H, d, J  = 3.5 Hz, 
thiophene 3-H), 6.94 (1 H, dd, J  = 3.5,5.0 Hz, thiophene 4-H), 4.48 (2 H, s, CH2); l3C 
NMR (CDCI3) 6 132.1 (thiophene 3-CH), 127.2 (thiophene 4-CH), 126.1 (thiophene
5-CH), 122.2 (thiophene 2-C), 91.2 (C=CCH2), 78.7 (O C C H 2), 51.4 (C=CCH2).
3-(5-Nitro-2-thienyl)propenoic acid (157)
5-Nitrothiophene-2-carboxaldehyde 118 (1.0 g, 6.4 mmol), propanedioic acid (1.8 g, 
17 mmol), pyridine (5 ml) and piperidine (1 ml) were heated at 100°C for 2 h and then 
boiled for 5 min. After cooling, the solution was poured into water and was treated 
with excess aq. HCI. The precipitate was filtered and reciystallised (aq. MeOH) to 
yield 157 (0.85 g, 85%) as a light buff solid: mp >230°C ( l i t173 mp 255-256°C); 'H 
NMR (CDClj) 8 12.50 (1 H, s, OH), 7.90 (1 H, d, J  = 4.4 Hz, thiophene 4-H), 7.65 (1 





A suspension of 157 (0.10 g, 0.5 mmol) in MeOH (3.3 ml) and conc. H2SO4 (0.66 ml) 
was stirred under reflux overnight. The mixture was cooled to 20°C and water was 
added (7 ml). The precipitate was filtered, washed with aq. NaHCOs and recrystallised 
(acetone/water) to yield 158 (0.094 g, 88%) as a light buff crystalline solid: mp 153- 
155°C (lit.174 mp 157-158°C); NMR (DMSO) 6 8.05 (1 H, d, J=  4.4 Hz, thiophene
4-H), 7.80 (1 H, d, / =  16.0 Hz, 3-H), 7.63 (1 H, d, J  = 4.4 Hz, thiophene 3-H), 6.70 (1 
H, d, J =  16.0 Hz, 2-H), 3.50 (3 H, s, CH3O).
CO2H
2-Thienyl-3-propenoic acid (160)
Thiophene-2-carboxaldehyde 130 (1.0 g, 8.9 mmol), propanedioic acid (1.8 g, 12 
mmol) pyridine (5 ml) and piperidine (1 ml) were heated at 100°C for 2 h and then 
boiled for 5 min. After cooling, the solution was poured into water and treated with 
excess aq. HCI. The precipitate was filtered and recrystallised (aq. MeOH) to yield 
160 (0.97 g, 70%) as a light buff solid: mp 142-143°C (lit.'63 mp 143-144°C); 'H  
NMR (CDCI3) 8 12.50 (1 H, s. OH). 7.88 (1 H, d, 7  = 15.5 Hz, 3-H), 7.41 (1 H, d, J  =
5.1 Hz, thiophene 5-H), 7.30 (1 H, d, J  = 3.3 Hz, thiophene 3-H), 7.08 (1 H, dd, J  = 
5.1, 3.3 Hz, thiophene 4-H), 6.24 (1 H, d, J =  15.5 Hz, 2-H).
C02CH3
Methyl 2-thienyl-3-propenoate (161)
Compound 160 (0.10 g, 0.5 mmol) in MeOH (3.3 ml) and conc. H2SO4 (0.66 ml) was 
stirred under reflux overnight. The mixture was then cooled to 20°C and water (7 ml) 
was added. The precipitate was filtered, washed with aq. NaHC03 and recrystallised
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(acetone/water) to yield 161 (0.86 g, 83%) as a shiny off-white crystalline solid: mp 
54-55°C (lit.175 mp 52-54°C); !H NMR (CDClj) 5 7.79 (1 H, d , J  = 15.5 Hz, 3-H),
7.37 (1 H, d, J  = 5.1 Hz, thiophene 5-H), 7.25 (1 H, d, J  = 3.3 Hz, thiophene 3-H),
7.05 (1 H, dd, J=  5.0,3.3 Hz, thiophene 4-H), 6.25 (1 H, d , / =  15.5 Hz, 2-H), 3.78 (3 
H ,s,C H 3).
2-(2-Thienyl)cyclopropane-l-carboxylate (162)
Diazomethane was prepared as previously described, a solution of N-methyl-N- 
nitroso-4-toluenesulfonamide (Diazald® 2.5g, 11.67 mmol) in diethyl ether (20 ml) 
was slowly added to a heated (65°C on an oil bath) mixture of KOH (2.5 g, mmol), 
water (4 ml), and ethanol (5 ml), the resulting ether solution of diazomethane was 
distilled and transferred by cannula into a flask containing 161 (77 mg, 0.36 mmol), 
Pd(OAc)2 (23 mg, 1.0 mmol) in diethyl ether (5 ml). The mixture was then stirred for 
1 h. The reaction was quenched by the addition of acetic acid (0.5 ml). The evapo­
ration residue in diethyl ether was washed with aq. NaHC03 and dried. Evaporation 
and chromatography (EtOAc/hexane 1:1) gave 162 (52 mg, 80%) as a brown oil: R f 
0.57 (EtOAc/hexane 1:1); IR 3001, 2951, 1727, 1628, 1438, 1205, 1172 cm'1; *H 
NMR (CDC13) 8 7.09 (1 H, dd, 5.0,1.5 Hz, thiophene 5-H), 6.89 (1 H, dd, J=  5.5,
3.5 Hz, thiophene 4-H), 6.81 (1 H, d, J  = 3.5 Hz, thiophene 3-H), 3.7 (3 H, s, CH3),
2.7 (1 H, m, 2-CH), 1.9 (1 H, m, 1-CH), 1.6 (1 H, m) and 1.3 (1 H, m) (3-H2); l3C 
NMR (CDCI3) 8 173.3 (CO), 144.1 (thiophene 2-C), 127.1 (thiophene 5-CH), 124.2 
(thiophene 3-CH), 123.4 (thiophene 4-CH), 52.3 (CH3), 25.1 (2-CH), 21.9 (1-CH),





Conc. HNO3 (0.05 ml, 0.8 mmol) was added to compound 162 (40 mg, 0.2 mmol) in 
TFA (2 ml) at -10°C and the mixture was stirred for 1 h at -10°C. The pH of the 
mixture was adjusted to 5 with 2 M  aq. NaOH and the mixture was extracted with 
EtOAc. The organic layer was washed with water, brine and dried. Evaporation and 
chromatography (EtOAc/hexane 1:1) yielded 163 (0.04 mg, 80%) as a dark yellow oil: 
R f 0.41 (EtOAc/hexane 1:1); IR 3006, 2953, 1728, 1647, 1537, 1336, 1438, 1396, 
1207,1174 cm'1; 'H NMR (CDClj) 5 7.75 (1 H, d, J=  4.3 Hz, thiophene 4-H), 6.79 (1 
H, d, J  = 4.3 Hz, thiophene 3-H), 3.8 (3 H, s, CHj), 2.65 (1 H, m, 2-H), 1.76 (1 H, m, 
1-H), 1.4 (1 H, m) and 1.3 (1H, m) (3-H2); 13C NMR (CDClj) 8 172.8 (CO), 152.9 
(thiophene 5-C), 144.5 (thiophene 2-C), 128.7 (thiophene 4-CH), 125.6 (thiophene 3- 
CH), 52.2 (CH30), 21.0 (2-CH), 18.4 (1-CH), 14.2 (3-CH2); MS (El) m/z 227.0244 
(M), (C9H9NO4S requires 227.0252).
Release Studies
Procedure 1
Previously dried 39/40/65/94/96/97/99 (10 mg) were dissolved in CDCI3 (0.6 ml) and 
transferred in an NMR tube. The !H NMR spectrum of each sample was run on the 
Varian EX400 spectrometer, followed by the gradual addition of SnCl2 in deuterated 
methanol by portions of 0.1 eq. A proton NMR analysis was run after each addition.
Procedure 2
Previously dried 65 (10 mg) preliminary dried was dissolved in in CDCI3 (0.6 ml) and 
transferred in an NMR tube. The JH NMR of the sample was run on the Varian 
EX400 spectrometer, followed by the gradual addition of Na2S20s in deuterated 




S11CI2 (0.5 g) was added to 42/97/129/139/140/141 (0.5 mg) in methanol (2 ml). The 
mixture was stirred. Aliquots (100 pi) were removed at regular time points and 
analysed by HPLC.
Procedure 4
SnCb (0.5 g) was added to 129 (0.5 mg) in methanol (2 ml). The mixture was boiled 
under reflux. Aliquots (100 pi) were removed at regular time points and analysed by 
HPLC.
Procedure 5
Zn dust (0.5 mg) was added to 42 (0.5 mg) and NH4CI (0.5 mg) in MeOH (2 ml) and 
H2O (0.05 ml). The mixture was stirred Aliquots (100 pi) were removed at regular 
time points, filtered and analysed by HPLC.
Procedure 6
NaBR* (2.0 mg) was added to a mixture of 42/129/139/140/141 (5.0 mg), palladium 
on carbon (10%, 5.0 mg), and H2O (0.04 ml) in isopropanol (5 ml). The mixture was 
stirred overnight. The evaporation residue was dissolved in deuterated methanol (0.6 
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APPENDIX I
A, HPLC trace of compound 97 (top) and of the mixture obtained after addition of 
tin(II) chloride (bottom); B, HPLC trace of compound 42 (top) and of the mixture 
obtained after addition of zinc powder and ammonium chloride (bottom); C, HPLC 
trace of compound 129 (top) and of the mixture obtained after addition of tin(II) 
chloride and heating (bottom).
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'H NMR spectrum of the mixture obtained after addition of 1 equivalent of tin(II) 
chloride to compound 96. ^
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'H NMR spectrum of the mixture obtained after addition of tin(II) chloride followed
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'H NMR spectrum of the mixture obtained after addition of tin(II) chloride followed
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H NMR spectrum of the mixture obtained after addition of tin(II) chloride to 
compound 140
CO N
P u l s e  S e q u e n c e :  s 2 p u l
S o l v e n t :  C 0 C 1 3  
A m b i e n t  t e m p e r a t u r e  
m e r c u r y - d 0 0 BB " n mr 2 "
PULSE SEQUENCE 
R e l a x .  P e l a y  1 . 0 0 0  s e c  
P u l s e  4 5 . 0  d e g r e e s  
A c q . t i m e  5 . 0 0 3  s e c  
W i d t h  6 3 9 6 . 6  Hz  
16 r e p e t  i t  i o n s  
OBSERVE H I ,  3 9 9 . 7 8 9 0 7 7 0  MHZ 
DATA PROCESSI NG  
FT s i z e  6 5 5 3 6  
T o t a l  t i m e  4 m l n ,  16 s e c
■U
a . a 8 . 3 8 . 2  8 . 1 . 0 7 . 9  7 . 7 . 7 7 . 6 7 . 7 . 4 7 . 3 7 . 2
r —|---- r






*H NMR spectrum of the mixture obtained after addition of tin(II) chloride to 
compound 141
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Synthesis and Evaluation in vitro of Bioreductively Activated Prodrugs of
Anti-Inflammatory Agents
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Scheme 1. Bioreduction of indo!e-4,7-dione prodrug trigger 
and selective release o f drug, in hypoxic tissue.
MeO MeO.
Introduction
Hypoxia is present in several 
diseases, such as rheumatoid 
arthritis, osteoarthritis, some cancers 
and diabetes. This physiological state 
facilitates selective drug release from 
prodrugs via reductively activatable 
triggers1, including indole-4,7-diones 
and nitroheterocycles. Up to 20% of 
the inflamed synovium is hypoxic in arthritic joints. Activities of key reductases (cytochrome 
P450 reductase, DT-diaphorase, cytochrome B5 reductase) are comparable to those found in 
tumour cell lines in which bioreductive prodrugs exhibit optimal efficacy2.
Discussion
The target prodrugs were 
indole-4,7-dione and nitrothiophene 
conjugates of the anti-inflammatory 
drugs prednisolone and aspirin. 5- 
Methoxy-2-methylindole (1) was 
converted to the quinone (2) in 7 
steps, after modification and 
optimisation of the sequence 
reported by Naylor et a?. Treatment 
of (2) with SOCI2 gave the chloro- 
methylindole which was used to 
alkylate the carboxylate derived 
from prednisolone hemisuccinate to 
give (3) in moderate yield. An
alternative strategy was used to generate the nitrothiophene analogue. Ring-opening of 
succinic anhydride with 5-nitrothiophene-2-methanol gave the succinate monoester. This was 
coupled to the 21-OH of prednisolone via the pentafluorophenyl ester in high yield. 
Preliminary biomimetic release studies showed rapid release of drug, using the system 
developed previously by us4.
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Regioselective methods were investigated to prepare N- and O-alkylated isoquinolin-l-ones efficiently. The predicted 
regioselective alkylation of the nitrogen with (hetero)-benzyl halides was complemented using (hetero)benzylic 
Mitsunobu electrophiles to alkylate predominantly at the oxygen. A series of drug-delivery conjugates was prepared 
demonstrating control over the site of alkylation. The Mitsunobu reaction provides a new approach to 1- 
alkoxyisoquinolines that were unavailable via previous harsher synthetic methods.
Introduction
Repair and maintenance of chromosomes are, in part, con­
trolled by the addition and removal of polymers of ADP-ribose 
to the DNA-binding proteins involved.1 ADP-ribose units are 
added by poly(ADP-ribose)polymerase (PARP) and removed 
by poIy(ADP-ribose)glycohydrolase (PARG). The involvement 
of poly(ADP-ribosyl)ation in a wide range of physiological and 
pathophysiological processes renders it a useful target to study 
biological systems and for therapeutic intervention strategies. 
Pathophysiological effects are mediated through overactivity of 
the isoform PARP-1, which depletes stores of nicotinamide 
adenine dinucleotide (N A D +), the PARP substrate, leading to 
cell death.
5-Substituted isoquinoline-1-ones are potent inhibitors2,3 of 
PARP with potential therapeutic applications in several dis­
eases, including cancer,4 myocardial infarction,5 diabetes,6 
stroke,7 rheumatoid arthritis,8 haemorrhagic shock3 and retro­
viral infections.9 As a regulatory enzyme, PARP has beneficial 
roles in health and detrimental roles in disease and, therefore, 
inhibitors need to be targeted selectively to diseased tissues. We 
are developing analogues with greater aqueous solubility and 
prodrugs for their site-specific release. Our aim is to develop 
strategies to control attachment of masking prodrug units via 
either the 2-nitrogen or the exocyclic oxygen to compare the 
pharmacokinetic and drug release properties of these series of 
prodrugs.
Results and discussion
Deprotonation of isoquinolin-l-ones with base and reaction of 
the resulting anions with alkyl halides or tosylates are 
reported10-12 to result in alkylation exclusively at nitrogen, giv­
ing 2-alkylisoquinolin-l-ones, although Kaneko et a /.13 note 
that traces (<2%) o f the corresponding O-alkylated products 
(1-alkoxyisoquinolines) are also obtained in reactions with 4- 
bromobut-l-ene and its homologues. Interestingly, harder elec­
trophiles, such as triffic anhydride14 and silylating agents,15 
react at exocyclic oxygen, although the nucleophile may be the 
neutral molecule in these cases. 1-Alkoxyisoquinolines have 
generally been prepared by displacement of halides or other 
leaving groups from the 1-position of isoquinolines with nucle-
ophilic alkoxides,14,16 although the range of groups that can be 
introduced is limited to simple examples by the harsh condi­
tions necessary.
Several routes were employed for the synthesis of the starting 





Scheme 1 Synthetic approaches to 5-iodoisoquinolin-l(2#)-one lb 
and 5-(Boc-amino)isoquinolin-l(2//)-one Id. Reagents and conditions: 
i, NaNOj-aq. HCI-KI, 0 °C; ii, NH,-MeOCH2CH2OH, reflux; iii, 
Boc20  (1.5 equiv.)-EtjN-CH2Cl2-DM F; iv, Boc20  (3.0 equiv.)-EtjN- 
CH2CI2-DM F; v, Boc20  (3.0 equiv.)-Et,N-DMF.
1-one la  (“isocarbostyril”) is commercially available. Our pre­
viously reported synthesis11 of 5-iodoisoquinolin-l-one lb, by 
Curtius rearrangement o f 2'-iodocinnamoyl azide and cyclisa- 
tion of the intermediate 2-(2-iodophenyl)ethenyl isocyanate at
DOI: 10.1039/b 109776h J. Chem. Soc., Perkin Trans. /, 2002, 1-7 1
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280 °C, proved not to be amenable to the routine preparation of 
large quantities and a new route was required. Following the 
newer route to lb, 5 -aminoisocoumarin 2 was diazotised and 
the diazonium group was replaced with iodine using potassium 
iodide; 5-iodoisocoumarin 4 was obtained in good yield 
(Scheme 1). Conversion to the isoquinolin-l-one lb  was 
achieved in the usual manner, in a reliable 48% yield from 2. 5- 
Bromoisoquinolin-l-one lc  was prepared by diazotisation and 
Sandmeyer reaction of 5-aminoisocoumarin 2, followed by; 
replacement of the ring oxygen with nitrogen by treatment with 
ammonia at high temperature, as described previously.17
5-Aminoisoquinolin-l(2//)-one le  is a particularly effective 
inhibitor of PARP in vivo3 but, to be able to study the nucle- 
ophilic reactivity o f  the 2-nitrogen and the exocyclic oxygen, 
the potentially more nucleophilic 5-amine required protection. 
In the first route to le , the Boc-amino unit was assembled on 
the isocoumarin prior to conversion to the isoquinolinone 
(Scheme 1). Reaction o f 5-aminoisocoumarin 2 with a small 
excess of di-terf-butyl dicarbonate led to the mono-Boc com­
pound 3a, whereas treatment with three equivalents gave the 
A.iV-diBoc analogue 3b in good yield. As expected, 3a was con­
verted to the mono-Boc isoquinolinone Id with ammonia in 
refluxing 2-methoxyethanol. When 3b was subjected to the 
same conditions, not only was the isocoumarin converted to the 
isoquinolinone but also one of the Boc groups was 
ammonolysed from the 5-amino function, also giving the 
mono-Boc isoquinolinone Id efficiently. Direct introduction of 
Boc protection to 5-aminoisoquinolin-l(2//)-one le also gave 
Id but in lower yield.
In model studies, (Scheme 2), the reactions o f the isoquinolin- 
l(2//)-ones 1 with simple benzyl electrophiles were investigated. 
The 5-unsubstituted isoquinolinone la  was deprotonated with 
sodium hydride and the anion reacted with benzyl bromide to 
give the //-benzylated compound 6a as the only isolable prod­
uct." Generation o f the anions from the 5-haloisoquinolinones 
lb,c with the soluble non-nucleophilic base lithium bis(trimeth- 
ylsilyl)amide was technically more facile. Again, alkylation with 
the benzyl chlorides 5b,c gave only the products of N- 
alkylation, 6b,c, respectively." In contrast, reaction of la  with 
benzyl alcohol under Mitsunobu conditions gave only the O- 
benzylated product 7.
Extension o f the study to pseudobenzyhc 5-membered ring 
heterocycles produced a similar outcome. The anion derived 
from isoquinolinone la  reacted only at nitrogen" with 2- 
chloromethylfuran 8a and 5-nitrofuran-2-yl tosylates 8b, 
affording the isoquinolinones 9a,b. The yield of the 
nitrofuranylmethylisoquinolinone was low, probably owing to 
side-reactions involving the relatively acidic methylene protons 
in 8b. Similarly, the anion of la  reacted with 2- 
chloromethylthiophene 8c only at nitrogen, giving 9c. However, 
this anion only served to degrade the corresponding nitrothi­
ophene electrophile 2-chloromethyl-5-nitrothiophene;18 the 
methylene protons are presumably even more acidic in these 
molecules than are those in 8b. In this series, the Mitsunobu 
alkylations were carried out using (5-nitro-2-thienyl)methanol 
8d as the electrophile; this represents a sterner test of the 
applicability of the process, owing to the possibility of reduc­
tion of the nitro group by the triphenylphosphine. Reaction of 
the isoquinolinones la -c  with 8d under the standard Mitsu­
nobu conditions, however, led to the O-alkylated products 10a- 
c, respectively, in moderate yields but without any trace of for­
mation of N-alkylated materials.
Thus, in the cases o f the monocyclic benzylic electrophiles 5 
and 8, the outcomes of the reactions are clearly defined: con­
ventional alkylation with benzylic halides and tosylates gives 
only reaction at nitrogen, whereas the Mitsunobu conditions 
give exclusively the O-alkylated products. With the bicyclic elec­
trophiles 11 based on the 4,7-dioxoindole-3-methylene unit, 
however, the outcomes are more subtle. AH attempts to alkylate 
the anions derived from the isoquinolinones la -c  with the
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chloromethyl-1 //-indo!e-4,7-dione 11a19 failed. The indoledi- 
one unit was destroyed under the basic reaction conditions; the 
isoquinolinone anions are clearly much more basic than are the 
phenolate anions which are reported 19 to react smoothly with 
this reagent. Naylor el al. 19 observed solvent-dependent regiose- 
lectivity in alkylation of 2-fluorophenolate and 4- 
fluorophenolate, ethyl acetate favouring C-alkylation and DM F 
favouring D-alkylation. When the isoquinolinones la -d  were 
treated with the corresponding alcohol l ib  under Mitsunobu 
conditions, both the vV-alkylated isoquinolinones 12 and the 1- 
alkoxyisoquinolines 13 were obtained, although never as mix­
tures. In repeated experiments, the 5-unsubstituted isoquino­
linone la  only reacted at oxygen, giving 13a. In contrast, the 5- 
bromo- and 5-Boc-amino analogues lc,d gave only the //-linked 
compounds 12c,d. Most surprisingly, the 5-iodoisoquinoiin- 
l(2//)-one lb  gave the iV-linked product 12b and the 0-linked 
product 13b not as a mixture but as the sole isolable products 
from different experiments under apparently the same 
conditions.
Distinction between the structures of the N- 
alkylisoquinolinones 6, 9, 12 and 1-alkoxyisoquinolines 7, 10, 
13 was made primarily on the basis of their 1H and l3C NMR 
spectra (Table 1). Taking the isomeric pair 6a and 7, the N CH 2
Table 1 Selected NMR chemical shifts" for the N- 
alkylisoquinolinones and 1-alkoxyisoquinolines
Compound 8h (CHj) <5C (CH2) SH (3-H) (4-H)
6a 5.20* 51.6* 7.06* 6.46*
6b 5.22* 51.9* 7.19* 6.72*
6c 5.15 1 7.18 6.82
7 5.58 8.00 7.25
9a 5.17* 44.2* 7.14* 6.45*
9b 5.23* 7.24* 6.58*
9c 5.34 7.5 6.49
10a 5.74 62.3 8.00 7.30
10b 5.74 62.8 8.10 7.49
10c 5.75 62.9 8.12 7.65
12b 5.29 32.6 7.80 6.66
12c 5.30 32.6 7.82 6.77
12d 5.25 7.47 6.57
13a 5.72 53.4 8.00 7.20
13b 5.71 56.4 8.08 7.40
* Spectra recorded of solutions in CDClj. * 
determined.
Data taken from ref. io c Not
protons of 6a resonate at 8 5.20, whereas the OCH2 proton 
signal o f 7 appears downfield at 8 5.58, due to the greater elec­
tronegativity of oxygen. Significant changes in chemical shift 
are also seen for two o f the isoquinoline protons. In 6a, the 3-H 
resonates at <5 7.06 and the 4-H at 8 6.46; in 7, the corresponding 
signals are at 8 8.00 and 8 7.25, respectively, reflecting the enam- 
ide character of the isoquinolin-l(2//)-one and the greater 
aromaticity of the 1-alkoxyisoquinoline. The signals of the pro­
tons o f the carbocyclic rings are relatively similar for the two 
compounds and are not diagnostic. Using this guide, 6b,c can 
be identified as A-benzylisoquinolinones in showing chemical 
shifts for the CH2 protons and for 3-H and 4-H as does 6a. 
Further confirmation o f the structure of 6b was given by an 
unequivocal synthesis, as shown in Scheme 3. 5-
Bromoisocoumarin 14 (prepared as described previously by 
u s17) was condensed with 4-methoxybenzylamine to give 6b in 
modest yield. Since the methoxybenzyl unit was attached to 
nitrogen in the reagent, the product o f this reaction must be 5- 
bromo-//-(4-methoxybenzyl)isoquinolin-l(2//)-one 6b, rather 
than any O-linked isomer. The general pattern of proton chem­
ical shifts was similar for the furans 9a,b and the thiophenes 9c, 
lOa-c. In the AMinked compounds 9, the CH2 protons reson­
ated in the range 8 5.1-5.4 and in the O-linked 10, the corres­
ponding signals appeared at 8 ca. 5.7. In 9, the isoquinoline 3-H
iv
v or vi or vii
a: R = H 
b: R = I 
c: R = Br 







a: R 1 = R2 =H 
b: R1 = I; R2 = H 
c: R 1 = Br; R2 = OMe
a: R = H; X = 0  
b: R = N 02; X = O 
c: R = H; X = S
10
a: R = H 
b: R = I 
c: R = Br
12
b: R = I 
c: R = Br 
d: R = NHBoc
13
a: R = H 





a: R1 = Br; R2 = H 
b: R1 = Cl; R2 = OMe
a. R1 = Cl; R = H, X = 0  
32 = I
11
a: R = Cl 
b: R = OH
c: R1 = Cl; R2 = H 
d: R1 = OH; R2 = H
b: R = OTs; R = N 02; X = 0  
c: R1 = Cl; R2 = H; X = S 
d: R1 = OH; R2 = N 02; X = S
Scheme 2 Studies on the N- and O-alkylation of isoquinolin-l(2//)-ones la-d. Reagents: i, NaH-DM F-5a; ii, LiN(SiMe3)2-THF-5b-NaI; iii, 
LiN(SiMe3)2-THF-5c-NaI; iv, Ph3P-diethyl azodicarboxylate (DEAD)-5d-THF; v, LiN(SiMe3)2-TH F-8a-N aI; vi, NaH-DMF-Sb; vii, 
LiN(SiMeJ)1-THF-8c; viii, Ph3P-DEAD-8d-THF; ix, Ph3P-D EAD-llb-THF.
and 4-H signals were at 8 7.1-7.5 and 8 6.4-6.6, whereas in 10, 
the signals were at 8 8.0-8.1 and 8 1.3-7.7, respectively. Clearly 
the range of chemical shifts for 4-H in 10 is greater than that for 
3-H, as the former is expected to be more influenced by the 
nature o f the 5-substituent than is the latter. Similarly, in the 
indole-4,7-dione series 12 and 13, highly diagnostic trends in 
chemical shift were observed. In these series, the nature of the 
O- or N-substituent is constant, so the chemical shifts should be 
more directly comparable. Hence, the resonances for the CH 2 
protons of 12b-d fall in the very narrow range 8 5.25-5.30 and
OMe
14 6c
Scheme 3 Unequivocal synthesis of 5-bromo-2-(4- 
methoxybenzyl)isoquinolin-l (2//)-one 6c. Reagents and conditions: i, 4- 
MeOBnNH2, MeOCH2CH2OH, reflux.
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the corresponding signals for 13a,b are at S 5.72 and S 5.71, 
respectively. As expected, the chemical shifts of 3-H and 4-H 
are sensitive to the nature of the 5-substituent. The chemical 
shifts in the ,3C NM R spectra show analogous trends, although 
the ranges are wider and sometimes overlapping. In the N- 
linked isoquinolinones 6, 9,12, the UCH 2 peaks are in the range 
6 32-52; whereas, in the CMinked isoquinolines 10, 13, the cor­
responding range is <5 53-63.
In this paper, we have reaffirmed the regioselectivity of; 
alkylation of isoquinolin-l-one anions with (hetero)benzyl hal­
ides as taking place essentially exclusively at nitrogen. In con­
trast, reaction with benzylic and heterobenzylic Mitsunobu 
electrophiles takes place at oxygen in most cases. In some cases, 
the outcome of the reaction is extremely sensitive to the reac­
tion conditions and to the nature of the 5-substituent of the 
isoquinolin-l-one; mixtures of products were never observed. 
Although Mitsunobu reactions with isoquinolin-l-ones as the 
nucleophilic component are previously unreported, Manhas et 
al.20 achieved reaction of quinazolin-4-ones with steroid alco­
hols through the exocyclic oxygen o f the heterocycles. These 
observations are consistent with regioselectivity being con­
trolled by the hardness/softness o f the nucleophiles and elec­
trophiles involved. Such control is also evident in the O- 
selective alkylation of amides and the .^-selective alkylation of 
thioamides with alcohols under Mitsunobu conditions;21 
phthalimide, of course, is alkylated at nitrogen in a synthetically 
useful approach to primary amines.22 The Mitsunobu electro­
phile derived from the 4,7-dioxoindol-3-ylmethanol l ib  must 
be very close to matching hardness with the O and N nucle­
ophilic centres of the isoquinolinone anions.
The Mitsunobu reaction is shown here to offer a potential 
approach to 1-alkoxyisoquinolines carrying useful functionality 
in the 1-substituent; such compounds are not available through 
previous harsh synthetic methods. The 2-(4,7-dioxo-l//-indol- 
3-ylmethyl)isoquinolin-l(2//)-ones and l-[(4,7-dioxo-l//-indol- 
3-yl)methoxy)isoquinolines may represent a new class of prod­
rugs to target PARP inhibitors to hypoxic regions of solid 
tum ours17 and other diseased tissues.
Experimental
NMR spectra were recorded on samples in CDCI3, unless 
otherwise stated. Mass spectra were obtained by fast atom 
bombardment (FAB) in the positive ion mode, unless otherwise 
stated. The stationary phase for chromatography was silica gel. 
Melting points are uncorrected. Solutions in organic solvents 
were dried with M gS04. Solvents were evaporated under 
reduced pressure. Experiments were conducted at ambient tem­
perature, unless otherwise stated. The brine was saturated. 
DEAD refers to diethyl azodicarboxylate. D M F refers to 
dimethylformam ide.
5-IodoisoquinoIin-l(2//)-one lb
Compound 4 (300 mg, 1.1 mmol), in 2-methoxyethanol (50 
cm3), was saturated with ammonia for 1 h after which the mix­
ture was boiled under reflux for 24 h. Evaporation yielded the 
isoquinolinone lb  as pale buff crystals (200 mg, 68%): mp 239- 
242 °C (lit." mp 238-244 °C); <5„ 6.67 (1 H, d, 7  = 1A  Hz, 4-H), 
7.13 (1 H, d, 7=  7.4 Hz, 3-H), 7.17 (1 H, t, 7=  7.5 Hz, 7-H), 8.15 
(1 H, dd, 7= 7 .5 , 1.1 Hz, 6-H), 8.35(1 H, dd, 7 = 7 .5 , 1.1 Hz, 8- 
H) and 11.20(1 H, s, NH).
5-(l, 1 -Dimethylethoxycarbonylamino)isoquinoIin-l(2T/)-one 1 d
Method A. Compound 3a was treated with ammonia, as in 
Method B, to give Id (76%) with properties as below.
Method B. Compound 3b (68 mg, 0.19 mmol), in 2- 
methoxyethanol (10 cm3), was saturated with N Hj for 1 h after
which the mixture was boiled under reflux for 24 h. Evaporation 
and chromatography (ethyl acetate-hexane 1 : 1 )  gave Id (35 
mg, 71%) as pale yellow crystals: mp >230 °C (Found: C, 63.5; 
H, 6.28; N, 10.58. C,4H l6N 2O 3-0.25 H20  requires C, 63.60; H, 
6.22, N, 10.20%); v*,, (KBr)/cm“‘ 3320, 1690 and 1670; SH 
(CDClj) 1.54 (9 H, s, BuO, 6.58 (1 H, d, 7 7.3, 4-H), 6.61 (1 H, 
brs, N //Boc), 7.22(1 H, d, 7 7.3, 3-H), 7.49(1 H, t, 7 =  8.1 Hz,
7-H), 8.04(1 H, d, 7=  8.1 Hz, 6-H), 8.22(1 H ,d ,7  = 8.1 Hz, 8- 
H) and 10.60 (1 H, brs, NH); m/z 261.1235 (M + H) 
(CI4H 17N 20 3 requires 261.1239) and 260.1169 (M) (C14H 16N 20 3 
requires 260.1161).
Method C. Triethylamine (1.8 g, 18 mmol) was added to 5- 
aminoisoquinolin-l(2//)-one le 3 (600 mg, 3.7 mmol) in DM F 
(40 cm3) and the solution was cooled to 0 °C. Di-ter<-butyl 
dicarbonate (2.45 g, 11.2 mmol) was added in portions during 2 
d. The evaporation residue, in ethyl acetate, was washed with 
water and brine and was dried. Evaporation and chroma­
tography (ethyl acetate-hexane 1 : 4) gave Id (0.57 g, 60%) as a 
pale yellow powder with properties as above.
5-(l ,l-DimethylethoxycarbonyIamino)isocoumarin 3a
To 5-aminoisocoumarin17 2 (700 mg, 4.4 mmol) in dichlo- 
romethane (3.0 cm3) was added D M F (3.5 cm3) and triethyl­
amine (0.070 cm3). The solution was cooled to 0 °C, di-terl- 
butyl dicarbonate (1.4 g, 6.4 mmol) in CH2C12 (3.0 cm3) was 
added and the mixture was stirred for 4 d. The evaporation 
residue, in ethyl acetate, was washed with water and brine. 
Evaporation and chromatography (ethyl acetate-hexane 1 : 4) 
gave 3a (895 mg, 79%) as very pale yellow crystals: mp 188-190 
°C (Found: C, 64.20; H, 5.83; N, 5.35. CmH.jN.O, requires C, 
64.36; H, 5.75; N, 5.36%); vMX (KBr)/cnT' 3320, 1720 and 1682; 
SH 1.45 (9 H, s, BuO, 6.49 (1 H, d, 7 =  5.9 Hz, 4-H), 6.50 (1 H, br 
s, NH), 7.22 (1 H, d, 7 = 5.9 Hz, 3-H), 7.42 (1 H, t, 7 = 7.9 Hz, 7- 
H), 7.97 (1 H, d, 7=  7.9 Hz, 6-H) and 8.02 (1 H, d, 7 = 7.9 Hz, 8- 
H); m /z 262.1085 (M + H) (C 14H 16N ,0 4 requires 262.1079), 
261.1008 (M ) (CI4H 15N 10 4 requires 261.1001) and 206 (M -  
BuO-
5-[/V, A-Bis(l, 1 -dimethylethoxycarbonyl)amino]isocoumarin 3b
To 5-aminoisocoumarin17 2 (100 mg, 0.62 mmol) in dichlo- 
romethane (1.0 cm3) was added D M F (0.5 cm3) and triethyl­
amine (0.010 cm3). The solution was cooled to 0 °C and di-tert- 
butyl dicarbonate (403 mg, 1.84 mmol) in dichloromethane (1.0 
cm3) was added during 10 min. The mixture was stirred for 4 d. 
The evaporation residue, in ethyl acetate, was washed with 
water and brine. Evaporation and chromatography (ethyl 
acetate-hexane 1 : 4) gave 3b (130 mg, 58%) as white crystals: 
mp 165-167 °C; (KBr)/cm_l 1720;<5H 1.38 (18 H, s, 2 x Bu1),
6.47 (1 H, dd, 7 =  5.9, 0.6 Hz, 4-H), 7.32 (1 H, d, 7 =  5.9 Hz, 3- 
H), 7.53(1 H, t, 7 =  7.9 Hz, 7-H), 7.54(1 H, d d ,7 = 7 .9 , 1.3 Hz,
6-H) and 8.29 (1 H, ddd, 7=  7.9, 1.3, 0.6 Hz, 8-H); m/z 362.1617 
(M + H) (Ci9H24N ,0 6 requires 362.1604), 361.1544 (M) 
(C19H23N ,0 6 requires 361.1525), 262 (M + H -  Boc) and 206 
(M + H -  Boc -  BuO-
5-Iodoisocoumarin 4
Sodium nitrite (2.6 g, 37.3 mmol) in water (200 cm3) was added 
to 5-aminoisocoumarin 2 17 (7.0 g, 43.4 mmol) in aq. hydro­
chloric acid (4.5 M, 250 cm3) at 0 °C. A chilled solution of 
potassium iodide (10.0 g, 60 mmol) in water (250 cm3) was 
added during 10 min. The mixture was stirred for 2 h before 
extraction with ethyl acetate. Evaporation and chromatography 
(hexane-ethyl acetate 4 : 1) yielded 4 (8.3 g, 70%) as off-white 
crystals: mp 155-156 °C; SH ((CD 3)2SO) 6.75 (1 H, d, 7=  5.9 Hz, 
3-H), 7.37 (1 H, d, 7 =  7.9 Hz, 7-H), 7.75 (1 H, d ,7=  5.9 Hz, 4- 
H), 8.22 (1 H, d, 7 = 7.6 Hz, 6-H) and 8.31 (1 H, d, 7=  7.9 Hz, 8- 
H). This material was used without further purification or
4 7. Chem. Soc., Perkin Trans. 1, 2002, 1-7
characterisation.
5-Bromo-2-(4-methoxypheny lmethyl)isoquinoIine-1 (2//)-one 6c
5-Bromoisocoumarin 1417 (100 mg, 0.44 mmol) in 2- 
methoxyethanol (1.0 cm1) was boiled under reflux with 4- 
methoxybenzylamine (61 mg, 0.44 mmol) for 24 h. Evapor­
ation, chromatography (hexane-ethyl acetate 5 : 1 )  and tritur­
ation (diethyl ether) gave 6c (40 mg, 27%) as white crystals: mp . 
97-100 °C (lit.11 mp 98-100 °C); ( K B r ) / c m 1640, 1610 and ’ 
690; SH 3.79 (3 H, s, Me), 5.15 (2 H, s, CH2), 6.82 (1 H, dd, 7 = 
7.6, 0.5 Hz, 4-H), 6.87 (2 H, d, 7 = 8.5 Hz, Ph 3,5-HJ, 7.18 (1 H, 
d, 7 = 7.6 Hz, 3-H), 7.27 (2 H ,7  = 8.5 Hz, Ph 2,6-H2), 7.33 (1 H, 
t, 7 = 8.0 Hz, 7-H), 7.87 (1 H, dd, 7 = 8.0, 1.5 Hz, 6-H) and 8.43 
(1 H, ddd, 7 = 8.0, 1.5, 0.5 Hz. 8-H).
1-Phenylmethoxy isoquinoline 7
IsoquinoIin-l(2//)-one la  was treated with triphenylphosphine, 
DEAD and 5d, as for the synthesis o f 10a, except that the 
chromatographic eluant was ethyl acetate, to give 7 (39%) as a 
colourless oil: dH 5.58 (2 H, s, CH2), 7.25 (1 H, d, 7  = 6.2 Hz, 4- 
H), 7.36 (5 H, m, Ph-H5), 7.55 (1 H, dd, 7 = 8.5, 8.2 Hz, 7-H), 
7.66 (1 H, t, 7=  8.2 Hz, 6-H), 7.70 (1 H, d, 7 =  8.2 Hz, 5-H), 8.00 
(1 H, d, 7  = 6.2 Hz, 3-H) and 8.31 (1 H, d, / =  8.5 Hz, 8-H); MS 
(EI+) m/z 235.0997 (M) (CI6H 13ON requires 235.0989).
2-(2-Thienylmethy!)isoquinolin-1 (2H)-one 9c
2-Chloromethylthiophene23 8c (270 mg, 2.0 mmol) and sodium 
iodide (5 mg) were added to isoquinolin-l-one la  (200 mg, 1.4 
mmol) and lithium bis(trimethylsilyl)amide (1.0 M in THF, 2.8 
mL, 2.8 mmol) in dry D M F (10 cm3) and the mixture was 
stirred for 2 d under Ar. The evaporation residue, in ethyl acet­
ate, was washed with water (2*) and brine (2x) and was dried. 
Evaporation and chromatography (ethyl acetate-hexane 1 : 1 )  
gave 9c (150 mg, 45%) as a pale buff glass; (KBr)/cm_I 
1640; <5„ 5.34 (2 H, s, CH2), 6.49 (1 H, d, 7 -  7.3 Hz, isoquino­
line 4-H), 6.95 (1 H, dd, 7 = 5.1, 3.5 Hz, thiophene 4-H), 7.11 (1 
H, br d, 7 = 3.5 Hz, thiophene 3-H), 7.14 (1 H, d, 7 = 7.3 Hz, 
isoquinoline 5-H), 7.24 (1 H, dd, 7 = 5.3, 1.4 Hz, thiophene 5- 
H), 7.5 (2 H, m, isoquinoline 3,7-H2), 7.62 (1 H, t, 7 =  7.5 Hz, 
isoquinoline 6-H) and 8.45 (1 H, d, 7  = 7.5 Hz, isoquinoline 8- 
H); Sc 46.5, 106.6, 125.9, 126.1, 126.8, 126.9, 127.3, 128.0(2 x 
C), 130.6, 132.3, 136.9, 138.8 and 161.9; m/z 242.0635 (M + H) 
(Cu H,,NOS requires 242.0639).
1 -(5-Nitro-2-thienylmethoxy)isoquinoline 10a
Isoquinolin-l(2//)-one la  (90 mg, 0.62 mmol) was stirred with 
triphenylphosphine (330 mg, 1.3 mmol) in dry tetrahydrofuran 
(20 cm3) under A r for 5 min. DEAD (209 mg, 1.2 mmol) was 
added dropwise. After 15 min, (5-nitro-2-thienyl)methanol18 8d 
(100 mg, 0.63 mmol) was added and the mixture was stirred for 
16 h. Evaporation and chromatography (ethyl acetate-hexane 1 
: 1) gave 10a (67 mg, 38%) as a pale buff oil: (film)/cm''
1631; <5h 5.74 (2 H, s, CH2), 7.12 (1 H, d, 7 = 4.0 Hz, thiophene
3-H), 7.30 (1 H, d, 7  = 6.0 Hz, isoquinoline 4-H), 7.55 (1 H, dd,
7 = 8.2, 7.7 Hz, isoquinoline 7-H), 7.70 (1 H, t, 7  = 7.7 Hz, 
isoquinoline 6-H), 7.75 (1 H, d, 7 =  7.7 Hz, isoquinoline 5-H), 
7.80 (1 H, d, 7 =  4.0 Hz, thiophene 4-H), 8.00 (1 H, d, 7 =  6.0 
Hz, isoquinoline 3-H) and 8.25 (1 H, d, J -  8.2 Hz, isoquinoline
8-H); Sc 62.3, 116.1, 126.1, 127.4, 128.1, 128.5, 130.0, 132.3,
131.8, 131.5, 148.2, 158.9 and 165.6; m/z 287.0486 (M + H) 
(CI4H 10N2OjS requires 287.0490).
5-Iodo-l-{5-nitro-2-thieny]methoxy)isoquinoline 10b
5-Iodoisoquinolin-l(2//)-one lb  was treated with triphenyl­
phosphine, DEAD and 8d, as for the synthesis o f 10a, to give 
10b (30%) as a yellow powder: mp 78-82 °C (Found: C, 40.7; H, 
2.09; N, 6.4. C MH9IN 20 3S requires C, 40.87; H, 2.18; N, 6.80%);
(K Br)/cm -‘ 1618; SH 5.74 (2 H, s, CH2), 7.12 (1 H, d, 7 = 3.9 
Hz, thiophene 3-H), 7.27 (1 H, dd, 7 = 7.4, 8.5 Hz, isoquinoline
7-H), 7.49(1 H , d , 7  = 6.3 Hz, isoquinoline 4-H), 7.83 (I H, d, 7 
= 3.9 Hz, thiophene 4-H), 8.10 (1 H, d, 7 =  6.3 Hz, isoquinoline 
3-H), 8.22 (1 H, d, 7 = 7.4 Hz, isoquinoline 6-H) and 8.27 (1 H, 
d, 7 -  8.5 Hz, isoquinoline 8-H); Sc 62.8, 96.9, 119.7, 120.0, 
124.3, 125.9, 127.9, 139.6, 140.5, 141.7, 147.6 and 158.9; MS 
(E I+) m/z 412 (M).
5-Bromo-l-(5-nitro-2-thienylmethoxy)isoquinoline 10c
5-Brom oisoquinolin-l(2//)-one2 lc  was treated with triphenyl­
phosphine, DEAD and 8d, as for the synthesis of 10a, to give 
10c (41%) as a yellow powder: mp 128-130 °C; v„„ (K.Br)/cm_l 
1616; SH 5.75 (2 H, s, CHj), 7.13 (1 H, d, 7 = 4.2 Hz, thiophene
3-H), 7.42 (1 H, dd, 7 =  8.2, 7.8 Hz, isoquinoline 7-H), 7.65 (1
H, d, 7  = 6.0 Hz, isoquinoline 4-H), 7.84 (1 H, d, 7 = 4.2 Hz, 
thiophene 4-H), 7.97 (1 H, d, 7 =  7.8 Hz, isoquinoline 6-H), 8.12 
(1 H, d, 7 =  6.0 Hz, isoquinoline 3-H) and 8.25 (1 H, d, 7 =  8.2 
Hz, isoquinoline 8-H); Sc 62.9, 115.2, 120.1, 121.5, 123.7, 126.1,
127.5, 128.2, 134.7, 139.0, 140.6, 147.8 and 158.9; m/z 366.9575 
(M + H) (CMH98,BrN20 3S requires 366.9589).
I,2-DimethyI-3-(5-iodo-l-oxo-2//-isoquinolin-2-ylmethyl)-5- 
methoxy-1//-indole-4,7-dione 12b
5-Iodoisoquinolin-l(2//)-one lb was treated with triphenyl­
phosphine, DEAD and lib , as for the synthesis of 10a, to give 
12b (36%) as a purple powder: mp >230 °C; (K B r)/cm '‘ 
1702; SH 2.47 (3 H, s, indole 2-Me), 3.81 (3 H, s, NMe), 3.88 (3 
H, s, OMe), 5.29 (2 H, s, C H ^, 5.62 (1 H, s, indole 6-H), 6.66 (1 
H, d, 7  = 7.9 Hz, isoquinoline 4-H), 7.12 (1 H, t, 7 = 7.8 Hz, 
isoquinoline 7-H), 7.80 (1 H, d, 7  = 7.9 Hz, isoquinoline 3-H), 
8.11 (1 H, dd, 7  = 7.8, 1.1 Hz, isoquinoline 6-H) and 8.38 (1 H, 
brd, 7  = 8.2 Hz, isoquinoline 8-H); <5C 10.2, 32.6, 42.2, 56.5,
106.5, 109.1, 121.1, 126.7, 127.2, 128.0, 128.7, 134.1, 138.7,
142.5, 138.9, 159.0, 161.1 and 178.1; m/z 489.0309 (M + H) 
(C21H 18IN 20 4 requires 489.0311).
3-(5-Bromo-l-oxo-2//-isoquinolin-2-ylmethyl)-l,2-dimethyl-5- 
methoxy-1 //-indole-4,7-dione 12c
5-Bromoisoquinolin-l(2//)-one lc was treated with triphenyl­
phosphine, DEAD and lib , as for the synthesis of 10a, to give 
12c (36%) as a purple powder: mp 278-280 °C; vMX (KBr)/cm"‘ 
1695; SH 2.47 (3 H, s, indole 2-Me), 3.81 (3 H, s, NMe), 3.88 (3 
H, s, OMe), 5.30 (2 H, s, CHJ,  5.62 (1 H, s, indole 6-H), 6.77 (1 
H, d, 7 = 8.0 Hz, isoquinoline 4-H), 7.27 (1 H, dd, 7 = 7.8, 7.3 
Hz, isoquinoline 7-H), 7.82 (1 H, d, 7 =  8.0 Hz, isoquinoline 3- 
H), 7.84 (1 H, dd, 7 =  7.3, 0.9 Hz, isoquinoline 6-H) and 8.36 (1
H, br d, 7 =  7.8 Hz, isoquinoline 8-H); 5C 10.2, 32.6, 42.2, 56.5,
104.3, 106.6, 116.1, 120.4, 121.2, 126.8, 127.4, 128.1, 128.5,
128.8, 134.1, 135.6, 136.3, 138.8, 159.3, 161.2 and 178.2; m/z 
441.0443 (M + H) (C21H lgN20 4Br requires 441.0449).
I,2-Dimethyl-3-[5-(l,l-dimethylethoxycarbonyIainino)-l-oxo- 
2//-isoquinolin-2-ylmethyl]-5-methoxy-l //-indole-4,7-dione 12d
Compound Id was treated with triphenylphosphine, DEAD 
and lib , as for the synthesis o f 10a, to give 12d (12%) as an 
orange solid: mp >230 °C; 8H 1.54 (9 H, s, Bu^, 2.47 (3 H, s, 
indole 2-Me), 3.81 (3 H, s, NMe), 3.88 (3 H, s, OMe), 5.25 (2 H, 
s, CH2), 5.62 (1 H, s, indole 6-H), 6.57 (1 H, d, 7 = 8.0 Hz, 
isoquinoline 4-H), 7.27 (1 H, t, 7 =  8.0 Hz, isoquinoline 7-H),




Isoquinolin-l(2//)-one la was treated with triphenylphosphine, 
DEAD and 1 lb, as for the synthesis of 10a, to give 13a (40%) as
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a red powder: mp >230 °C; vma„ (KBr)/cm 1 1725, 1694; SH 2.38 
(3 H, s, indole 2-Me), 3.80 (3 H, s, NMe), 3.89 (3 H, s, OMe), 
5.62 (1 H, s, indole 6-H), 5.72 (2 H, s, CH2), 7.20 (1 H, d, J  = 5.8 
Hz, isoquinoline 4-H), 7.45 (1 H, td, J  = 8.2, 1.1 Hz, isoquino­
line 7-H), 7.61 (1 H, td, J  = 8.2, 1.1 Hz, isoquinoline 6-H), 7.70 
(1 H, d, J  = 8.2 Hz, isoquinoline 5-H), 8.00 (1 H, d, J=  5.8 Hz, 
isoquinoline 3-H) and 8.17 (1 H, d, J  = 8.6 Hz, isoquinoline 8- 
H);<5C 9.8, 50.8, 53.4, 56.4, 114.8, 117.3, 119.8, 122.0, 124.4,
125.9, 126.4, 129.0, 130.3, 137.9, 138.0, 139.6, 142.4, 159.7,;
160.3, 177.6 and 178.9; MS (EI+) m/z 363.1346 (M) 
(C21H 18N 20 4 requires 363.1344).
1,2-Dimethy l-3-(5-iodoisoquinoIin-l -yloxymethyl)-5-methoxy- 
17/-indole-4,7-dione 13b
2-Iodoisoquinolin-l(2//)-one j c was treated with triphenyl­
phosphine, DEAD and lib , as for the synthesis o f 10a, to give 
13b (39%) as a purple powder: mp >230 °C; (KBr)/cmH 
1702; <5„ 2.37 (3 H, s, indole 2-Me), 3.81 (3 H, s, NMe), 3.88 (3 
H, s, OMe), 5.62 (1 H, s, indole 6-H), 5.71 (2 H, s, CHj), 7.16 (1 
H, dd, J  = 8.3, 7.4 Hz, isoquinoline 7-H), 7.40 (1 H, d, / =  6.1 
Hz, isoquinoline 4-H), 8.08 (1 H, d, J  = 6.1 Hz, isoquinoline 3- 
H), 8.15 (1 H, dd, J  = 7.4, 1.0 Hz, isoquinoline 6-H) and 8.20 (1 
H, br d, J  = 8.3 Hz, isoquinoline 8-H); Sc 9.9, 32.4, 56.4, 58.6,
106.6, 117.0, 118.5, 120.6, 125.1, 127.5, 128.9, 134.5, 138.0,
139.5, 141.1, 159.7, 160.5, 177.6 and 178.9; m/z 489.0309 (M + 
H) (C2,H 18IN20 4 requires 489.0311).
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